Conditions: Myasthenia Gravis, MuSK AChR Myasthenia Gravis
Keywords: Amifampridine Phosphate Amifampridine 3,4-Diaminopyridine Phosphate 3,4-Diaminopyridine 3,4-DAP Firdapse® Myasthenia Gravis MuSK AChR
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 63
Healthy volunteers: no

Brief summary:
Evaluate the long-term safety of amifampridine phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis.

Detailed description:
The Primary objective :

To characterize the long-term safety and tolerability of amifampridine phosphate in patients with MG

The Secondary Objective:

To assess the clinical efficacy of amifampridine phosphate over time in patients with MG based on change in Myasthenia Gravis Activities of Daily Living Score (MG-ADL)

This was a long-term extension study for subjects who participated in Protocol MSK-002 where the efficacy and safety of amifampridine was evaluated in subjects diagnosed with MuSK MG or AChR-MG. The optimal dose and schedule for amifampridine from the end of the Run-in Period from Study MSK-002 was initially used for each patient. The Investigator could adjust the dose of amifampridine during the course of the trial, in order to optimize neuromuscular benefit for the patient. Clinic visits for safety assessment and for evaluation of MG-ADL were made at Months 3, 6, 9, 12, 15, 21, 27, 33 and 39. Additional visits could occur at the discretion of the Investigator.

The Original protocol (12 Nov 2017) included analysis of MG-ADL change over time, however, Statistical Analysis Plan (SAP), dated 21 Feb 2023, removed the analysis of MG-ADL score change over time.

Arms:
arm 1: tablets equivalent to 10mg amifampridine, 3 to 4 times per day. Initially, the daily amifampridine doses were to be the doses that were determined at the end of the Run-in Period from the MSK-002 study. The usual range was from 30 to 80 mg total daily dose, given in three (3) or four (4) doses, with no single dose \> 20 mg

Interventions: intervention 1: Amifampridine Phosphate
Intervention descriptions: intervention 1: tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day

Protocol document:
SAP_002.pdf: 


Statistical Analysis Plan
Study:  Catalyst MSK-003
STATISTICAL ANALYSIS PLAN
Final v1.0
Protocol: MSK-003 (Amendment to the Final Version 1, 07 February 2020)
Long Term Safety Study of Amifampridine Phosphate in Patients with MuSK
Antibody Positive and AChR Antibody Positive Myasthenia Gravis Patients
Date:  October 25, 2022
Page 1 of 12


Catalyst MSK-003
              Statistical Analysis Plan
TABLE OF CONTENTS
List of Abbreviations................................................................................................................................3
1.
INTRODUCTION..............................................................................................................................4
1.1
Objectives.................................................................................................................................4
1.2
Design.......................................................................................................................................4
2.
ELABORATION OF STUDY PROTOCOL........................................................................................5
2.1
Study Populations.....................................................................................................................5
2.2
Study Endpoints........................................................................................................................5
2.2.1
Safety Endpoint.................................................................................................................5
2.2.2
Efficacy Endpoint...............................................................................................................5
2.3
Sample Size..............................................................................................................................5
3.
STATISTICAL METHODS................................................................................................................5
3.1
General.....................................................................................................................................5
3.1.1
Display of Decimal Places.................................................................................................5
3.1.2
Visit Windowing.................................................................................................................6
3.1.3
Missing Data Handling.......................................................................................................6
3.1.4
Sub-group Analyses..........................................................................................................6
3.2
Subject Disposition, Demographics, Baseline Characters and Study Drug Compliance...........6
3.2.1
Patient Disposition.............................................................................................................6
3.2.2
Protocol Deviations............................................................................................................6
3.2.3
Demographics and Baseline Characters............................................................................6
3.2.4
Study Drug Exposure.........................................................................................................7
3.3
Safety Analysis..........................................................................................................................7
3.3.1
General..............................................................................................................................7
3.3.2
Adverse Events.................................................................................................................7
3.3.3
Vital Signs..........................................................................................................................7
3.3.4
Electrocardiogram (ECG)..................................................................................................7
3.3.5
Clinical Laboratory Assessments.......................................................................................8
3.3.6
Physical Examinations.......................................................................................................8
3.3.7
Concomitant Medications..................................................................................................8
3.4
Efficacy Analysis.......................................................................................................................8
3.5
Analysis Report.........................................................................................................................8
3.6
Key Data Items..........................................................................................................................8
3.7
Change to Planned Protocol Analysis.......................................................................................9
4.
OUTPUT PLANNED FOR THE STUDY REPORTs.........................................................................9
4.1
Tables Planned for Interim Reports and Final Study Report.....................................................9
4.2
Listings Planned for Interim Reports and Final Study Report..................................................10
5.
References.....................................................................................................................................11
6.
Attachment: The Shells of Tables and Listings planned for interim and final Study Reports..........11
Page 2 of 12


Catalyst MSK-003
              Statistical Analysis Plan
LIST OF ABBREVIATIONS
AE
Adverse Events
AChR-MG
Acetylcholine receptor Myasthenia Gravis
CRF
Case Report Form
DBP
Diastolic Blood Pressure
DSUR
Development Safety Update Report
ECG
Electrocardiograms
FDA
Food and Drug Administration 
ICF
Informed Consent Form
ICH
International Committee for Harmonization
MedDRA
Medical Dictionary for Drug Regulatory Affairs
MG-ADL
Myasthenia Gravis Activities of Daily Living
MuSK-MG
Muscle-specific receptor tyrosine Kinase-Myasthenia Gravis
PBRS 
Peachtree BioResearch Solution
PT
Preferred Term
SAE
Serious Adverse Events
SAP
Statistical Analysis Plan
SAS
Statistical Analysis System
SBP
Systolic Blood Pressure
SOC
System Organ Class
TEAE
Treatment-Emergent Adverse Events
US
United States
WHODRUG
World Health Organization Drug Dictionary
Page 3 of 12


Catalyst MSK-003
              Statistical Analysis Plan
1.
 INTRODUCTION
1.1 Objectives
The present long-term extension study will evaluate safety and tolerability of amifampridine on 
clinical laboratory test variables, ECGs, AEs, vital signs, physical examinations and the effects on 
MG-ADL score over several months in patients with MuSK-MG or AchR-MG. This information is 
needed to demonstrate that the product is safe and provides continued benefit to patients with MG.

The primary objective of the study is to evaluate the long-term safety and tolerability of
amifampridine in patients with MuSK-MG; and with AChR-MG.

The secondary objective of the study is to assess the effect of amifampridine phosphate on
Myasthenia Gravis Activities of Daily Living Score (MG-ADL).
This Statistical Analysis Plan (SAP) corresponds to the Statistical Approach section of Clinical 
Protocol MSK-003, amendment to the Final v1.0, dated February 07, 2020.
1.2 Design
The study will enroll those patients who have completed the MSK-002 study and after all final 
evaluations for that study have been completed, or those who demonstrated benefit after completing
the dose titration period but failed to meet the randomization criteria on Day 0 of MSK-002. 
The duration of participation for each patient is expected to be at least 9 months as patients may 
continue in the study until amifampridine is approved by Regulatory Agencies or the clinical 
development of amifampridine is terminated for this indication. In addition to amifampridine, patients 
will continue to receive previous concomitant medications, as needed. 
After a new informed consent is signed and inclusion / exclusion criteria for the current protocol are 
satisfied, eligible patients will be given the optimal dose and dosing schedule that was identified in 
the Run-in Period from Protocol MSK-002.  
The findings from the physical exam (including vital signs, weight); 12-lead ECG; clinical laboratory 
test results (including pregnancy testing) and any ongoing adverse events will be used as the 
baseline for the Long-Term safety evaluation.  
The only efficacy measurement is the MG-ADL which will be completed every 3 or 6 months. Safety 
and tolerability assessments will be made every 3 or 6 months or more frequently at the discretion of
the Investigator. The study will continue until amifampridine is approved by Regulatory Agencies or 
until development of the product for this indication is halted. The Investigator may alter the dose and 
dosing frequency during the Long-Term Study as well as schedule additional clinic visits for any 
reason.  
Patients will be seen in the clinic at the end of Months 3, 6, 9, 12, 15, 21, 27, 33 and 39. In between 
the 3-or 6-month visits, patients may also have telephone/video contact with the site, or unscheduled
visits, if needed.
Any unused medication must be brought back to the clinic at each visit for drug accountability, and 
an additional supply will be dispensed.
Page 4 of 12


Catalyst MSK-003
              Statistical Analysis Plan
2.
ELABORATION OF STUDY PROTOCOL 
2.1 Study Populations

Safety Population: All enrolled patients who receive at least one dose of study drug will be
included in the safety population.
All analyses will be performed on the safety population.
2.2 Study Endpoints
2.2.1
Safety Endpoint 
Safety endpoints of this study are:

Incidence of patients experiencing treatment-emergent adverse events (TEAEs)

Incidence of patients experiencing study drug related TEAEs

Incidence of patients experiencing equal or greater than Grade 3 TEAEs Incidence of
patients discontinuing from the study due to TEAEs

Physical exam and weight

Vital signs including systolic blood pressure (SBP) and diastolic blood pressure (DBP),
heart rate, respiration, and body temperature

Clinical laboratory tests, including hematology, chemistry and urinalysis

Concomitant medication review

Electrocardiogram (ECG) parameters
2.2.2 Efficacy Endpoint
Efficacy endpoint of this study is change in MG-ADL score over time.
2.3 Sample Size
This is an observational study and no hypothesis is being tested. Collection of long term safety and 
MG-ADL scores are required to demonstrate that amifampridine is safe and well tolerated in the MG
population and if there is a change in dose requirements with time.
3.
STATISTICAL METHODS 
3.1 General
All data will be analyzed using the Statistical Analysis System (SAS®; Version 9.2 or higher). 
Continuous variables will be presented by descriptive statistics: n, mean, standard deviation, 
median, minimum, and maximum.  Categorical variables will be tabulated by frequency count and 
percentage.  No hypothesis testing will be performed.  
3.1.1
Display of Decimal Places
Means and medians will be reported to one decimal place more than the original unit reported on 
the case report form (CRF) or by the laboratory/vendor.  Standard deviations will be reported to two 
decimal places more than the original unit.  Minimum and maximum values will be reported to the 
same number of decimal places displayed on the CRF or by the laboratory/vendor.  
Page 5 of 12


Catalyst MSK-003
              Statistical Analysis Plan
3.1.2
Visit Windowing
For Vital signs, ECG, Lab and physical exam, the following protocol-specified visits are further 
defined for summary tables as below.

Baseline (Day 1): the date of ICF signed 

Follow-up visit (3 Months):  the visit date was most close to 91 days after baseline visit. 

Follow-up visit (6 Months): the visit date was most close to 183 days after baseline visit.

Follow-up visit (9 Months): the visit date was most close to 274 days after baseline visit. 

Follow-up visit (12 Months): the visit date was most close to 365 days after baseline visit.

Follow-up visit (15 Months): the visit date was most close to 456 days after baseline visit.

Follow-up visit (21 Months): the visit date was most close to 640 days after baseline visit.

Follow-up visit (27 Months): the visit date was most close to 822 days after baseline visit 

Follow-up visit (33 Months): the visit date was most close to 1005 days after baseline visit 

Follow-up visit (39 Months): the visit date was most close to 1187 days after baseline visit 

End of study or early termination visit does not coincide the scheduled 3- or 6-month visit.

Other visits will be listed as “Unscheduled Visits”.
3.1.3
Missing Data Handling
In general, all categories that appear on the CRF and in summary table templates will be reported 
even if no patients reported that category (e.g., if there are no patients of a particular race).  The 
“Missing” category displayed for categorical variables in summary table templates will only be 
displayed if missing observations are present.  If no observations meet the criteria for inclusion in a 
data display (e.g., if there are no SAEs), the table or listing will be generated with a line in the body 
of the listing such as “None reported.”
No imputation will be conducted for the missing data.
3.1.4
Sub-group Analyses
All safety endpoints will be analyzed by MG type: MuSK-MG and AChR-MG.
3.2 Subject Disposition, Demographics, Baseline Characters and Study Drug 
Compliance
3.2.1
Patient Disposition 
Study completion status will be summarized for all patients. The duration of treatment will be
summarized for treated patients.  Categories summarized will include patients who were planned,
screened, screen failure, enrolled, received study drug, completed the study or withdrew early.
Reasons for screen failure and withdrawal will be summarized.
3.2.2
Protocol Deviations 
Individual protocol deviations will be presented in a data listing.
3.2.3
Demographics and Baseline Characters 
Demographic  characteristics  of  all  patients  enrolled  will  be  summarized  descriptively.   The
summary will include age, gender, race/ethnicity, height, weight.    
3.2.4
Study Drug Exposure 
Page 6 of 12


Catalyst MSK-003
              Statistical Analysis Plan
The total number of days exposed, the total dose (mg) administered and average daily dose will be
tabulated. 
3.3 Safety Analysis
3.3.1
General
All safety summaries will be presented overall for the safety population.  The evaluation will take 
into account the recorded adverse events (AE), clinical laboratory tests, vital signs, physical exam, 
ECG assessments and concomitant medications.
3.3.2
Adverse Events
Since patients started taking study medication before enrolled the study, all AE reported are 
considered as treatment-emergent adverse events (TEAE). 
Tabular summaries will be provided by indication for the number and percentage of patients with:

Any TEAE by SOC and PT. This summary will include the number of unique events 
reported.

Any study drug-related TEAE by SOC and PT

Any TEAEs by SOC, PT and maximum severity

Any treatment-emergent serious adverse event (TESAE) by SOC and PT

Any TEAE that results in patient discontinuation from the study by SOC and Preferred Term 
(PT)
A listing of all adverse events will be provided.  In addition, separate data listings will be presented 
for the following:

Patient deaths 

Serious Adverse Events (SAEs)

Listing of Grade 3 (Severe) or Grade 4 (Life-threatening) AEs

Listing of AEs leading to study discontinuation
3.3.3
Vital Signs
A summary of values and changes from Baseline will be provided by vital signs parameter and visit
of at 3, 6, 9, 12, 15, 21, 27, 33 and 39 months.    
3.3.4
Electrocardiogram (ECG)
Each over-read ECG interval and change from baseline in each interval will be summarized 
descriptively by visit at 3, 6, 9, 12, 15, 21, 27, 33 and 39 months
Treatment-emergent cardiac abnormalities, as well as the overall interpretation, will be summarized. 
Treatment-emergent ECG findings considered by the investigator to be clinically significant will be 
presented only in a listing.
3.3.5
Clinical Laboratory Assessments
Page 7 of 12


Catalyst MSK-003
              Statistical Analysis Plan
A summary of laboratory values and changes from Baseline will be provided by test and visit of at 3, 
6, 9, 12, 15, 21, 27, 33 and 39 months.  In addition, laboratory measures out of range or abnormal 
will be presented for each visit.  Values deemed clinically significant by the Investigator will not be 
summarized, but will be presented in a listing.  
3.3.6
Physical Examinations
The number and percent of patients with physical examination abnormalities will summarized by 
body system and visit of at 3, 6, 9, 12, 15, 21, 27, 33 and 39 months.  
3.3.7
Concomitant Medications
A detailed listing of any concomitant medication taken by a patient during the course of the study will
be provided.  All medications, including those taken prior to study drug administration, will be listed 
by indication and sorted by patient and medication start date.  
The following summaries will be provided by drug class and WHODRUG preferred term: 

Prior medications (medications started prior to taking study medication), 

Concomitant medications (medications started during study treatment), 

Ongoing medication (medications given during treatment, and still ongoing after completed
study).
3.4 Efficacy Analysis
Summary table of MG-ADL score and change from baseline in MG-ADL score will be provided over 
time.  Individual data listing of MG-ADL score will also be provided.
3.5 Analysis Report
Multiple interim analyses may be conducted upon requested.  For example, the annual development 
safety update report (DSUR) and/or 120 Day safety update.  The final study report will be conducted 
after study completed.  One database lock is planned for this study at the end of the study.  
3.6 Key Data Items
Study Analysis Population Definition:
All Subjects:  All subjects, including screening failures, who provided clinical information in the 
database.
Safety Population:  All enrolled subjects who receive at least one dose of study drug. 
Important Derived Variables:
Age (in year) = (Screening Date – Date of Birth +1)/365.25.
Prior Medications and Treatments: The medications and treatments started before enrolled to 
the study (date of Informed Consent signed)
Concomitant Medication and Treatments:  The medications and treatments started on or after 
the date of Informed Consent signed
Page 8 of 12


Catalyst MSK-003
              Statistical Analysis Plan
Baseline: All safety measurements collected at Day 1 or before the first dose of study drug will 
be used as baseline 
Post Baseline Visit:  follow up visit of 6, 9, 12, 15, 21, 27, 33 and 39 months after baseline and 
etc, or unscheduled visit after first dose of the study drug
Study Day for follow-up visit:  The visit date – Baseline date +1
o
Follow-up visit at 3 months: The visit that is closest to study day 91
o
Follow-up visit at 6 months: The visit that is closest to study day 183
o
Follow-up visit at 12 months: The visit that is closest to study day 365 
o
Follow-up visit at 15 months: The visit that is closest to study day 456
o
Follow-up visit at 21 months: The visit that is closest to study day 640 
o
Follow-up visit at 27 months: The visit that is closest to study day 822 
o
Follow-up visit at 33 months: The visit that is closest to study day 1005 
o
Follow-up visit at 39 months: The visit that is closest to study day 1187 
Duration of Disease (year): 
(Date of Informed Consent signed – Date of original Diagnosis +1) / 365.25

Treatment Duration 
o
In Day:  The Last Visit Date – The First Dose Date +1
o
In Month :  Treatment Duration(Day) / 30.4375 

Total Dose (mg):  Sum of the daily dose (mg) over the Treatment Duration

Average Daily Dose:  Total Dose (mg) / Number of Treatment Duration days
Treatment emergent Adverse Events (TEAE):  All AEs reported in this study are TEAE 
Formulas of Metric Conversion:  

1 inch = 2.54 cm 

1 lb = 0.4536 kg

 oC = (oF – 32)x5/9 
3.7
Change to Planned Protocol Analysis
Not applicable.
4.
OUTPUT PLANNED FOR THE STUDY REPORTS  
4.1
Tables Planned for Interim Reports and Final Study Report
Table
#
Table Title
CSR
DSUR
T01 
Subject Disposition (All subjects) 
X
X
T02 
Demographics and Baseline Data Summary Statistics (Safety Population) 
X
X
T03
Summary of Study Drug Compliance (Safety Population) 
X
X
Page 9 of 12


Catalyst MSK-003
              Statistical Analysis Plan
T04 
MG-ADL Total Score Summary Statistics by Visit (Safety Population) 
X
T05 
MG-ADL Score Shift of At Least 2 Points by Visit (Safety Population) 
X
T06 
Number and Percent of Subjects with Treatment Emergent Adverse Events 
(Safety Population) 
X
X
T07 
Summary of Treatment Emergent Adverse Events (Safety Population) 
X
X
T08 
Number and Percent of Subjects with Treatment Emergent Serious Adverse 
Events (Safety Population) 
X
X
T09 
Number and Percent of Subjects with Treatment Emergent Adverse Events by 
Relationship to Treatment (Safety Population) 
X
X
T10 
Number and Percent of Subjects with Treatment Emergent Adverse Events of 
Grade 2 or Higher (Safety Population) 
X
X
T11 
Serum Chemistry Clinical Laboratory Summary Statistics by Visit (Safety 
Population) 
X
T12 
Hematology Clinical Laboratory Summary Statistics by Visit (Safety Population) 
X
T13 
Urinalysis Clinical Laboratory Summary Statistics by Visit (Safety Population) 
X
T14 
Serum Chemistry Shift Table by Visit (Safety Population) 
X
X
T15 
Hematology Shift Table by Visit (Safety Population) 
X
X
T16
Urinalysis Shift Table by Visit (Safety Population) 
X
X
T17 
Vital Sign Parameters Summary Statistics by Visit (Safety Population) 
X
T18 
Vital Signs Shift Table by Assessment Category and Visit (Safety Population) 
X
X
T19 
Summary of ECG by Assessment Category and Visit (Safety Population) 
X
T20 
ECG Shift Table by Assessment Category and Visit (Safety Population)
X
X
T21 
Number and Percent of Subjects Taking Concomitant Medications by ATC Level
3 and Preferred Term (Safety Population) 
X
4.2
Listings Planned for Interim Reports and Final Study Report
Listing #                         Data Listing Title
CSR
DSUR
DL01 
Subject Disposition Data Listing 
X
X
DL02 
Protocol Deviations Data Listing 
X
DL03 
Demographics Data Listing 
X
DL04 
Medical History Data Listing 
X
DL05 
Prior and Concomitant Medications Data Listing 
X
DL06a 
Adverse Events Data Listing 
X
X
DL06b
Serious Adverse Events Data Listing
X
DL06c
Adverse Events with Grade 3 or Higher Data Listing
X
DL06d
Adverse Events Leading to Study Discontinuation
X
DL07 
Physical Exam Data Listing 
X
DL08 
Vital Signs Data Listing 
X
X
DL09 
ECG Data Listing 
X
DL10 
Study Drug Administration Data Listing 
X
DL11 
Serum Chemistry Data Listing 
X
X
DL12 
Hematology Data Listing 
X
X
DL13 
Urinalysis Data Listing 
X
X
DL14 
MG-ADL Data Listing 
X
DL15
Pregnancy Test Data Listing
X
Page 10 of 12


Catalyst MSK-003
              Statistical Analysis Plan
5.
REFERENCES
Protocol MSK-003:  Long Term Safety Study of Amifampridine Phosphate in Patients with MuSK 
Antibody Positive and AChR Antibody Positive Myasthenia Gravis Patients, amendment to Final 
v1.0, Catalyst Pharmaceuticals, Inc.  February 07, 2020
6.
ATTACHMENT: THE SHELLS OF TABLES AND LISTINGS PLANNED FOR INTERIM AND 
FINAL STUDY REPORTS
Page 11 of 12


Statistical Analysis Plan
Study:  Catalyst MSK-003
Approval for 
Statistical Analysis Plan
Title:
Long Term Safety Study of Amifampridine Phosphate in Patients 
with MuSK Antibody Positive and AChR Antibody Positive 
Myasthenia Gravis Patients
Reference:
MSK-003/SAP
Version:
1.0
Date effective:
Author:  
Dion Chen, PhD. 
Author’s signature:
Date:
The above Statistical Analysis Plan has been reviewed and approved by the Sponsor:
Name of 
Reviewer/Approver
Gary Ingenito, MD
Position: 
Chief Medical Officer, Catalyst Pharmaceuticals, Inc.
Signature for 
sponsor:
Date:
Name of 
Reviewer/Approver
Position:
Signature for 
sponsor:
Date:
Page 12 of 12
10/25/2022
10/25/2022


TRANSACTION DETAILS
DOCUMENT DETAILS
Reference Number
568F1A35-369F-4E41-8B78-A02BCD61BD9C
Transaction Type
Signature Request
Sent At
10/25/2022 13:00 EDT
Executed At
10/25/2022 13:20 EDT
Identity Method
email
Distribution Method
email
Signed Checksum
28b07f7cc64c259ccb05dfa95f358b78b36c078c128d44a38af86293b6e471cd
Signer Sequencing
Disabled
Document Passcode
Disabled
Document Name
Catalyst Msk-003 Sap Final V1 0 25oct2022
Filename
catalyst_msk-003_sap_final_v1_0_25oct2022.docx
Pages
12 pages
Content Type
application/vnd.openxmlformats-officedocument.wordprocessingml.document
File Size
103 KB
Original Checksum
9a11935cf693fa99ae8af933054645ac1828bbe2de0df2dad847445b5dee84ac
S I G N E R S
SIGNER
E-SIGNATURE
EVENTS
Name
Gary Ingenito
Email
gingenito@catalystpharma.com
Components
2
Status
signed
Multi-factor Digital Fingerprint Checksum
7aef15334c3d6f0198d28eea51bf0d4d47263a11354b0dc0874888b47cd4c19f
IP Address
75.90.182.161
Device
Chrome via Windows
Typed Signature
Signature Reference ID
E187E27C
Viewed At
10/25/2022 13:19 EDT
Identity Authenticated At
10/25/2022 13:20 EDT
Signed At
10/25/2022 13:20 EDT
Name
Dion Chen
Email
dion.chen@peachtreebrs.com
Components
2
Status
signed
Multi-factor Digital Fingerprint Checksum
2ea1ddf3a295601313270293b8be9521ac7d6ec9146361c30233305e3aba2888
IP Address
96.227.219.228
Device
Chrome via Windows
Typed Signature
Signature Reference ID
0989506F
Viewed At
10/25/2022 13:02 EDT
Identity Authenticated At
10/25/2022 13:03 EDT
Signed At
10/25/2022 13:03 EDT
A U D I T S
TIMESTAMP
AUDIT
10/25/2022 13:00 EDT
Dion Chen (dion.chen@peachtreebrs.com) created document 'catalyst_msk-
S I G N A T U R E  C E R T I F I C A T E
R E F E R E N C E  N U M B E R
568F1A35-369F-4E41-8B78-A02BCD61BD9C


003_sap_final_v1_0_25oct2022.docx' on Chrome via Windows from 96.227.219.228.
10/25/2022 13:00 EDT
Gary Ingenito (gingenito@catalystpharma.com) was emailed a link to sign.
10/25/2022 13:02 EDT
Dion Chen (dion.chen@peachtreebrs.com) was emailed a reminder.
10/25/2022 13:02 EDT
Dion Chen (dion.chen@peachtreebrs.com) viewed the document on Chrome via Windows from
96.227.219.228.
10/25/2022 13:03 EDT
Dion Chen (dion.chen@peachtreebrs.com) authenticated via email on Chrome via Windows from
96.227.219.228.
10/25/2022 13:03 EDT
Dion Chen (dion.chen@peachtreebrs.com) signed the document on Chrome via Windows from
96.227.219.228.
10/25/2022 13:19 EDT
Gary Ingenito (gingenito@catalystpharma.com) viewed the document on Chrome via Windows
from 75.90.182.161.
10/25/2022 13:20 EDT
Gary Ingenito (gingenito@catalystpharma.com) authenticated via email on Chrome via Windows
from 75.90.182.161.
10/25/2022 13:20 EDT
Gary Ingenito (gingenito@catalystpharma.com) signed the document on Chrome via Windows
from 75.90.182.161.

SAP_004.pdf: 


Statistical Analysis Plan
Study:  Catalyst MSK-003
STATISTICAL ANALYSIS PLAN
Final v2.0
Protocol: MSK-003 (Amendment to the Final Version 1, 07 February 2020)
Long Term Safety Study of Amifampridine Phosphate in Patients with MuSK
Antibody Positive and AChR Antibody Positive Myasthenia Gravis Patients
Date:  February 21, 2023
Page 1 of 12


Catalyst MSK-003
              Statistical Analysis Plan
TABLE OF CONTENTS
List of Abbreviations..................................................................................................................................4
1.
INTRODUCTION................................................................................................................................5
1.1
Objectives...................................................................................................................................5
1.2
Design.........................................................................................................................................5
2.
ELABORATION OF STUDY PROTOCOL.........................................................................................6
2.1
Study Populations.......................................................................................................................6
2.2
Study Endpoints..........................................................................................................................6
2.2.1
Safety Endpoint...................................................................................................................6
2.2.2
Efficacy Endpoint.................................................................................................................6
2.3
Sample Size................................................................................................................................6
3.
STATISTICAL METHODS.................................................................................................................6
3.1
General.......................................................................................................................................6
3.1.1
Display of Decimal Places...................................................................................................6
3.1.2
Visit Windowing...................................................................................................................7
3.1.3
Missing Data Handling.........................................................................................................7
3.1.4
Sub-group Analyses............................................................................................................7
3.2
Subject Disposition, Demographics, Baseline Characters and Study Drug Compliance............7
3.2.1
Patient Disposition...............................................................................................................7
3.2.2
Protocol Deviations..............................................................................................................8
3.2.3
Demographics and Baseline Characters.............................................................................8
3.2.4
Study Drug Exposure..........................................................................................................8
3.3
Safety Analysis............................................................................................................................8
3.3.1
General................................................................................................................................8
3.3.2
Adverse Events...................................................................................................................8
3.3.3
Vital Signs............................................................................................................................9
3.3.4
Electrocardiogram (ECG)....................................................................................................9
3.3.5
Clinical Laboratory Assessments........................................................................................9
3.3.6
Physical Examinations.........................................................................................................9
3.3.7
Concomitant Medications....................................................................................................9
3.4
Analysis Report...........................................................................................................................9
3.5
Key Data Items.........................................................................................................................10
3.6
Change to Planned Protocol Analysis.......................................................................................11
4.
OUTPUT PLANNED FOR THE STUDY REPORTs........................................................................11
4.1
Tables Planned for Interim Reports and Final Study Report....................................................11
4.2
Listings Planned for Interim Reports and Final Study Report...................................................12
5.
References.......................................................................................................................................12
6.
Attachment: The Shells of Tables and Listings planned for interim and final Study Reports..........12
Page 2 of 12


Catalyst MSK-003
              Statistical Analysis Plan
LIST OF ABBREVIATIONS
AE
Adverse Events
AChR-MG
Acetylcholine receptor Myasthenia Gravis
CRF
Case Report Form
DBP
Diastolic Blood Pressure
DSUR
Development Safety Update Report
ECG
Electrocardiograms
FDA
Food and Drug Administration 
ICF
Informed Consent Form
ICH
International Committee for Harmonization
MedDRA
Medical Dictionary for Drug Regulatory Affairs
MG-ADL
Myasthenia Gravis Activities of Daily Living
MuSK-MG
Muscle-specific receptor tyrosine Kinase-Myasthenia Gravis
PBRS 
Peachtree BioResearch Solution
PT
Preferred Term
SAE
Serious Adverse Events
SAP
Statistical Analysis Plan
SAS
Statistical Analysis System
SBP
Systolic Blood Pressure
SOC
System Organ Class
TEAE
Treatment-Emergent Adverse Events
US
United States
WHODRUG
World Health Organization Drug Dictionary
Page 3 of 12


Catalyst MSK-003
              Statistical Analysis Plan
1.
 INTRODUCTION
1.1 Objectives
The present long-term extension study will evaluate safety and tolerability of amifampridine on 
clinical laboratory test variables, ECGs, AEs, vital signs, physical examinations and the effects on 
MG-ADL score over several months in patients with MuSK-MG or AChR-MG.  is needed to 
demonstrate that the product is safe and in patients with MG.

The primary objective of the study is to evaluate the long-term safety and tolerability of
amifampridine in patients with MuSK-MG; and with AChR-MG.

The secondary objective of the study is to assess the effect of amifampridine phosphate on
Myasthenia Gravis Activities of Daily Living Score (MG-ADL).
This Statistical Analysis Plan (SAP) corresponds to the Statistical Approach section of Clinical 
Protocol MSK-003, amendment, dated February 07, 2020, with additional changes included to the 
Version 1.0 dated 25 Oct 2022.
1.2 Design
The study will enroll those patients who have completed the MSK-002 study and after all final 
evaluations for that study have been completed, or those who demonstrated benefit after completing
the dose titration period but failed to meet the randomization criteria on Day 0 of MSK-002. 
The duration of participation for each patient is expected to be at least 9 months as patients may 
continue in the study until amifampridine is approved by Regulatory Agencies or the clinical 
development of amifampridine is terminated for this indication. In addition to amifampridine, patients 
will continue to receive previous concomitant medications, as needed. 
After a new informed consent is signed and inclusion / exclusion criteria for the current protocol are 
satisfied, eligible patients will be given the optimal dose and dosing schedule that was identified in 
the Run-in Period from Protocol MSK-002.  
The findings from the physical exam (including vital signs, weight); 12-lead ECG; clinical laboratory 
test results (including pregnancy testing) and any ongoing adverse events will be used as the 
baseline for the long-term safety evaluation.  
The only efficacy measurement is the MG-ADL which will be completed every 3 or 6 months. Safety 
and tolerability assessments will be made every 3 or 6 months or more frequently at the discretion of
the Investigator. The study will continue until amifampridine is approved by Regulatory Agencies or 
until development of the product for this indication is halted or until month 39 is reached. The 
Investigator may alter the dose and dosing frequency during the Long-Term Study as well as 
schedule additional clinic visits for any reason.  
Patients will be seen in the clinic at the end of Months 3, 6, 9, 12, 15, 21, 27, 33 and 39. In between 
the 3-or 6-month visits, patients may also have telephone/video contact with the site, or unscheduled
visits, if needed.
Page 4 of 12


Catalyst MSK-003
              Statistical Analysis Plan
Any unused medication must be brought back to the clinic at each visit for drug accountability, and 
an additional supply will be dispensed.
2.
ELABORATION OF STUDY PROTOCOL 
2.1 Study Populations

Safety Population: All enrolled patients who receive at least one dose of study drug will be
included in the safety population.
All analyses will be performed on the safety population.
2.2 Study Endpoints
2.2.1
Safety Endpoint 
Safety endpoints of this study are:

Incidence of patients experiencing treatment-emergent adverse events (TEAEs)

Incidence of patients experiencing study drug-related TEAEs

Incidence of patients experiencing equal or greater than Grade 3 TEAEs Incidence of
patients discontinuing from the study due to TEAEs

Physical exam and weight

Vital signs including systolic blood pressure (SBP) and diastolic blood pressure (DBP),
heart rate, respiration, and body temperature

Clinical laboratory tests, including hematology, chemistry and urinalysis

Concomitant medication review

Electrocardiogram (ECG) parameters
2.2.2 Efficacy Endpoint
Efficacy endpoint of this study is change in MG-ADL score over time.
2.3 Sample Size
The study is not powered with respect to any endpoint, but is an observational study to assess long 
term safety and lack of tolerance to the effects of amifampridine on MG-ADL.  No sample size 
power calculation was conducted for this study.
3.
STATISTICAL METHODS 
3.1 General
All data will be analyzed using the Statistical Analysis System (SAS®; Version 9.2 or higher). 
Continuous variables will be presented by descriptive statistics: n, mean, standard deviation, 
median, minimum, and maximum.  Categorical variables will be tabulated by frequency count and 
percentage.  No hypothesis testing will be performed.  
3.1.1
Display of Decimal Places
Page 5 of 12


Catalyst MSK-003
              Statistical Analysis Plan
Means and medians will be reported to one decimal place more than the original unit reported on 
the case report form (CRF) or by the laboratory/vendor.  Standard deviations will be reported to two 
decimal places more than the original unit.  Minimum and maximum values will be reported to the 
same number of decimal places displayed on the CRF or by the laboratory/vendor.  
3.1.2
Visit Windowing
For Vital signs, ECG, Lab and physical exam, the following protocol-specified visits are further 
defined for summary tables as below.

Screening Visit (Baseline): the day subject was screened following the ICF signing

Follow-up visit (3 Months):  the visit date was most close to 91 days after baseline visit. 

Follow-up visit (6 Months): the visit date was most close to 183 days after baseline visit.

Follow-up visit (9 Months): the visit date was most close to 274 days after baseline visit. 

Follow-up visit (12 Months): the visit date was most close to 365 days after baseline visit.

Follow-up visit (15 Months): the visit date was most close to 456 days after baseline visit.

Follow-up visit (21 Months): the visit date was most close to 640 days after baseline visit.

Follow-up visit (27 Months): the visit date was most close to 822 days after baseline visit 

Follow-up visit (33 Months): the visit date was most close to 1005 days after baseline visit 

Follow-up visit (39 Months): the visit date was most close to 1187 days after baseline visit 
For completed subjects, Follow-up visit (39 Months) is considered End of study visit.
For discontinued subjects, if the assessments at the scheduled visit prior to the early termination 
(ET) visit were not done, the ET visit will be assigned as the prior scheduled visit.  Otherwise, the 
ET visit will be assigned to the next scheduled visit. 
Other visits will be listed as “Unscheduled Visits”, and data collected at unscheduled visits will not 
be included in the summary table, but will be presented in the data listings.
3.1.3
Missing Data Handling
In general, all categories that appear on the CRF and in summary table templates will be reported 
even if no patients reported that category (e.g., if there are no patients of a particular race).  The 
“Missing” category displayed for categorical variables in summary table templates will only be 
displayed if missing observations are present.  If no observations meet the criteria for inclusion in a 
data display (e.g., if there are no SAEs), the table or listing will be generated with a line in the body 
of the listing such as “None reported.”
No imputation will be conducted for the missing data.
3.1.4
Sub-group Analyses
All safety endpoints will be analyzed by MG type: MuSK-MG and AChR-MG.
3.2 Subject Disposition, Demographics, Baseline Characters and Study Drug 
Compliance
3.2.1
Patient Disposition 
Study completion status will be summarized for all patients. The duration of treatment will be
summarized for treated patients.  Categories summarized will include patients who were planned,
screened, screen failure, enrolled, received study drug, completed the study, were lost to follow-up,
or withdrew early.  Reasons for screen failure and withdrawal will be summarized.
Page 6 of 12


Catalyst MSK-003
              Statistical Analysis Plan
3.2.2
Protocol Deviations 
Individual protocol deviations will be presented in a data listing.
3.2.3
Demographics and Baseline Characters 
Demographic  characteristics  of  all  patients  enrolled  will  be  summarized  descriptively.   The
summary will include age, gender, race/ethnicity, height, weight.    
3.2.4
Study Drug Exposure 
The treatment duration (day), the total dose (mg) of study drug administered, average daily dose of
study drug, and study drug compliance (%) will be tabulated. 

Treatment Duration (day) is calculated as The Last Dose Date – The First Dose Date +1. If the
last dose date is missing, then the last visit date will be used. 

Total Dose (mg) will be calculated as the sum of the daily dose (mg) over the Treatment
Duration,  considering  different  doses  during  individual  time  periods  within  the  study,  as
documented in the IP Accountability eCRF page.

Average Daily Dose (mg) will be calculated as Total Dose (mg) / Treatment Duration (day). This
will  be  calculated  considering  each  time  period  and  Daily  dose  during  that  period,  as
documented in the IP Accountability eCRF page.

Study Drug Compliance (%): 100 × Total Dose Taken (mg) / Total Dose Prescribed (mg)
3.3 Safety Analysis
3.3.1
General
All safety summaries will be presented overall for the safety population.  The evaluation will take 
into account the recorded adverse events (AE), clinical laboratory tests, vital signs, physical exam, 
ECG assessments and concomitant medications.
3.3.2
Adverse Events
Since patients started taking study medication before enrolled the study, all AE reported are 
considered as treatment-emergent adverse events (TEAE). 
Tabular summaries will be provided by indication for the number and percentage of patients with:

Any TEAE by SOC and PT. This summary will include the number of unique events 
reported.

Any study drug-related TEAE by SOC and PT

Any TEAEs by SOC, PT and maximum severity

Any treatment-emergent serious adverse event (TESAE) by SOC and PT

Any TEAE that results in patient discontinuation from the study by SOC and Preferred Term 
(PT)
A listing of all adverse events will be provided.  In addition, separate data listings will be presented 
for the following:

Patient deaths 
Page 7 of 12


Catalyst MSK-003
              Statistical Analysis Plan

Serious Adverse Events (SAEs)

Listing of Grade 3 (Severe) or Grade 4 (Life-threatening) AEs

Listing of AEs leading to study discontinuation
3.3.3
Vital Signs
A summary of values and changes from Baseline will be provided by vital signs parameter and visit
of at 3, 6, 9, 12, 15, 21, 27, 33 and 39 months.    
3.3.4
Electrocardiogram (ECG)
Each over-read ECG interval and change from baseline in each interval will be summarized 
descriptively by visit at 3, 6, 9, 12, 15, 21, 27, 33 and 39 months
Treatment-emergent cardiac abnormalities, as well as the overall interpretation, will be summarized. 
Treatment-emergent ECG findings considered by the investigator to be clinically significant will be 
presented only in a listing.
3.3.5
Clinical Laboratory Assessments
A summary of laboratory values and changes from Baseline will be provided by test and visit of at 3, 
6, 9, 12, 15, 21, 27, 33 and 39 months.  In addition, laboratory measures out of range or abnormal 
will be presented for each visit.  Values deemed clinically significant by the Investigator will not be 
summarized, but will be presented in a listing.  
3.3.6
Physical Examinations
The number and percent of patients with physical examination abnormalities will summarized by 
body system and visit of at 3, 6, 9, 12, 15, 21, 27, 33 and 39 months.  
3.3.7
Concomitant Medications
A detailed listing of any concomitant medication taken by a patient during the course of the study will
be provided.  All medications, including those taken prior to study drug administration, will be listed 
by indication and sorted by patient and medication start date.  
The following summaries will be provided by drug class and WHODRUG preferred term: 

Prior medications (medications started prior to taking study medication), 

Concomitant medications (medications started during study treatment), 

Ongoing medication (medications given during treatment, and still ongoing after completed
study).
3.4 Analysis Report
Multiple interim analyses may be conducted upon requested.  For example, the annual development 
safety update report (DSUR) and/or 120 Day safety update.  The final study report will be conducted 
after study completed.  One database lock is planned for this study at the end of the study.  
3.5 Key Data Items
Page 8 of 12


Catalyst MSK-003
              Statistical Analysis Plan
Study Analysis Population Definition:
All Subjects:  All subjects, including screening failures, who provided clinical information in the 
database.
Safety Population:  All enrolled subjects who receive at least one dose of study drug. 
Important Derived Variables:
Age (in year) = (Screening Date – Date of Birth +1)/365.25.
Prior Medications and Treatments: The medications and treatments started before enrolled to 
the study (date of Informed Consent signed)
Concomitant Medication and Treatments:  The medications and treatments started on or after 
the date of Informed Consent signed
Baseline: All safety measurements collected at Day 1 or before the first dose of study drug will 
be used as baseline 
Post Baseline Visit:  follow up visit of 6, 9, 12, 15, 21, 27, 33 and 39 months after baseline and 
etc, or unscheduled visit after first dose of the study drug
Study Day for follow-up visit:  The visit date – Baseline date +1
o
Follow-up visit at 3 months: The visit that is closest to study day 91
o
Follow-up visit at 6 months: The visit that is closest to study day 183
o
Follow-up visit at 12 months: The visit that is closest to study day 365 
o
Follow-up visit at 15 months: The visit that is closest to study day 456
o
Follow-up visit at 21 months: The visit that is closest to study day 640 
o
Follow-up visit at 27 months: The visit that is closest to study day 822 
o
Follow-up visit at 33 months: The visit that is closest to study day 1005 
o
Follow-up visit at 39 months: The visit that is closest to study day 1187 
Duration of Disease (year): 
(Date of Informed Consent signed – Date of original Diagnosis +1) / 365.25

Study drug compliance (%): 100 × Total Dose (mg) / Total Prescribed Dose (mg), where total 
dose taken will be calculated as (Dispensed # - Retuned # - Lost #) × 10 mg (refer to CRF IP 
Accountability page (DA domain), and the total prescribed dose is collected at each IP 
accountability CRF (EX domain) 
Treatment emergent Adverse Events (TEAE):  All AEs reported in this study are TEAE 
Formulas of Metric Conversion:  

1 inch = 2.54 cm 

1 lb = 0.4536 kg

 oC = (oF – 32)x5/9 
3.6
Change to Planned Protocol Analysis
Page 9 of 12


Catalyst MSK-003
              Statistical Analysis Plan
In a randomized, placebo-controlled MSK-002 study, amifampridine phosphate was not effective in 
demonstrating a difference over placebo in MG-ADL score change from Day 0 (Baseline) to Day 10.  
Based on the sponsor decision, no statistical analysis will be conducted for the efficacy endpoint, 
change from baseline in MG-ADL score.
4.
OUTPUT PLANNED FOR THE STUDY REPORTS  
4.1
Tables Planned for Interim Reports and Final Study Report
Table
#
Table Title
CSR
DSUR
T01 
Subject Disposition (All subjects) 
X
X
T02 
Demographics and Baseline Data Summary Statistics (Safety Population) 
X
X
T03
Summary of Study Drug Exposure and Compliance (Safety Population) 
X
X
T06 
Number and Percent of Subjects with Treatment Emergent Adverse Events 
(Safety Population) 
X
X
T07 
Summary of Treatment Emergent Adverse Events (Safety Population) 
X
X
T08 
Number and Percent of Subjects with Treatment Emergent Serious Adverse 
Events (Safety Population) 
X
X
T09 
Number and Percent of Subjects with Treatment Emergent Adverse Events by 
Relationship to Treatment (Safety Population) 
X
X
T10 
Number and Percent of Subjects with Treatment Emergent Adverse Events of 
Grade 2 or Higher (Safety Population) 
X
X
T11 
Serum Chemistry Clinical Laboratory Summary Statistics by Visit (Safety 
Population) 
X
T12 
Hematology Clinical Laboratory Summary Statistics by Visit (Safety Population) 
X
T13 
Urinalysis Clinical Laboratory Summary Statistics by Visit (Safety Population) 
X
T14 
Serum Chemistry Shift Table by Visit (Safety Population) 
X
T15 
Hematology Shift Table by Visit (Safety Population) 
X
T16
Urinalysis Shift Table by Visit (Safety Population) 
X
T17 
Vital Sign Parameters Summary Statistics by Visit (Safety Population) 
X
X
T19 
Summary of ECG by Assessment Category and Visit (Safety Population) 
X
T20 
ECG Shift Table by Assessment Category and Visit (Safety Population)
X
T21 
Number and Percent of Subjects Taking Concomitant Medications by ATC Level
3 and Preferred Term (Safety Population) 
X
4.2
Listings Planned for Interim Reports and Final Study Report
Listing #                         Data Listing Title
CSR
DSUR
DL01 
Subject Disposition Data Listing 
X
X
DL02 
Protocol Deviations Data Listing 
X
DL03 
Demographics Data Listing 
X
DL05 
Prior and Concomitant Medications Data Listing 
X
DL06a 
Adverse Events Data Listing 
X
X
DL06b
Serious Adverse Events Data Listing
X
DL06c
Adverse Events with Grade 3 or Higher Data Listing
X
DL06d
Adverse Events Leading to Study Discontinuation
X
DL07 
Physical Exam Data Listing 
X
DL08 
Vital Signs Data Listing 
X
X
DL09 
ECG Data Listing 
X
DL10 
Study Drug Administration Data Listing 
X
Page 10 of 12


Catalyst MSK-003
              Statistical Analysis Plan
DL11 
Serum Chemistry Data Listing 
X
X
DL12 
Hematology Data Listing 
X
X
DL13 
Urinalysis Data Listing 
X
X
DL15
Pregnancy Test Data Listing
X
5.
REFERENCES
Protocol MSK-003:  Long Term Safety Study of Amifampridine Phosphate in Patients with MuSK 
Antibody Positive and AChR Antibody Positive Myasthenia Gravis Patients, amendment to Final 
v1.0, Catalyst Pharmaceuticals, Inc.  February 07, 2020
6.
ATTACHMENT: THE SHELLS OF TABLES AND LISTINGS PLANNED FOR INTERIM AND 
FINAL STUDY REPORTS
Page 11 of 12


Statistical Analysis Plan
Study:  Catalyst MSK-003
Approval for 
Statistical Analysis Plan
Title:
Long Term Safety Study of Amifampridine Phosphate in Patients 
with MuSK Antibody Positive and AChR Antibody Positive 
Myasthenia Gravis Patients
Reference:
MSK-003/SAP
Version:
2.0
Date effective:
Author:  
Dion Chen, PhD. 
Author’s signature:
Date:
The above Statistical Analysis Plan has been reviewed and approved by the Sponsor:
Name of 
Reviewer/Approver
Gary Ingenito, MD
Position: 
Chief Medical Officer, Catalyst Pharmaceuticals, Inc.
Signature for 
sponsor:
Date:
Name of 
Reviewer/Approver
Position:
Signature for 
sponsor:
Date:
Page 12 of 12
02/22/2023
02/22/2023


TRANSACTION DETAILS
DOCUMENT DETAILS
Reference Number
45C4E3D9-2459-4FEA-B536-81619B53E0C6
Transaction Type
Signature Request
Sent At
02/22/2023 10:18 EST
Executed At
02/22/2023 10:30 EST
Identity Method
email
Distribution Method
email
Signed Checksum
1dcc282be45f0db05a5584a9f449306e67af6845f4e7651c45a81e9a96b32900
Signer Sequencing
Disabled
Document Passcode
Disabled
Document Name
Catalyst Msk-003 Sap Final V2 0 21feb2023
Filename
catalyst_msk-003_sap_final_v2_0_21feb2023.docx
Pages
12 pages
Content Type
application/vnd.openxmlformats-officedocument.wordprocessingml.document
File Size
105 KB
Original Checksum
03b1ca951190c7e72b358f2e64cd8eb4ba2e77139d1e977063465d529da2196c
S I G N E R S
SIGNER
E-SIGNATURE
EVENTS
Name
Gary Ingenito
Email
gingenito@catalystpharma.com
Components
2
Status
signed
Multi-factor Digital Fingerprint Checksum
fb88e3f64e9136be440d66a4822988c6de2a364ef501e563e56ec1ad096165aa
IP Address
75.117.53.12
Device
Microsoft Edge via Windows
Typed Signature
Signature Reference ID
0D6FF0A4
Viewed At
02/22/2023 10:29 EST
Identity Authenticated At
02/22/2023 10:30 EST
Signed At
02/22/2023 10:30 EST
Name
Dion Chen
Email
dion.chen@peachtreebrs.com
Components
2
Status
signed
Multi-factor Digital Fingerprint Checksum
785d3e0ff5d97f1b4e4e673eeb2091cb9591501115601728ac85d4e3c4e0be71
IP Address
108.29.20.213
Device
Chrome via Windows
Typed Signature
Signature Reference ID
58FE9908
Viewed At
02/22/2023 10:18 EST
Identity Authenticated At
02/22/2023 10:19 EST
Signed At
02/22/2023 10:19 EST
A U D I T S
TIMESTAMP
AUDIT
02/22/2023 10:18 EST
Dion Chen (dion.chen@peachtreebrs.com) created document 'catalyst_msk-
S I G N A T U R E  C E R T I F I C A T E
R E F E R E N C E  N U M B E R
45C4E3D9-2459-4FEA-B536-81619B53E0C6


003_sap_final_v2_0_21feb2023.docx' on Chrome via Windows from 108.29.20.213.
02/22/2023 10:18 EST
Gary Ingenito (gingenito@catalystpharma.com) was emailed a link to sign.
02/22/2023 10:18 EST
Dion Chen (dion.chen@peachtreebrs.com) was emailed a reminder.
02/22/2023 10:18 EST
Dion Chen (dion.chen@peachtreebrs.com) viewed the document on Chrome via Windows from
108.29.20.213.
02/22/2023 10:19 EST
Dion Chen (dion.chen@peachtreebrs.com) authenticated via email on Chrome via Windows from
108.29.20.213.
02/22/2023 10:19 EST
Dion Chen (dion.chen@peachtreebrs.com) signed the document on Chrome via Windows from
108.29.20.213.
02/22/2023 10:29 EST
Gary Ingenito (gingenito@catalystpharma.com) viewed the document on Microsoft Edge via
Windows from 75.117.53.12.
02/22/2023 10:30 EST
Gary Ingenito (gingenito@catalystpharma.com) authenticated via email on Microsoft Edge via
Windows from 75.117.53.12.
02/22/2023 10:30 EST
Gary Ingenito (gingenito@catalystpharma.com) signed the document on Microsoft Edge via
Windows from 75.117.53.12.

SAP_003.pdf: 


 
 
Statistical Analysis Plan (SAP) 
 
 
Study No. MSK-003 
 
 
 
Long Term Safety Study of Amifampridine Phosphate in 
Patients with MuSK Antibody Positive and AChR Antibody 
Positive Myasthenia Gravis Patients 
 
 
Version 1.0 
 
 
October 15, 2021 
 
 
Prepared for 
Catalyst Pharmaceuticals, Inc. 
355 Alhambra Circle, Suite 1250 
Coral Gables, FL 33134 
 
 
 
Prepared by 
STATKING Clinical Services 
759 Wessel Drive 
Fairfield, OH  45014 
513-858-2989 
www.statkingclinical.com 
 
 




Statistical Analysis Plan 
 
MSK-003 
 
 
Page 3 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
Revision History 
 
N/A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 4 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
Table of Contents 
 
1.0  SYNOPSIS OF STUDY DESIGN PROCEDURES ...................................... 6 
1.1 Design and Treatment ........................................................................................................................ 6 
1.2 Study Procedures ................................................................................................................................ 7 
1.3 Sample Size .......................................................................................................................................... 8 
2.0  DATA ANALYSIS CONSIDERATIONS ...................................................... 8 
2.1 Types of Analyses ................................................................................................................................ 8 
2.2 Analysis Populations ........................................................................................................................... 8 
2.3 Missing Data Conventions .................................................................................................................. 9 
2.4 Interim Analyses ................................................................................................................................. 9 
2.5 Study Center Considerations in the Data Analysis .......................................................................... 9 
2.6 Documentation and Other Considerations ....................................................................................... 9 
3.0 ANALYSIS OF BASELINE SUBJECT CHARACTERISTICS ..................... 9 
4.0 ANALYSIS OF EFFICACY ........................................................................ 10 
4.1 Description of Efficacy Variables .....................................................................................................10 
4.2 Analysis of Efficacy Variables ..........................................................................................................10 
5.0  ANALYSIS OF SAFETY ........................................................................... 10 
6.0 OTHER RELEVANT DATA ANALYSES/SUMMARIES ............................ 12 
6.1 Subject Completion ............................................................................................................................12 
6.2 Study Drug Administration and Compliance ..................................................................................12 
6.3 Patient Data Profiles ..........................................................................................................................12 
7.0 LIST OF ANALYSIS TABLES, FIGURES AND LISTINGS ....................... 13 
8.0  REFERENCES .......................................................................................... 15 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 5 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
APPENDIX A – TABLES, FIGURES AND LISTING SPECIFICATIONS ........ 16 
APPENDIX B – TABLE SHELLS .................................................................... 18 
 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 6 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
1.0 Synopsis of Study Design Procedures 
 
This is an open label observational study. The purpose of this study is to evaluate 
the long-term safety and tolerability of amifampridine phosphate in patients with 
muscle-specific receptor tyrosine kinase (MuSK) antibody positive and 
Acetylcholine receptor (AChR) antibody positive myasthenia gravis (MG) 
patients who participated in the MSK-002 study. The objectives of this Phase 3 
study are as follows: 
 
• 
Primary  
o To characterize the long-term safety and tolerability of 
amifampridine phosphate in patients with MG. 
 
• 
Secondary  
o To assess the clinical efficacy of amifampridine phosphate over 
time in patients with MG based on change in Myasthenia Gravis 
Activities of Daily Living Score (MG-ADL). 
 
1.1 Design and Treatment 
 
The study will enroll patients who have completed the MSK-002 study and after 
all final evaluations for that study have been completed, or those who 
demonstrated benefit after completing the dose titration period but failed to meet 
the randomization criteria on Day 0 of MSK-002.  
 
The duration of participation for each patient is expected to be at least 9 months 
as patients may continue in the study until amifampridine is approved by 
Regulatory Agencies or the clinical development of amifampridine is terminated 
for this indication. In addition to amifampridine, patients will continue to receive 
previous concomitant medications, as needed. 
 
After a new informed consent is signed and inclusion / exclusion criteria for the 
current protocol are satisfied, eligible patients will be given the optimal dose and 
dosing schedule that was identified in the Run-in Period from Protocol MSK-002.  
The findings from the physical exam (including vital signs, weight); 12-lead ECG; 
clinical laboratory test results (including pregnancy testing) and any ongoing 
adverse events will be used as the baseline for the Long-Term safety evaluation.  
 
The only efficacy measurement is the MG-ADL which will be completed every 3 
or 6 months. Safety and tolerability assessments will be made every 3 or 6 
months or more frequently at the discretion of the Investigator. The study will 
continue until amifampridine is approved by Regulatory Agencies or until 
development of the product for this indication is halted. The Investigator may alter 
the dose and dosing frequency during the Long-Term Study as well as schedule 
additional clinic visits for any reason.  


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 7 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
 
Patients will be seen in the clinic at the end of Months 3, 6, 9, 12, 15, 21, 27, 33, 
39.  In between the 3-or 6-month visits, patients may also have telephone/video 
contact with the site, or unscheduled visits, if needed. 
 
1.2 Study Procedures 
 
• Start of Long Term Study 
The following procedures are to be performed as scheduled Day 0 and can 
serve as baseline for the Long-Term study. Any procedure not performed for 
MSK-002 protocol needs to be completed for this trial.  
o Informed Consent for MSK-003;  
o Inclusion/Exclusion criteria for the current study must be verified;  
o Standard 12-lead ECG after 5 minutes in the supine position;  
o Complete physical examination including weight;  
o Vital signs (seated position), including SBP, DBP, heart rate, 
respiration, and body temperature; 
o Clinical laboratory tests including hematology, chemistry, and 
urinalysis;  
o Urine pregnancy test in females of childbearing potential only;  
o MG-ADL (use data from Day 0 of MSK-002 for all patients);  
o Adverse Events (AEs);  
o Concomitant medications.  
 
• End of Months 3, 6, 9, 12, 15, 21, 27, 33 and 39 
The following assessments and procedures will be determined at the end of 
Months 3, 6, 9, 12, 15 and 21, 27, 33 and 39. Each month has a clinic visit 
window of ± 1 week. Additional visits are allowed as necessary.  
o Assessment of AEs/ Serious Adverse Events (SAEs);  
o Complete physical exam with weight;  
o Vital signs (seated position), including SBP, DBP, heart rate, 
respiration, and body temperature;  
o Standard 12-lead ECG after 5 minutes in the supine position;  
o Clinical laboratory tests including hematology, chemistry, and 
urinalysis;  
o Urine pregnancy test in females of childbearing potential only;  
o Concomitant medications;  
o IP accountability of medication;  
o MG-ADL. 
 
• End of Study Visit  
o Month 39 is the last subject visit in the study, and no IP should be 
dispensed at Month 39 visit. End of study assessments and 
procedures listed below should be performed for each subject along 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 8 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
with final IP accountability. This visit may be incorporated at the 
scheduled 3-or 6-month visit.  
o Assessment of AEs/SAEs;  
o Complete physical exam with weight;  
o Vital signs (seated position), including SBP, DBP, heart rate, 
respiration, and body temperature;  
o 12-Lead Electrocardiogram (ECG);  
o Clinical laboratory tests;  
o Urine pregnancy test in females of childbearing potential only;  
o Concomitant medications;  
o MG-ADL. 
   
1.3 Sample Size 
 
The study is not powered with respect to any endpoint but is an observational 
study to assess long term safety and lack of tolerance to the effects of 
amifampridine on MG-ADL. 
 
 
2.0 Data Analysis Considerations 
 
2.1 Types of Analyses 
 
The following standards will be applied for the analyses unless otherwise 
specified. Simple summary statistics (descriptive statistics) for continuous data 
are: n (number of non-missing observations), mean, median, standard deviation, 
minimum, and maximum. The frequency count and percentage will be used to 
summarize categorical data. Summary statistics will be presented by treatment. 
All data collected will be presented in the by-subject data listings, sorted by 
subject and by time point, where appropriate.    
 
2.2 Analysis Populations 
 
The following analysis populations will be defined:  
Safety Population: The safety population will consist of all subjects who are 
enrolled in the study and have received at least one dose of amifampridine. 
Full Analysis Set (FAS), Intent to Treat Population: This population consists 
of all subjects who receive at least 1 dose of IP (amifampridine) and have at least 
one post-treatment efficacy assessment. 
The FAS population will be the primary data set for all effectiveness analyses. 
The Safety population will be used to analyze all safety variables and baseline 
characteristics. 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 9 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
2.2.1 Subgroup Definitions 
 
Subgroup analyses for safety will be performed independently on the MuSK-MG 
and AChR-MG groups. No pooled analyses are planned.   
 
2.3 Missing Data Conventions 
 
No missing value imputation will be used. That is, all analyses will be based on 
the observed data (i.e., complete case analysis). 
    
2.4 Interim Analyses 
     
There are no interim analyses planned for this study.  
   
2.5 Study Center Considerations in the Data Analysis 
 
A study center is defined as a treatment administration site or group of treatment 
administration sites under the control and supervision of the same Principal 
Investigator (PI). 
 
There will be no selective pooling of study centers in the analysis.  All calculations 
will be made on the combined results of all centers. 
 
2.6 Documentation and Other Considerations 
 
The data analyses will be conducted using SAS® Software, version 9.4 or later. 
 
All SAS code used to generate SDTM and ADaM datasets and the final tables 
and listings will be provided. 
 
3.0 Analysis of Baseline Subject Characteristics 
 
Baseline and demographic characteristics will be summarized by MG type and 
overall for all subjects in the safety population.  Age and baseline height and 
weight will be displayed via summary statistics (mean, median, sample size, 
standard deviation, minimum, and maximum).  Gender and ethnicity will be 
summarized via counts and percentages. 
    
A detailed listing of demographics data for each subject will also be provided as 
shown in Appendix B. 
 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 10 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
4.0 Analysis of Efficacy 
 
4.1 Description of Efficacy Variables 
 
For this study the efficacy endpoints are secondary endpoints. The efficacy 
variable is the MG-ADL score at months 3, 6, 9, 12, 15, 21, 27, 33 and 39. 
 
4.2 Analysis of Efficacy Variables 
 
4.2.1 Secondary Efficacy Analysis 
 
Summary statistics (n, mean, standard deviation, minimum, median and 
maximum) for the MG-ADL score at Months 3, 6, 9, 12, 15, 21, 27, 33 39, and 
change from baseline (Day 0 of MSK-002 for all patients) will be presented  
 
All secondary efficacy data will be listed as shown in Appendix B. 
     
5.0 Analysis of Safety  
 
For this study, the primary endpoint is safety and tolerability of amifampridine at 
Months 3, 6, 9, 12, 15 and 21, 27, 33 and 39. 
 
The safety variables for this study are: 
• AEs 
• Vital signs  
• Physical examination 
• ECG 
• Clinical laboratory results 
• Concomitant medications 
 
Adverse Events 
All AEs will be observed for each subject from enrollment until termination from 
the study. Prior to analysis, all AEs will be coded using Medical Dictionary for 
Regulatory Activities (MedDRA). Based on these coded terms, treatment 
emergent AEs (TEAEs) will be summarized using system organ class and 
preferred term by MG type and overall for all subjects in the safety population.  
This analysis will be repeated for serious TEAEs (TESAEs). 
TEAEs will also be summarized by severity and relationship to IP.  An overall 
summary table will provide the highest relationship and maximum severity 
observed per subject, as well as the counts of subjects with at least one TESAE. 
All AEs will be listed, regardless of whether or not they were treatment emergent.      


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 11 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
Vital Signs 
Summary statistics (mean, median, sample size, standard deviation, minimum, 
and maximum) will be computed on the raw and change from baseline values for 
each vital sign parameter by time point, for each MG type.  The screening time 
point will serve as baseline.  If there are multiple vital signs taken at any time 
point, then the latest set of vital signs will be used for the analysis.  All vital sign 
data will be listed. 
Physical Exam 
A shift table of physical exam results will be created showing the shifts in results 
by parameter relative to the normal ranges.  The number and percentage of 
subjects with the following shifts will be presented: normal/normal, normal/low, 
normal/high, low/low, low/normal, low/high, high/low, high/normal, and high/high. 
The physical exam data collected at screening, or termination from the study will 
be listed. 
 
Electrocardiogram 
A table containing descriptive statistics for QTc values measured at screening, 
or termination from the study and CFB by MG type will be created. A shift table 
showing 
normal/normal, 
normal/abnormal, 
abnormal/normal 
and 
abnormal/abnormal shifts as counts and percentages will be created.  The ECG 
data collected will be listed. 
Clinical Laboratory Results 
Tables containing descriptive statistics for serum chemistry, hematology and 
urinalysis values measured at screening (pre-treatment level, the baseline 
value), or termination from the study and Change From Screen Level (CFS) by 
MG type will be created. In addition, a shift table will be constructed to show the 
shifts in laboratory results by parameter relative to the normal ranges.  The 
number and percentage of subjects with the following shifts will be presented: 
normal/normal, normal/low, normal/high, low/low, low/normal, low/high, high/low, 
high/normal, and high/high. 
Concomitant Medications 
A table of the WHO-coded medications will be constructed by MG type group 
and overall with medications summarized by anatomical therapeutic chemical 
(ATC) level 3 term and preferred term.  The number and percent of subjects on 
each drug will be summarized.  A data listing for all concomitant medications will 
be provided. 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 12 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
6.0 Other Relevant Data Analyses/Summaries 
 
6.1 Subject Completion 
 
A table will be constructed with counts of screen failures and enrolled subjects.  
Of those enrolled, counts and percentages of the number of subjects withdrawing 
from the study before study completion and the number completing the study will 
be displayed.  For those subjects that withdraw before completion of the study, 
counts and percentages of the reasons for withdrawal will be tabulated.  The 
table will include summary counts and percentages by MG type.  A data listing 
of all subject completion and withdrawal data will also be constructed. 
6.2 Study Drug Administration and Compliance 
 
Duration of treatment administration will be computed per subject as: 
 
Duration (in days) = (Date of last dose) – (Date of randomization) + 1 
 
Duration will be summarized using descriptive statistics by treatment group. 
 
Compliance will be computed per subject as: 
 
Compliance = 100%*(Number consumed)/(Number prescribed), 
 
where number prescribed is defined as the duration times the number of tablets 
to have been taken daily.  Compliance will be summarized using descriptive 
statistics by MG type. 
 
6.3 Patient Data Profiles 
 
A Patient Data Profile listing will be provided. It will contain demographic 
information, randomization information, all endpoint assessments and laboratory 
measurements. See Appendix B, Data Listing 18 for full details. Some variation 
in the appearance of this table is acceptable to accommodate unformatted SAS® 
output provided that all information is present. 
 
 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 13 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
7.0 List of Analysis Tables, Figures and Listings 
 
 
Table 
No. 
 
 
Table Title 
Included 
in Final 
Tables 
 
Shown in 
Appendix B 
 
 
 
 
1 
Subject Disposition (All subjects) 
X 
X 
2 
Demographics and Baseline Data Summary Statistics – 
Continuous Variables (Safety Population) 
X 
X 
3 
Demographics and Baseline Data Summary Statistics – 
Categorical Variables (Safety Population) 
X 
X 
4 
Summary of Study Drug Administration and Compliance 
(Safety Population) 
X 
X 
5 
MG-ADL Total Score Summary Statistics by Time Point 
and MG Type (FAS Population) 
X 
X 
6 
Number and Percent of Subjects with Treatment 
Emergent Adverse Events (Safety Population) 
X 
X 
7 
Summary of Treatment Emergent Adverse Events 
(Safety Population) 
X 
X 
8 
Number and Percent of Subjects with Treatment 
Emergent Serious Adverse Events (Safety Population) 
X 
X 
9 
Number and Percent of Subjects with Treatment 
Emergent Adverse Events by Relationship to MG Type 
(Safety Population) 
X 
X 
10 
Number and Percent of Subjects with Treatment 
Emergent Adverse Events by Severity Grade (Safety 
Population) 
X 
X 
11 
ECG Shift Summary Statistics by MG Type (Safety 
Population) 
X 
X 
12 
ECG QTc Interval Summary Statistics by Time Point 
and MG Type (Safety Population) 
X 
X 
13 
Serum Chemistry Clinical Laboratory Summary 
Statistics by Time Point and MG Type (Safety 
Population) 
X 
X 
14 
Hematology Clinical Laboratory Summary Statistics by 
Time Point and MG Type (Safety Population) 
X 
 
15 
Urinalysis Clinical Laboratory Summary Statistics by 
Time Point and MG Type (Safety Population) 
X 
 
16 
Serum Chemistry Shift Table by MG Type (Safety 
Population) 
X 
X 
17 
Hematology Shift Table by MG Type (Safety Population) 
X 
 
18 
Urinalysis Shift Table by MG Type (Safety Population) 
X 
 
19 
Vital Sign Parameters Summary Statistics by MG Type 
(Safety Population) 
X 
X 
20 
Vital Signs Shift Table by MG Type (Safety Population) 
X 
X 
21 
Number and Percent of Subjects Taking Concomitant 
Medications by ATC Level 3 and Preferred Term (Safety 
Population) 
X 
X 
 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 14 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
 
Listing 
No. 
 
 
Data Listing Title 
Included 
in Final 
Listings 
 
Shown in 
Appendix B 
 
 
 
 
DL1 
Subject Disposition Data Listing 
X 
X 
DL2 
Protocol Deviations Data Listing 
X 
X 
DL3 
Demographics Data Listing   
X 
X 
DL4 
Subjects Excluded from FAS Population Data Listing 
X 
X 
DL5 
Subjects Excluded from PP Population Data Listing 
X 
X 
DL6 
Medical History Data Listing 
X 
X 
DL7 
Prior and Concomitant Medications Data Listing 
X 
X 
DL8 
Adverse Events Data Listing 
X 
X 
DL9 
Physical Exam Data Listing 
X 
X 
DL10 
Vital Signs Data Listing 
X 
X 
DL11 
ECG Data Listing 
X 
X 
DL12 
Study Drug Administration Data Listing  
X 
X 
DL13 
Serum Chemistry Data Listing 
X 
X 
DL14 
Hematology Data Listing 
X 
X 
DL15 
Urinalysis Data Listing 
X 
X 
DL16 
Amifampridine Level Data Listing 
X 
X 
DL17 
MG-Activities of Daily Living Data Listing  
X 
X 
DL18 
Subject Data Profile 
X 
X 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 15 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
8.0  References 
 
NA 
 
 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 16 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
Appendix A – Tables, Figures and Listing Specifications 
 
Orientation 
 
Tables, figures, and listings will be displayed in landscape with the exception of 
the Patient Data Profile Listing (DL18), which will be in portrait layout.  
 
Margins  
 
Margins will be 1 inch on all sides.  Table, figure, and listing boundaries will not 
extend into the margins. 
 
Font 
 
Courier New, 8 point. 
 
Headers 
 
The table number will be on the second line of the title area.  The title area will 
contain the Sponsor name, the study number, and the name of the table.  The 
title area will contain the page number (Page x of y) on the far right, one line 
above the name of the table. 
 
Footers 
 
- The first line will be a solid line. 
- Next will be any footnotes regarding information displayed in the table. 
- Below these footnotes will be displayed “STATKING Clinical Services (Date)” 
on the far left. 
- The last line will display the name of the SAS program that generated the 
table and (if applicable) the source data reference. 
 
Table Disclaimer 
 
The format of the mock tables shown in the appendix of this Statistical Analysis 
Plan (SAP) will be the format of the deliverable tables to the extent that Word 
document constructed tables can match production tables produced by SAS.  
This formatting includes the content and format of the header and footer areas 
of the tables.  The Sponsor agrees to the format of the tables as shown in the 
appendix. 
 
Further programming charges will be applicable for changes in the format of 
tables (including title statements, notes, data dependent footnotes, etc.) made 
after the approval of the SAP. 


Statistical Analysis Plan 
 
MSK-003 
 
 
Page 17 of 59 
STATKING Clinical Services                                                    Catalyst Pharmaceuticals, Inc. 
Version 1.0                                                                                                        October 15, 2021 
 
                                                                                                           
 
Missing Values 
 
All missing values will be displayed on the output tables/listings as blanks. 
 
Computation Values for Study Dates 
 
The date format to be used is dd-mmm-yyyy.  Missing parts of dates are not 
shown (e.g., for a missing day value, the value displayed is in mmm-yyyy 
format).  When date computations are necessary, the following table indicates 
the substitutions used in order to make those computations. 
 
Scenario 
Value Used for Computations 
Start date – Missing month and day values  
January 1 of the indicated year 
Start date – Missing day values  
The first day of the indicated month 
Stop date – Missing month and day values  
December 31 of the indicated year 
Stop date – Missing day values  
The last day of the indicated month 
 
 
  
 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 18 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
Appendix B – Table Shells  
 
 
 
 
 
 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 19 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
   Page x of y 
 
Table 1. Subject Disposition (All subjects) 
 
 
Catalyst Pharmaceuticals, Inc. – MSK-003 
 
 
 
 
 
 
 
            
 
 
 
 
 
 
 
MuSK 
AChR 
 
Overall 
Screen Failures 
 
 
 
xx 
 
 
 
 
 
Enrolled 
 
xx 
xx 
xx 
 
 
 
 
 
Completed 
 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
 
 
 
 
Withdrawn  
 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
 
 
 
 
Reason for Withdrawal 
Adverse Event 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
Lost To Follow-Up 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
Death 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
Physician Decision 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
Protocol Deviation 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
Study Terminated by Sponsor 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
Withdrawal by Subject 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
Other 
xx (xxx%) 
xx (xxx%) 
xx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
The denominator for all percentages in the table is the number of enrolled subjects in the respective MG treatment group and overall. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 1 


Statistical Analysis Plan 
MSK-003 
 
 
Page 20 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 2. Demographics and Baseline Data Summary Statistics – Continuous Variables 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
             
 
Variable 
 
MG Type 
 
Mean 
 
Std Dev 
 
n 
 
Min 
 
Max 
 
Median 
 
 
 
 
 
 
 
 
Age (years) 
MuSK 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
AChR 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Overall 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Baseline Weight (kg) 
MuSK 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
AChR 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Overall 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Baseline Height (cm) 
MuSK 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
AChR 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Overall 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 3 


Statistical Analysis Plan 
MSK-003 
 
 
Page 21 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 3. Demographics and Baseline Data Summary Statistics – Categorical Variables 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
                   
 
Demographics 
Variable 
 
 
Category 
 
MuSK 
(N=xxx) 
 
AChR 
(N=xxx) 
 
Overall 
(N=xxx) 
 
 
 
 
 
Gender 
Male 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
Female 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
Ethnicity 
Hispanic or Latino 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
Not Hispanic or Latino 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 3 


Statistical Analysis Plan 
MSK-003 
 
 
Page 22 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 4. Summary of Study Drug Administration and Compliance 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
           
 
 
 
Statistic 
 
 
MuSK 
(N=xxx) 
 
AChR  
(N=xxx) 
 
 
 
 
Duration (days) 
n 
xxx 
xxx 
 
Mean (Std Dev) 
xxx (xxx) 
xxx (xxx) 
 
Median 
xxx 
xxx 
 
Minimum, Maximum 
xxx, xxx 
xxx, xxx 
 
 
 
 
Compliance (%) 
n 
xxx 
xxx 
 
Mean (Std Dev) 
xxx (xxx) 
xxx (xxx) 
 
Median 
xxx 
xxx 
 
Minimum, Maximum 
xxx, xxx 
xxx, xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 12                  


Statistical Analysis Plan 
MSK-003 
 
 
Page 23 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 5. MG-ADL Total Score Summary Statistics by Time Point and MG Type 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
FAS Population (N=xxx) 
 
 
 
Part 1 of 2 
 
 
MG Typea 
Time Pointa 
Data Typeb 
Mean 
Std 
Dev 
n 
Min 
Max 
Median 
 
 
 
 
 
 
 
 
 
MuSK 
Day 0 of MSK-002 
(Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 3  
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 6 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 9 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 12 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 15 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 21 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 27 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 33 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 39 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
a The treatment of MG result will be the result obtained at Months 3, 6, 9, 12, 15, 21, 27, 33 and 39, unless the subject discontinued 
treatment of MG early, in which case the post-treatment result may be obtained at an earlier time point. 
b RAW = observed data entered in the database; CFB = change from baseline.  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 17 


Statistical Analysis Plan 
MSK-003 
 
 
Page 24 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 5. MG-ADL Total Score Summary Statistics by Time Point and MG Type 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
FAS Population (N=xxx) 
 
 
 
Part 2 of 2 
 
                   
 
 
 
MG Typea 
Time Pointa 
Data Typeb 
Mean 
Std 
Dev 
n 
Min 
Max 
Median 
 
 
 
 
 
 
 
 
 
AChR 
Day 0 of MSK-002 
(Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 3  
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 6 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 9 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 12 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 15 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 21 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 27 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 33 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 39 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________________________________________________ 
a The treatment of MG result will be the result obtained at Months 3, 6, 9, 12, 15, 21, 27, 33 and 39, unless the subject discontinued 
treatment of MG early, in which case the post-treatment result may be obtained at an earlier time point. 
b RAW = observed data entered in the database; CFB = change from baseline.  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 17 


Statistical Analysis Plan 
MSK-003 
 
 
Page 25 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 6. Number and Percent of Subjects with Treatment Emergent Adverse Events  
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
Adverse Event Categorya: 
MuSK  
(N=xxx) 
AChR  
(N=xxx) 
 
 
 
Total Number of Treatment Emergent Adverse 
Events (TEAEs) 
xxx 
xxx 
 
 
 
Subjects with at Least One TEAE 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
  System Organ Class 1 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
  System Organ Class 2 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version XXX. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 8 


Statistical Analysis Plan 
MSK-003 
 
 
Page 26 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 7. Summary of Treatment Emergent Adverse Events  
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxxx) 
 
 
 
 
 
MuSK  
(N=xxx) 
AChR  
(N=xxx) 
 
 
 
Subjects with at Least One Treatment Emergent Adverse Event 
(TEAE) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
Maximum TEAE Severity Grade  
 
 
    Mild (Grade 1) 
xxx (xxx%) 
xxx (xxx%) 
    Moderate (Grade 2) 
xxx (xxx%) 
xxx (xxx%) 
    Severe (Grade 3) 
xxx (xxx%) 
xxx (xxx%) 
    Life-threatening (Grade 4) 
xxx (xxx%) 
xxx (xxx%) 
    Death (Grade 5) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
Highest Relationship of TEAE to Treatment 
 
 
    Not Related  
xxx (xxx%) 
xxx (xxx%) 
    Possibly 
xxx (xxx%) 
xxx (xxx%) 
    Probably  
xxx (xxx%) 
xxx (xxx%) 
 
 
 
Subjects with at Least One Serious TEAE 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 8 


Statistical Analysis Plan 
MSK-003 
 
 
Page 27 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 8. Number and Percent of Subjects with Treatment Emergent Serious Adverse Events  
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
Adverse Event Categorya: 
MuSK 
N=xxx) 
AChR  
(N=xxx) 
 
 
 
Total Number of Serious Treatment Emergent 
Adverse Events (TESAEs) 
xxx 
xxx 
 
 
 
Subjects with at Least One TESAE 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
  System Organ Class 1 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
  System Organ Class 2 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version XXX. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 8 


Statistical Analysis Plan 
MSK-003 
 
 
Page 28 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 9. Number and Percent of Subjects with Treatment Emergent Adverse Events  
by Relationship to MG Type 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
MuSK  
(N=xxx) 
AChR  
(N=xxx) 
 
Adverse Event Categorya: 
Not Related 
Possibly 
Probably 
Not Related 
Possibly 
Probably 
 
 
 
 
 
 
 
Total Number of Treatment Emergent Adverse 
Events (TEAEs) 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
Subjects with at Least One TEAE 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
  System Organ Class 1 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
  System Organ Class 2 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version XXX. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 8 


Statistical Analysis Plan 
MSK-003 
 
 
Page 29 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
Page x of y 
Table 10. Number and Percent of Subjects with Treatment Emergent Adverse Events by Severity Grade  
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
Safety Population (N=xxx) 
 
 
 
 
Part 1 of 2 
 
 
 
MuSK  
(N=xxx) 
 
Adverse Event Categorya: 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
 
 
 
 
 
 
Total Number of Treatment Emergent 
Adverse Events (TEAEs) 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
Subjects with at Least One TEAE 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
 
 
 
 
 
 
  System Organ Class 1 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
 
 
 
 
 
 
  System Organ Class 2 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version XXX. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 8 


Statistical Analysis Plan 
MSK-003 
 
 
Page 30 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 10. Number and Percent of Subjects with Treatment Emergent Adverse Events by Severity Grade  
 
 
Catalyst Pharmaceuticals, Inc. - MSK-002 
 
 
Safety Population (N=xxx) 
 
 
 
Part 2 of 2 
 
 
 
AChR  
(N=xxx) 
 
Adverse Event Categorya: 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
 
 
 
 
 
 
Total Number of Treatment Emergent 
Adverse Events (TEAEs) 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
Subjects with at Least One TEAE 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
 
 
 
 
 
 
  System Organ Class 1 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
 
 
 
 
 
 
  System Organ Class 2 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 1 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
    Preferred Term 2 
xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version XXX. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 8 


Statistical Analysis Plan 
MSK-003 
 
 
Page 31 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 11. ECG Shift Summary Statistics by MG Type 
 
 
Catalyst Pharmaceuticals, Inc. MuSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
MG Type 
 
 
Screening (Baseline) 
Normal/ 
End of Studya Normal 
 
 
Screening (Baseline) 
Normal/ 
End of Studya Abnormal 
 
 
Screening (Baseline) 
Abnormal/ 
End of Studya Normal 
 
 
Screening (Baseline) 
Normal/ 
End of Studya Abnormal 
 
 
 
 
 
MuSK (N=xxx) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
AChR (N=xxx) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________________________________________________________________________________  
a End of study is at least 9 months (i.e. until amifampridine is approved by Regulatory Agencies for the treatment of MG or the 
development program is discontinued for this indication).  
STATKING Clinical Services (month day, year) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 11 


Statistical Analysis Plan 
MSK-003 
 
 
Page 32 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Table 12. ECG QTc Interval Summary Statistics  
By Time Point and MG Type 
Page x of y 
 
Catalyst Pharmaceuticals, Inc. MuSK-003 
Safety Population (N=xxx) 
 
Part 1 of 2 
 
 
 
 
 
 
 
 
 
 
                       
 
 
 
MG Type 
 
 
 
Visit 
 
 
Data 
Typea 
 
 
 
n 
 
 
Mean 
(msec) 
 
 
Std 
Dev 
 
 
 
Min 
 
 
 
Median 
 
 
 
Max 
 
 
 
 
 
 
 
 
 
MuSK 
Screening (Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
Month 3  
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 6 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 9 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 12 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 15 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 21 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 27 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 33 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 39 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________  
a CFB refers to Change from Baseline (Screening ECG). 
STATKING Clinical Services (month day, year) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 11 


Statistical Analysis Plan 
MSK-003 
 
 
Page 33 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Table 19. ECG QTc Interval Summary Statistics  
By Time Point and MG Type 
Page x of y 
 
Catalyst Pharmaceuticals, Inc. MuSK-003 
Safety Population (N=xxx) 
 
Part 2 of 2 
 
 
 
 
 
 
 
 
 
 
                       
 
 
 
MG Type 
 
 
 
Visit 
 
 
Data 
Typea 
 
 
 
n 
 
 
Mean 
(msec) 
 
 
Std 
Dev 
 
 
 
Min 
 
 
 
Median 
 
 
 
Max 
 
 
 
 
 
 
 
 
 
AChR 
Screening (Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
Month 3  
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 6 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 9 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 12 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 15 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 21 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 27 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 33 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
Month 39 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________  
a CFB refers to Change from Baseline (Screening ECG). 
STATKING Clinical Services (month day, year) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 11 


Statistical Analysis Plan 
MSK-003 
 
 
Page 34 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Table 13.  Serum Chemistry Clinical Laboratory Summary Statistics  
by Time Point and MG Type 
Page x of y 
Catalyst Pharmaceuticals, Inc. MuSK-003 
Safety Population (N=xxx) 
 
 
 
Laboratory Panel: Serum Chemistry 
 
 
 
 
 
 
                       
 
Parameter 
 
MG Type 
 
Visit 
 
Data 
Typea 
 
 
n 
 
 
Mean 
 
Std 
Dev 
 
 
Min 
 
 
Median 
 
 
Max 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxxxxxxxxxxx 
MuSK 
Screening (Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
End of study 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxxxxxxxxxxx 
AChR 
Screening (Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
End of study 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________  
a CFB refers to Change from Baseline (Screening sample). 
STATKING Clinical Services (month day, year) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 13 
The format of this table is repeated for hematology and urinalysis panels. 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 35 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 16. Serum Chemistry Shift Table by MG Type 
 
 
Catalyst Pharmaceuticals, Inc. MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
Lab Parameter 
 
 
 
 
 
MG Type 
 
 
 
 
Low/ 
Low 
 
 
 
 
Low/ 
Normal 
 
 
 
 
Low/ 
High 
 
 
 
 
Normal/ 
Low 
 
 
 
 
Normal/ 
Normal 
 
 
 
 
Normal/ 
High 
 
 
 
 
High/ 
Low 
 
 
 
 
High/ 
Normal 
 
 
 
 
High/ 
High 
 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxx 
MuSK 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxx 
AChR 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________________________________________________________________________________  
a Shifts represent screening/end of study, where end of study is least 9 months (i.e. until amifampridine is approved by Regulatory 
Agencies for the treatment of MG or the development program is discontinued for this indication). 
STATKING Clinical Services (month day, year) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 13 
Table repeats for hematology and urinalysis panels. 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 36 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 19.  Vital Signs Parameters Summary Statistics by MG Type 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
Part 1 of 2 
 
 
 
 
 
 
 
Vital Sign Parameter (units) 
MG Type 
Visit  
Data Typea 
n 
Mean 
Std 
Dev 
Min 
Max 
Median 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxx (xxx) 
MuSK 
Screening (Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
Month 3  
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 6 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 9 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 12 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 15 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 21 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 27 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 33 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 39 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________  
a RAW = observed data recorded in database; CFB = change from baseline  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 10 


Statistical Analysis Plan 
MSK-003 
 
 
Page 37 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 19.  Vital Signs Parameters Summary Statistics by MG Type  
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
Part 2 of 2 
 
 
 
 
 
 
 
Vital Sign Parameter (units) 
MG Type 
Visit  
Data Typea 
n 
Mean 
Std 
Dev 
Min 
Max 
Median 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxx (xxx) 
AChR 
Screening (Baseline) 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
Month 3  
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 6 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 9 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 12 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 15 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 21 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 27 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 33 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
Month 39 
RAW 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
CFB 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________  
a RAW = observed data recorded in database; CFB = change from baseline  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 10 


Statistical Analysis Plan 
MSK-003 
 
 
Page 38 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
 
 
 
Table 20. Vital Signs Shift Table by MG Type 
 
 
Catalyst Pharmaceuticals, Inc. MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
Lab Parameter 
 
 
 
 
 
MG Typea 
 
 
 
 
Low/ 
Low 
 
 
 
 
Low/ 
Normal 
 
 
 
 
Low/ 
High 
 
 
 
 
Normal/ 
Low 
 
 
 
 
Normal/ 
Normal 
 
 
 
 
Normal/ 
High 
 
 
 
 
High/ 
Low 
 
 
 
 
High/ 
Normal 
 
 
 
 
High/ 
High 
 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxx 
MuSK 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
xxxxxxxxxx 
AChR 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx 
(xxx%) 
xxx (xxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
___________________________________________________________________________________________________________________________________  
a End of study is least 9 months (i.e. until amifampridine is approved by Regulatory Agencies for the treatment of MG or the 
development program is discontinued for this indication). withdrawal from study, whichever is earlier. 
STATKING Clinical Services (month day, year) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 10 


Statistical Analysis Plan 
MSK-003 
 
 
Page 39 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Table 21. Number and Percent of Subjects Taking Concomitant Medications  
by ATC Level 3 and Preferred Term  
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
Concomitant Medication Categorya,b 
MuSK  
(N=xxx) 
AChR  
(N=xxx) 
Overall 
(N=xxx) 
 
 
 
 
 
 
ATC Level 3 Term 
xxxx (xxxx%) 
xxxx (xxxx%) 
xxxx (xxxx%) 
 
    WHO Preferred Term 
xxxx (xxxx%) 
xxxx (xxxx%) 
xxxx (xxxx%) 
 
    WHO Preferred Term 
xxxx (xxxx%) 
xxxx (xxxx%) 
xxxx (xxxx%) 
 
 
 
 
 
 
ATC Level 3 Term 
xxxx (xxxx%) 
xxxx (xxxx%) 
xxxx (xxxx%) 
 
    WHO Preferred Term 
xxxx (xxxx%) 
xxxx (xxxx%) 
xxxx (xxxx%) 
 
    WHO Preferred Term 
xxxx (xxxx%) 
xxxx (xxxx%) 
xxxx (xxxx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________  
a Concomitant medications coded with WHO Coding Dictionary xxxxxxxxxxxxx. 
b Concomitant medication categories will include anatomical therapeutic chemical (ATC) level 3 term followed by preferred term.  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
Source Listing: Data Listing 7 


Statistical Analysis Plan 
MSK-003 
 
 
Page 40 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 1. Subject Disposition Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
 
 
 
 
 
 
 
 
 
                         
 
                                                                                                                                       
 
 
Subject 
No. 
 
 
MG Type 
 
 
Disposition Status 
 
Date of Disposition 
 
 
Withdrawal Reason 
 
 
 
 
 
xxxx 
xxxxxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxx 
xxxxxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxx 
xxxxxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxx 
xxxxxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 41 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 2. Protocol Deviations Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
 
                         
 
                                                                                                                                       
 
 
 
Subject 
No. 
 
 
MG Type 
 
Date of 
Deviation 
Deviation Description  
 
 
Deviation Major or 
Minor 
 
 
 
 
 
xxxx 
xxxxxx 
xxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 42 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 3. Demographics Data Listing  
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
                        
 
                                                                                                                             
 
 
 
MG Type 
 
 
Subject 
No. 
 
Informed 
Consent 
Date 
 
Date of 
Birth 
 
 
Age 
(yrs) 
 
 
 
Gender 
 
 
 
Ethnicity 
 
Screening 
Weight (kg) 
 
 
 
Height (cm) 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxx 
xxxxxx 
xxxxxx 
xxxxxx 
xxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 43 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 4. Subjects Excluded from FAS Population Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
 
                         
 
                                                                                                                                       
 
 
 
MG Type 
 
 
Subject No. 
 
 
Reason for Exclusion 
 
 
 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 44 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 5. Subjects Excluded from PP Population Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
All Enrolled Subjects (N=xxx) 
 
 
 
 
 
 
 
 
 
 
                         
 
                                                                                                                                       
 
 
 
MG Type 
 
 
Subject No. 
 
 
Reason for Exclusion 
 
 
 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________  
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 45 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 6. Medical History Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
  
 
 
MG Type 
 
 
Subject 
No. 
 
 
 
 
MedDRA System Organ Classa/ 
MedDRA Preferred Term/ 
CRF Verbatim Term 
Start Date  
 
 
 
 
 
 
Ongoing? 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxx 
xxx 
 
 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxx 
xxx 
 
 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxx 
xxx 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
a Medical history terms coded with MedDRA Coding Dictionary Version xxx. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 46 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 7. Prior and Concomitant Medications Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
  
 
MG Type 
 
 
Subject 
No. 
 
 
WHO Preferred Terma/ 
Verbatim Drug Name/ 
Indication/ 
ATC Level 1 Term/ 
ATC Level 3 Term 
 
 
 
 
 
Start 
Date 
 
 
 
 
 
 
Stop 
Date 
 
 
 
 
 
 
Route 
 
 
 
 
 
 
Ongoing? 
 
 
 
 
 
 
 
xxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxx 
xxxxxxx  xxxxx 
xxxxx 
 
 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxx 
xxxxxxx  xxxxx 
xxxxx 
 
 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
a Concomitant medications coded with WHO Coding Dictionary xxxxxxxxx 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 47 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 8. Adverse Events Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
 
 
MG Type 
 
 
Subject 
No. 
Start 
Date and 
Time/ 
End Date 
and Time 
Treatment 
Start Date  
MedDRA System 
Organ Classa/ 
MedDRA Preferred 
Term/ 
CRF Verbatim Term 
Severity 
Grade 
Relation to 
Treatment 
Serious? 
Outcome 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxxxxxxx 
xxxxxxx 
xxxxxxx/ 
xxxxxxx 
xxxxxxx 
xxxxxxx 
xxxxxxx 
xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxx 
xxxxxxxx 
xxxxxxxx 
xxx 
 
xxxxxxxx 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxxxxxxx 
xxxxxxx 
xxxxxxx/ 
xxxxxxx 
xxxxxxx 
xxxxxxx 
xxxxxxx 
xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxx 
xxxxxxxxxxxxxxxxxx 
xxxxxxxx 
xxxxxxxx 
xxx 
 
xxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version xxx. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 48 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 9. Physical Exam Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
  
 
 
MG Type 
 
 
Subject 
No. 
 
 
 
 
 
Visit 
 
 
 
 
Date 
Conducted 
 
 
 
 
 
Body System 
 
 
 
 
 
Result 
 
 
 
 
 
Abnormality 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxx 
xxxxxxx 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxxxxx 
xxxxxxxx 
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 49 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 10. Vital Signs Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
   
 
 
MG Type 
 
 
Subject 
No. 
 
 
 
 
Visit 
 
 
 
 
Date 
 
 
 
 
Time  
 
 
 
Temp. 
(°F) 
 
Systolic 
Blood 
Pressure 
(mmHg) 
Diastolic 
Blood 
Pressure 
(mmHg) 
Heart 
Rate 
(bpm) 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxx 
 
xxxxxxx 
xxxxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
xxxxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
xxxxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxx 
 
xxxxxxx 
xxxxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
xxxxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
xxxxx 
xxx 
xxx 
xxx 
xxx 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 50 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 11. ECG Data Listing 
 
 
Catalyst Pharmaceuticals – MuSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
   
 
 
 
MG Type 
 
 
Subject 
No. 
 
 
 
Age 
 
 
 
Time Point 
 
 
 
Date 
 
 
 
Time  
 
 
Heart  
Rate 
 
 
PR 
Interval 
QRS 
Duration 
QT 
Interval 
 
 
ECG Assessment/ If 
Abnormal, Specify 
 
 
 
 
 
 
 
 
 
 
 
xxxx 
xxxxxx 
xxxx 
  Screen 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
  Month 3 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
  Month 9 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
Month 12 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
Month 15 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
Month 21 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
Month 27 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
Month 33 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
Month 36 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
    
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 51 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 12. Study Drug Administration Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
 
                         
 
 
MG Type 
 
 
Subject 
No. 
Treatment 
Start 
Date  
Treatment 
End Date 
Treatment 
Duration 
(Days) 
Tablets 
Consumed 
 
 
 
 
Dose (mg/day) 
Tablets 
Prescribeda 
 
 
 
 
Compliance (%)b 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxx 
xxxxxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
a Number of tablets prescribed is computed as the duration times the number of tablets to have been taken daily. 
b Compliance is computed as 100%*(number of tablets consumed)/(number of tables prescribed). 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 52 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 13. Serum Chemistry Data Listing 
 
 
Catalyst Pharmaceuticals – MuSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
   
 
 
 
MG Type 
 
 
Subject No. 
 
 
 
Time Point 
 
 
 
Date 
 
 
 
Parameter 
(Units)  
 
 
Value 
 
 
Assessment/ If Abnormal, 
Specify 
 
 
 
 
 
 
 
xxxx 
xxxxxx 
xxxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 53 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 14. Hematology Data Listing 
 
 
Catalyst Pharmaceuticals – MuSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
   
 
 
 
MG Type 
 
 
Subject No. 
 
 
 
Time Point 
 
 
 
Date 
 
 
 
Parameter 
(Units)  
 
 
Value 
 
 
Assessment/ If Abnormal, 
Specify 
 
 
 
 
 
 
 
xxxx 
xxxxxx 
xxxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 54 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 15. Urinalysis Data Listing 
 
 
Catalyst Pharmaceuticals – MuSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
 
   
 
 
 
MG Type 
 
 
Subject No. 
 
 
 
Time Point 
 
 
 
Date 
 
 
 
Parameter 
(Units)  
 
 
Value 
 
 
Assessment/ If Abnormal, 
Specify 
 
 
 
 
 
 
 
xxxx 
xxxxxx 
xxxxxx 
xxxxx 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
 
xxxxx 
xxxxx 
xxxxxxx/ 
xxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
 
 


Statistical Analysis Plan 
MSK-003 
 
 
Page 55 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 16. Amifampridine Levels Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
                         
 
MG Type 
 
 
Subject 
No. 
 
 
 
 
 
 
 
Visit 
 
 
 
 
Date of 
Sample 
 
 
 
Time of 
Sample   
 
 
 
 
Amifampridine Level 
(Units) 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxxx 
xxxxxxxx 
xx:xx 
xxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxxx 
xxxxxxxx 
xx:xx 
xxxxxxxxxxxxxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 56 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
Page x of y 
 
Data Listing 17. MG-Activities of Daily Living Data Listing 
 
 
Catalyst Pharmaceuticals, Inc. - MSK-003 
 
 
Safety Population (N=xxx) 
 
 
 
 
 
 
 
 
                         
 
MG Type 
Subject 
No. 
 
 
Visit 
ADL Score 
Baseline Value 
Change from 
Baseline 
Best-Case Imputed 
Value 
Worst-Case 
Imputed Value 
 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
 
 
 
 
 
 
 
 
xxxxxx 
xxxx 
xxxxxxxx 
xxxx 
xxxx 
xxxx 
xxxx 
xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________________________________________________________________________________________________________ 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 57 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
 
Page x of y 
Data Listing 18. Subject Data Profile  
Catalyst Pharmaceuticals, Inc. - MSK-003 
Safety Population (N=xxx) 
 
Study Number: MSK-003 
Site: xxxxxxxxx 
Subject ID: xxxxx 
 
 
 
 
 
Randomization Code: xxxx 
Treatment: xxxxxx 
Dose: xxxxxx 
Dose Group: xxxx 
Age (yrs): xxxx 
 
Gender: xxxxxx 
Ethnicity: xxxxxxx 
Screening Weight (kg): xxxx 
MG Type: xxxxxxxx 
 
 
 
 
 
 
 
Endpoint Measurements 
 
 
 
Myasthenia Gravis – Activities of Daily Living Scores   
 
 
Visit 
Date 
 
Score 
CFB 
Baseline 
xx-xxx-xxxxx 
Total 
xxxxx 
-- 
Month x 
xx-xxx-xxxx 
Total 
xxxxx 
xxxxx 
 
 
 
 
 
Quantitative Myasthenia Gravis Scores 
 
 
Visit 
Date 
Item 
Score 
CFB 
Baseline 
xx-xxx-xxxxx 
Double Vision Sec. 
xxxxx 
-- 
 
 
Bothersome Ptosis  
xxxxx 
-- 
 
 
Facial Muscles 
xxxxx 
-- 
 
 
Swallowing 
xxxxx 
-- 
 
 
Speech Following Counting From 1-50  
xxxxx 
-- 
 
 
Right Arm Outstretched 
xxxxx 
-- 
 
 
Left Arm Outstretched 
xxxxx 
-- 
 
 
Forced Vital Capacity 
xxxxx 
-- 
 
 
Right Hand Grip (kg) 
xxxxx 
-- 
 
 
Left Hand Grip (kg) 
xxxxx 
-- 
 
 
Head, Lifted  
xxxxx 
-- 
 
 
Right Leg Outstretched 
xxxxx 
-- 
 
 
Left Leg Outstretched 
xxxxx 
-- 
 
 
Limb Total 
xxxxx 
-- 
 
 
Total 
xxxxx 
-- 
Month x 
xx-xxx-xxxxx 
Double Vision Sec. 
xxxxx 
xxxxx 
 
 
Bothersome Ptosis  
xxxxx 
xxxxx 
 
 
Facial Muscles 
xxxxx 
xxxxx 
 
 
Swallowing 
xxxxx 
xxxxx 
 
 
Speech Following Counting From 1-50  
xxxxx 
xxxxx 
 
 
Right Arm Outstretched 
xxxxx 
xxxxx 
 
 
Left Arm Outstretched 
xxxxx 
xxxxx 
 
 
Forced Vital Capacity 
xxxxx 
xxxxx 
 
 
Right Hand Grip (kg) 
xxxxx 
xxxxx 
____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version xxx. 
b Concomitant medications coded with WHO Coding Dictionary xxxxxxxxxxxxx. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 58 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
 
Page x of y 
Data Listing 18. Subject Data Profile  
Catalyst Pharmaceuticals, Inc. - MSK-003 
Safety Population (N=xxx) 
 
Study Number: MSK-003 
Site: xxxxxxxxx 
Subject ID: xxxxx 
Quantitative Myasthenia Gravis Scores 
 
 
Visit 
Date 
Item 
Score 
CFB 
Month x 
xx-xxx-xxxxx 
Left Hand Grip (kg) 
xxxxx 
xxxxx 
 
 
Head, Lifted  
xxxxx 
xxxxx 
 
 
Right Leg Outstretched 
xxxxx 
xxxxx 
 
 
Limb Total 
xxxxx 
xxxxx 
 
 
Total 
xxxxx 
xxxxx 
 
 
 
 
 
Safety Measurements 
 
 
 
Laboratory Values 
 
 
 
Visit 
Date 
Parameter (units) 
Result 
Abnormal Criterion 
Baseline 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
Month x 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
 
 
 
Electrocardiogram Values 
 
 
 
Visit 
Date 
Parameter (units) 
Result 
Abnormal Criterion 
Baseline 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
Month x 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
 
 
 
Vital Sign Values 
 
 
 
Visit 
Date 
Parameter (units) 
Result 
Abnormal Criterion 
Baseline 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
____________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version xxx. 
b Concomitant medications coded with WHO Coding Dictionary xxxxxxxxxxxxx. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 


Statistical Analysis Plan 
MSK-003 
 
 
Page 59 of 59 
STATKING Clinical Services    
Version 1.0 
Catalyst Pharmaceuticals, Inc. 
October 15, 2021 
 
 
 
 
Page x of y 
Data Listing 18. Subject Data Profile  
Catalyst Pharmaceuticals, Inc. - MSK-003 
Safety Population (N=xxx) 
 
Study Number: MSK-003 
Site: xxxxxxxxx 
Subject ID: xxxxx 
 
 
 
 
 
 
 
 
 
 
Vital Sign Values 
 
 
 
Visit 
Date 
Parameter (units) 
Result 
Abnormal Criterion 
Month x 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
Month x 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
xxxxxxxxxxxxxxxxxxxx 
xxxx 
 
 
 
 
 
 
Adverse Events 
 
 
 
 
Preferred Term 
Date 
System Organ Class 
Severity 
Treatment Related? 
xxxxxxxxxxx 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxx 
 
xxxxxxxxxxx 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxx 
xxxxxxxxxxx 
xxxxxxxxxxx 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxx 
xxxxxxxxxxx 
xxxxxxxxxxx 
xx-xxx-xxxx 
xxxxxxxxxxxxxxxxxxxxxx 
xxxx 
xxxxxxxxxxx 
 
 
 
 
 
 
 
 
 
 
Concomitant Medications 
 
 
 
Preferred Term 
Dose (units, freq) 
Start Date 
Stop Date 
 
xxxxxxx 
xxxxx (xxxx, xxxx) 
xx-xxx-xxxx 
xx-xxx-xxxx 
 
xxxxxxx 
xxxxx (xxxx, xxxx) 
xx-xxx-xxxx 
xx-xxx-xxxx 
 
xxxxxxx 
xxxxx (xxxx, xxxx) 
xx-xxx-xxxx 
xx-xxx-xxxx 
 
xxxxxxx 
xxxxx (xxxx, xxxx) 
xx-xxx-xxxx 
xx-xxx-xxxx 
 
xxxxxxx 
xxxxx (xxxx, xxxx) 
xx-xxx-xxxx 
xx-xxx-xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
______________________________________________________________________________________________________________________________________ 
a Adverse events coded with MedDRA Coding Dictionary Version xxx. 
b Concomitant medications coded with WHO Coding Dictionary xxxxxxxxxxxxx. 
STATKING Clinical Services (DD-MMM-YYYY) 
Source Program: xxxxxxx.sas 
 
Table repeats per subject beginning on a new page. 

Prot_001.pdf: 


 
MSK-003 
Page 1 
 
Proprietary and Confidential  
07 February 2020
CLINICAL STUDY PROTOCOL 
Study Title: 
Long Term Safety Study of Amifampridine Phosphate in 
Patients with MuSK Antibody Positive and AChR Antibody 
Positive Myasthenia Gravis Patients 
Protocol Number: 
MSK-003 
Investigational Product: Amifampridine phosphate (3,4-diaminopyridine phosphate) 
IND/EUDRACT 
Number: 
106263 / 2017-004777-14 
Indication: 
Musk Antibody Positive Myasthenia Gravis 
External Support: 
Catalyst Pharmaceuticals, Inc. 
Development Phase: 
Phase 3 
Medical Officer: 
Stanley Iyadurai, MD, PhD 
Study Design: 
Open Label  
Dose: 
30-80 mg total daily dose  
Patient Population: 
Patients with MuSK antibody positive Myasthenia Gravis and a 
sample of patients with AChR antibody positive Myasthenia 
Gravis 
Date of Original 
Protocol: 
Date of Amended 
Protocol:  
12 November 2017 – USA 
 
07 February 2020 - USA 
 
Property of Catalyst Pharmaceuticals, Inc. 
CONFIDENTIAL 
May not be divulged, published, or otherwise disclosed to others without prior written 
approval from Catalyst Pharmaceuticals, Inc. 
 
This study will be conducted according to the principles of Good Clinical Practice as 
described in the U.S. Code of Regulations and the International Conference on 
Harmonisation Guidelines, including the archiving of essential documents. 
 
 
 


 
MSK-003 
Page 2 
 
Proprietary and Confidential  
07 February 2020
 
 
PROCEDURES IN CASE OF AN EMERGENCY 
Emergency Contact Information 
Role in Study 
Name 
Contact Information 
Medical Monitor 
Stanley Iyadurai, MD, PhD 
Vice President, Clinical 
Affairs 
Catalyst Pharmaceuticals, Inc. 
355 Alhambra Circle, Suite 1250 
Coral Gables, FL 33134 
Tel: 305-420-3200, ext. 139 
Email: 
siyadurai@catalystpharma.com  
 
Coordinating Investigator 
Renato Mantegazza, MD 
Director Department of 
Neuroimmunology and 
Neuromuscular Diseases 
Carlo Besta Neurological 
Institute 
Via Celoria 11-201332 Milan, 
Italy 
 
Clinical Project Lead 
Syune Nersisyan, PhD  
Catalyst Pharmaceuticals, Inc. 
355 Alhambra Circle, Suite 1250 
Coral Gables, FL 33134 
Tel: 305-420-3238 
Email: 
snersisyan@catalystpharma.com 
 
Safety Reporting 
 
Ronaldo Reyes, MD 
Medical Director, 
Pharmacovigilance 
 
Catalyst Pharmaceuticals, Inc. 
Tel: 305-420-3228 
Email: 
rreyes@catalystpharma.com  
 
 
 
 


 
MSK-003 
Page 3 
 
Proprietary and Confidential  
07 February 2020
Synopsis 
TITLE OF STUDY: 
Long Term Safety Study of Amifampridine Phosphate in Patients with MuSK Antibody Positive 
and AChR Antibody Positive Myasthenia Gravis Patients 
PROTOCOL NUMBER: 
MSK-003 
STUDY SITES:  
Up to 20 sites in USA and Europe 
PHASE OF DEVELOPMENT: 
Phase 3 
STUDY RATIONALE: 
The purpose of this study is to evaluate the long-term safety and tolerability of amifampridine 
phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis  
(MG) patients who participated in the  MSK-002 study. 
OBJECTIVES: 
Primary 
• 
To characterize the long-term safety and tolerability of amifampridine phosphate in patients 
with MG  
Secondary 
• 
To assess the clinical efficacy of amifampridine phosphate over time in patients with MG 
based on change in Myasthenia Gravis Activities of Daily Living Score (MG-ADL)  
STUDY DESIGN AND PLAN:  
This is a long-term extension study for patients who participated in Protocol MSK-002 where the 
efficacy and safety of amifampridine was evaluated, in patients diagnosed with MuSK-MG or 
AChR-MG. The planned duration of participation for each patient is at least 9 months (i.e. until 
amifampridine is approved by Regulatory Agencies for the treatment of MG or the development 
program is discontinued for this indication). 
All patients who have completed study MSK-002 and sign an informed consent may enroll in the 
long-term study.  Those patients who demonstrated benefit after completing the dose titration 
period but failed to meet the randomization criteria on Day 0 of MSK-002 may also be eligible for 
this study.  The evaluations for MSK-002 can serve as baseline for the Long-Term study, if 
available 
 


 
MSK-003 
Page 4 
 
Proprietary and Confidential  
07 February 2020
The optimal dose and schedule for amifampridine from the end of the Run-in Period from Study 
MSK-002 will initially be used for each patient. The Investigator may adjust the dose of 
amifampridine during the course of this trial, in order to optimize neuromuscular benefit for the 
patient. Clinic visits for safety assessment and for evaluation of MG-ADL will be made at Months 
3, 6, 9, 12, 15, 21, 27, 33 and 39.  Additional visits may occur at the discretion of the Investigator.   
NUMBER OF PATIENTS PLANNED:  
Up to about 60 MuSK-MG patients and approximately 10 AChR-MG patients will be studied. 
CRITERIA FOR INCLUSION AND EXCLUSION:  
Individuals eligible to participate in this study must meet all the following inclusion criteria: 
1. Participated in the MSK-002 study 
2. Willing and able to provide written informed consent after the nature of the study has been 
explained and before the start of any research-related procedures. 
3. Female patients of childbearing potential must have a negative pregnancy test (urine 
human chorionic gonadotropin [HCG] at the end of MSK-002 study); and must practice an 
effective, reliable contraceptive regimen during the study and for up to 30 days following 
discontinuation of treatment. 
4. Ability to participate in the study based on overall health of the patient and disease 
prognosis, as applicable, in the opinion of the Investigator; and able to comply with all 
requirements of the protocol, including completion of study questionnaires. 
 
Individuals who met any of the exclusion criteria in the original protocol or those listed below are 
not eligible to participate in the study: 
1. Epilepsy and currently on medication. 
2. Clinically significant abnormalities in 12 lead ECG, in the opinion of the Investigator. 
3. Breastfeeding or pregnant at Screening or planning to become pregnant at any time during 
the study. 
4. Intolerable amifampridine-related side effects   
5. Treatment with an investigational drug (other than amifampridine) or device while 
participating in this study. 
6. Any medical condition that, in the opinion of the Investigator, might interfere with the 
patient’s participation in the study, poses an added risk for the patient, or confound the 
assessment of the patient. 
 


 
MSK-003 
Page 5 
 
Proprietary and Confidential  
07 February 2020
INVESTIGATIONAL PRODUCT(S), DOSE, ROUTE, AND REGIMEN:  
The investigational product (IP) is amifampridine tablets 10 mg, and it will be provided in round, 
white-scored tablets, containing amifampridine phosphate formulated to be the equivalent of 10 mg 
amifampridine base per tablet. Dosing is up to 80 mg/day in 3 or 4 divided doses. 
 
The investigational product will be provided by Catalyst Pharmaceuticals, Inc., 355 Alhambra 
Circle, Suite 1250, Coral Gables, Florida, 33134, United States. 
REFERENCE THERAPY, DOSE, ROUTE, AND REGIMEN:  
None 
DURATION OF TREATMENT: 
Amifampridine will be continued as long as patients benefit from the treatment until the drug is 
approved by Regulatory Agencies or until the development of the drug is discontinued for this 
indication.  
CRITERIA FOR EVALUATION: 
Safety (primary endpoint): 
Safety will be assessed by the incidence of treatment-emergent adverse events (TEAEs), including 
serious adverse events (SAEs). Vital signs, 12-lead ECGs, clinical laboratory tests, physical 
examination findings, and concomitant medications will also be evaluated.  
Efficacy (secondary endpoint):  
Efficacy will be assessed by change in MG-ADL score over time. 
STATISTICAL METHODS: 
Sample Size Determination 
The study is not powered with respect to any endpoint, but is an observational study to assess long 
term safety and lack of tolerance to the effects of amifampridine on MG-ADL.   
Safety Analysis 
Safety analyses will be conducted on the safety population (i.e. all patients who receive at least 1 
dose of amifampridine. The safety analysis will be descriptive and will be presented on observed 
data only. 
 
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). Only 
TEAEs will be included in the safety analysis. The incidence of TEAEs will be summarized by 
system organ class, preferred term, relationship to treatment, and severity.  
 
All other safety measures including ECGs, vital signs, laboratory tests, physical examination and 
concomitant medications data will also be summarized. 
 
Subgroup analyses for safety will be performed independently on the MuSK-MG and AChR-MG 
groups.  No pooled analyses are planned. 
 


 
MSK-003 
Page 6 
 
Proprietary and Confidential  
07 February 2020
Efficacy Analysis 
Efficacy analysis will be conducted on all patients who receive at least 1 dose of amifampridine 
and have at least one post-treatment efficacy assessment. The efficacy analysis will be descriptive 
and will be presented on observed data only independently on the MuSK-MG and AChR-MG 
groups.  No pooled analyses are planned. 
 
 
Summary of Changes 
Version 
Summary of Changes 
Author(s)/Title 
12 Nov 2017 
Initial Protocol 
Gary Ingenito, Chief Medical 
Officer 
07 Feb 2020 
• 
Cover page revised with updated Catalyst 
clinical personnel and contact information 
including the Medical Officer, Clinical 
Project Lead and Safety Reporting. 
• 
Synopsis revised to include grammatical 
edits and the addition of study visits, Months 
27, 33, and 39. 
• 
Section 6.1 updated with new reference 
information. 
• 
Section 8 updated with additional study 
visits, Months 27, 33, and 39. 
• 
Table 1, Schedule of Events updated with  
additional study visits, Months 27, 33, and 
39. 
• 
Section 8.6 updated with grammatical edits. 
• 
Section 9.6 updated with revised Medical 
Officer contact information. 
• 
Section 11 updated with additional study 
visits, Months 27, 33, and 39. 
• 
Section 13.3 and 13.4 updated with 
additional study visits, Months 27, 33 and 
39.   
Stanley Iyadurai, VP, Clinical 
Affairs 
 
 


 
MSK-003 
Page 7 
 
Proprietary and Confidential 
 
07 February 2020 
2 TABLE OF CONTENTS 
1 TITLE PAGE .......................................................................................................................1 
2 TABLE OF CONTENTS .....................................................................................................7 
3 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ....................................11 
4 ETHICS..............................................................................................................................13 
4.1 Independent Ethics Committee / Institutional Review Board ...................................13 
4.2 Ethical Conduct of Study ..........................................................................................13 
4.3 Patient Information and Informed Consent ...............................................................14 
5 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE ........................14 
6 INTRODUCTION .............................................................................................................15 
6.1 Effectiveness in MuSK-MG and Other Indications ..................................................15 
6.2 Safety of Amifampridine and Amifampridine Phosphate .........................................16 
6.3 Overall Risks and Benefits ........................................................................................18 
6.4 Study Rationale .........................................................................................................18 
7 STUDY OBJECTIVES ......................................................................................................18 
7.1 Primary Objective .....................................................................................................18 
7.2 Secondary Objective .................................................................................................18 
8 INVESTIGATIONAL PLAN ............................................................................................19 
8.1 Overall Study Design and Plan .................................................................................19 
8.2 Selection of Study Population ...................................................................................21 
8.2.1 
Inclusion Criteria .........................................................................................21 
8.2.2 
Exclusion Criteria ........................................................................................21 
8.2.3 
Removal of Patients from Treatment or Assessment ..................................22 
8.2.4 
Patient Identification ...................................................................................23 
8.3 Treatments .................................................................................................................23 
8.3.1 
Treatments Administered ............................................................................23 
8.3.2 
Identity of Investigational Product ..............................................................23 
8.3.3 
Product Characteristics and Labeling ..........................................................23 
8.3.4 
Storage .........................................................................................................24 
8.3.5 
Directions for Administration .....................................................................24 


 
MSK-003 
Page 8 
 
Proprietary and Confidential 
 
07 February 2020 
8.3.6 
Method of Assigning Patients to Treatment Groups ...................................24 
8.3.7 
Selection of Doses Used in the Study .........................................................24 
8.3.8 
Blinding .......................................................................................................25 
8.3.9 
Treatment Compliance ................................................................................25 
8.3.10 Investigational Product Accountability .......................................................25 
8.3.11 Return and Disposition of Clinical Supplies ...............................................25 
8.4 Prior and Concomitant Medications .........................................................................25 
8.5 Dietary or Other Protocol Restrictions......................................................................26 
8.5.1 
Dietary Restrictions .....................................................................................26 
8.5.2 
Contraception ..............................................................................................26 
8.6 Safety Variables ........................................................................................................26 
8.6.1 
Adverse Events ............................................................................................26 
8.6.2 
Vital Signs ...................................................................................................26 
8.6.3 
Clinical Laboratory Assessments ................................................................27 
8.6.4 
Pregnancy Testing .......................................................................................28 
8.6.5 
Electrocardiogram (ECG) ............................................................................28 
8.6.6 
Physical Examination ..................................................................................28 
8.7 Efficacy Variable ......................................................................................................29 
8.7.1 
Myasthenia Gravis-Specific Activities of Daily Living (MG-ADL) ..........29 
9 REPORTING ADVERSE EVENTS .................................................................................29 
9.1 Adverse Events .........................................................................................................29 
9.2 Serious Adverse Events ............................................................................................32 
9.3 Safety Blood Collection ............................................................................................34 
9.4 Pregnancy ..................................................................................................................34 
9.5 Urgent Safety Measures ............................................................................................34 
9.6 Medical Monitor Contact Information ......................................................................35 
10 APPROPRIATENESS OF MEASUREMENTS ...............................................................35 
11 STUDY PROCEDURES ...................................................................................................35 
11.1 Start of Long Term Study .........................................................................................35 
11.2 End of Months 3, 6, 9, 12, 15, 21, 27, 33 and 39 ......................................................36 


 
MSK-003 
Page 9 
 
Proprietary and Confidential 
 
07 February 2020 
11.2.1 End of Study Visit .......................................................................................37 
12 DATA QUALITY ASSURANCE .....................................................................................37 
13 STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE ..................38 
13.1 Statistical and Analytical Plans .................................................................................38 
13.1.1 Interim Analyses ..........................................................................................38 
13.2 Analysis Populations .................................................................................................38 
13.3 Primary Endpoint ......................................................................................................38 
13.4 Secondary Endpoint ..................................................................................................38 
13.5 Safety Analysis .........................................................................................................38 
13.6 Determination of Sample Size ..................................................................................39 
13.7 Changes in the Conduct of the Study or Planned Analyses ......................................39 
14 COMPENSATION, INSURANCE, AND INDEMNITY .................................................40 
15 CASE REPORT FORMS AND SOURCE DOCUMENTS ..............................................40 
16 STUDY MONITORING AND AUDITING .....................................................................41 
17 RETENTION OF RECORDS ...........................................................................................42 
18 USE OF INFORMATION AND PUBLICATION ...........................................................43 
19 REFERENCES ..................................................................................................................44 
20 INVESTIGATOR RESPONSIBILITIES ..........................................................................47 
20.1 Conduct of Study and Protection of Human Patients ...............................................47 
21 SIGNATURE PAGE .........................................................................................................48 
APPENDIX 1: MYASTHENIA GRAVIS-SPECIFIC ACTIVITIES OF DAILY 
LIVING (MG-ADL) ..........................................................................................................49 
 
 
 


 
MSK-003 
Page 10 
 
Proprietary and Confidential 
 
07 February 2020 
List of In-text Tables 
Table 1 Schedule of Events......................................................................................................20 
Table 2 Clinical Laboratory Tests ............................................................................................27 
Table 3 Categories of Severity of Adverse Events ..................................................................31 
Table 4 Description of Relationship to Adverse Event Categories .........................................32 
 
List of In-text Figure 
Figure 1 Chemical Structure of Amifampridine Phosphate .....................................................23 
 


 
MSK-003 
Page 11 
 
Proprietary and Confidential 
 
07 February 2020 
3 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviations 
Abs 
Antibodies 
ACh 
Acetylcholine 
AChR 
Acetylcholine receptor 
AChR-MG 
Acetylcholine receptor Myasthenia Gravis 
ADL 
Activities of Daily Living 
AE(s) 
adverse event(s) 
ALT 
alanine aminotransferase  
AST 
aspartate aminotransferase 
ATU 
Autorisations Temporaires d'Utilisation Normative 
CMS 
congenital myasthenia syndromes 
CRA(s) 
clinical research associate(s) 
CRF 
CRO 
case report form 
contract research organization 
DBP 
diastolic blood pressure 
ECG(s) 
electrocardiogram(s) 
eCRF 
electronic case report form 
EFNS 
European Federation of Neurological Societies  
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HCG 
human chorionic gonadotropin 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
ICH E6 
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 
IEC 
independent ethics committee 
IP 
investigational product 
IRB 
institutional review board 
K+ 
potassium ion 
kg 
kilogram 
LEMS 
Lambert-Eaton myasthenic syndrome 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
milligram 


 
MSK-003 
Page 12 
 
Proprietary and Confidential 
 
07 February 2020 
MG-ADL 
Myasthenia Gravis-Specific Activities of Daily Living 
MG 
Myasthenia Gravis 
MI 
myocardial infarction 
mmHg 
millimeters of mercury 
MS 
multiple sclerosis 
MuSK 
muscle-specific receptor tyrosine kinase 
MuSK-MG 
muscle-specific receptor tyrosine Kinase-Myasthenia Gravis 
ng/mL 
nanograms per milliliter 
PI 
Principal Investigator 
PK 
pharmacokinetic 
QTc 
QT wave corrected for heart rate 
REB 
research ethics board 
SAE(s) 
serious adverse event(s) 
SAP 
statistical analysis plan 
SBP 
systolic blood pressure 
SOPs 
standard operating procedures 
TEAE(s) 
treatment emergent adverse event(s) 
US 
United States 
 
Definition of Terms:  
Investigational Product (IP): 
“A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical trial, including a product with a marketing authorization when used or assembled 
(formulated or packaged) in a way different from the approved form, or when used for an 
unapproved indication, or when used to gain further information about an approved use” 
(from International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline: 
Guideline for Good Clinical Practice E6 [ICH E6]). The terms “IP” and “study drug” may be 
used interchangeably in the protocol. 


 
MSK-003 
Page 13 
 
Proprietary and Confidential 
 
07 February 2020 
4 
ETHICS 
4.1 
Independent Ethics Committee / Institutional Review Board 
Before initiating the study, the Investigator will obtain written confirmation that the 
institutional review board (IRB), independent ethics committee (IEC), or Research Ethics 
Board (REB) is properly constituted and compliant with International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH) and Good Clinical Practice (GCP) requirements, applicable laws and local 
regulations. A copy of the confirmation from the IRB/IEC/REB will be provided to Catalyst 
Pharmaceuticals, Inc. (Catalyst) or its designee. The Investigator will provide the 
IRB/IEC/REB with all appropriate material, including the protocol, Investigator’s Brochure 
or Package Insert, the Informed Consent Form (ICF) including compensation procedures, and 
any other written information provided to the patients, including all ICFs translated to a 
language other than the native language of the clinical site. The study will not be initiated 
and Investigational Product (IP) supplies will not be shipped to the site until appropriate 
documents from the IRB/IEC/REB confirming unconditional approval of the protocol, the 
ICF, and all patient recruitment materials are obtained in writing by the Investigator, and 
copies are received at Catalyst or its designee. The approval document should refer to the 
study by protocol title and Catalyst protocol number (if possible), identify the documents 
reviewed, and include the date of the review and approval. The Investigator is responsible to 
ensure that the appropriate reports on the progress of the study are made to the IRB/IEC/REB 
in accordance with applicable guidance documents and governmental regulations. 
4.2 
Ethical Conduct of Study 
This study will be conducted in accordance with the following: 
• ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 
(ICH E6); and 
• The ethical principles established by the Declaration of Helsinki. 
Specifically, this study is based on adequately performed laboratory and animal 
experimentation. The study will be conducted under a protocol reviewed and approved by an 
IRB/IEC/REB and will be conducted by scientifically and medically qualified persons. The 
benefits of the study are in proportion to the risks. The rights and welfare of the patients will 
be respected and the Investigators conducting the study do not find the hazards to outweigh 


 
MSK-003 
Page 14 
 
Proprietary and Confidential 
 
07 February 2020 
the potential benefits. Each patient will provide written, informed consent prior to any 
study-related tests or evaluations being performed. 
4.3 
Patient Information and Informed Consent 
A properly written and executed ICF, in accordance with the Declaration of Helsinki, ICH E6 
(Section 4.8), and other applicable local regulations, will be obtained for each patient before 
entering the patient into the study. The Investigator will prepare the ICF and provide the 
documents to Catalyst, or designee, for review. The IRB/IEC/REB must approve the 
documents before their implementation. A copy of the approved ICF, and if applicable, a 
copy of the approved patient information sheet and all ICFs translated to a language other 
than English must also be received by Catalyst, or designee, prior to any study-specific 
procedures being performed. 
The Investigator will provide copies of the signed ICF to each patient and will maintain the 
original in the record file of the patient. 
 
5 
INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE 
Before beginning the study, the Investigator must provide to Catalyst or designee, a fully 
executed and signed US Food and Drug Administration (FDA) Form FDA 1572 and a 
Financial Disclosure Form.  All sub-investigators must be listed on Form FDA 1572 and 
provide a Financial Disclosure Form. 
Clinical research associates (CRAs) or trained designees will monitor the site on a periodic 
basis, both remotely and with onsite visits, and perform verification of source documentation 
for a representative sample of patients as well as other required review processes. Principal 
Investigator (PI) will be responsible for the timely reporting of serious adverse events (SAEs) 
to Catalyst, or designee, and the IRB. Catalyst Medical Department (or designee) will be 
responsible for the timely reporting of SAEs to appropriate regulatory authorities, as 
required. 
Laboratory evaluations will be performed at the local laboratory associated with the study 
site.  
 


 
MSK-003 
Page 15 
 
Proprietary and Confidential 
 
07 February 2020 
6 
INTRODUCTION 
Information on disease background, amifampridine, previously completed nonclinical and 
clinical studies of amifampridine, is described in the Introduction of the MSK-002 protocol 
and in the Investigator’s Brochure supplied by Catalyst. Investigators are to review this 
document before initiating this study.  
Amifampridine is a non-specific voltage-dependent potassium (K+) channel blocker. 
Blockade of K+ channels causes depolarization of the presynaptic membrane and slows down 
or inhibits repolarization. Prolonged depolarization results in opening of slow voltage-
dependent calcium (Ca2+) channels and allows a subsequent influx of Ca2+. The increased 
concentration of intracellular Ca2+ induces exocytosis of the synaptic vesicles containing 
acetylcholine (ACh), thus releasing an increased level of ACh into the synaptic cleft 
(Maddison, 1998a; Maddison, 1998b). The influx of ACh into the presynaptic cleft enhances 
neuromuscular transmission, providing improved muscle function. 
Mori et al. (2012) found that amifampridine improved neuromuscular transmission by 
predominantly increasing ACh release in the neuromuscular junction of in mice with MG 
induced by antibodies against muscle-specific kinase (MuSK).  Furthermore, a mouse model 
of MuSK-MG, amifampridine significantly enhanced neuromuscular transmission after 1 
week of treatment without exacerbating loss of endplate AChRs (Morsch et al. 2013).  
Multiple studies were conducted to evaluate the cardiac safety, pharmacokinetics and 
toxicity profile in rats and dogs. Reproductive and developmental toxicity studies with 
amifampridine were also conducted in rats and rabbit as well a variety of in vitro and in vivo 
genotoxicity studies, and in vitro metabolism/transporter studies. The main nonclinical 
findings related to amifampridine were central and autonomic nervous system effects, the 
development of Schwannomas, and histologic changes in muscle tissues. Below is an 
abbreviated summary of the effectiveness of amifampridine in MuSK-MG and overall safety 
in other patient populations. 
6.1 
Effectiveness in MuSK-MG and Other Indications 
Small studies have demonstrated the beneficial effects of amifampridine in patients with 
MuSK-MG in 2 children, who achieved some benefit (Skjei, 2013) and 1 adult (Evoli, 2016).  
Following 4 months of treatment, the authors report the adult patient had obvious 
improvement of ptosis, decreased neck weakness and arm fatigability. In an Investigator-
Sponsored MuSK-MG randomized, double-blind, placebo-controlled, cross-over study 


 
MSK-003 
Page 16 
 
Proprietary and Confidential 
 
07 February 2020 
conducted in Italy, 7 MuSK-MG patients demonstrated statistically significantly higher 
functional performance in all validated assessment scales when they were administered 
amifampridine compared to placebo. Tolerability to amifampridine was excellent (Bonano et 
al., 2018).Results from the MSK-002 study will also be used to establish efficacy of 
amifampridine in MuSK-MG. 
A review of the literature documents that amifampridine is a safe and effective treatment in 
multiple neurologic disorders and is recommended by the EFNS for first-line symptomatic 
treatment of patients with LEMS (Skeie, 2006; Skeie, 2010; Lindquist, 2011). Since then 
amifampridine has been approved for treatment in patients with LEMS in Europe in 2009 and 
adult LEMS patients in the USA in 2018. 
6.2 
Safety of Amifampridine and Amifampridine Phosphate 
Safety data collected from 1,454 patients or healthy volunteers in controlled study LMS-002 
[(Lambert-Eaton myasthenic syndrome LEMS)], controlled and uncontrolled published 
studies of LEMS or other neurologic conditions, a 3-year safety surveillance study (ATU), 
and pharmacokinetic (PK) studies demonstrate amifampridine is well tolerated up to and 
including 80 mg/day (Firdapse Investigator Brochure, June 2017). The most common 
adverse events observed from the clinical safety data were perioral and peripheral 
paresthesias and gastrointestinal disorders (abdominal pain, nausea, diarrhea, epigastralgia).  
These events were typically mild or moderate in severity, and transient, seldom requiring 
dose reduction or withdrawal from treatment. In the pharmacogenomic study in healthy 
subjects (classified as either slow acetylators or fast acetylators), slow acetylators 
experienced >80% more drug-related AEs compared with fast acetylators (FIR-001). 
Clinically significant or serious adverse events were infrequent in all studies for all 
indications. A total of 12 deaths were reported in the 1,454 patients or healthy subjects. Six 
of 12 deaths were associated with accompanying malignancy (1 of 6 with pulmonary 
embolus as terminal event), 1 due to tracheobronchitis, and 2 due to myocardial infarction 
(MI). Attribution to amifampridine for 2 of 3 deaths from the ATU study was specified as 
unrelated; causality for the third death was not reported. No attribution was specified in the 
academic series, but the author singled out the fatal MI as the only serious incident during 
amifampridine therapy, implying that the 2 deaths due to malignancy, the 1 due to 
malignancy and pulmonary embolus and the 1 due to tracheobronchitis were not related in 
his opinion. The author further states that no pathological findings related to amifampridine 
were found in the patient who died of tracheobronchitis. For 1 of the fatal MIs, the author 
speculates that a “sudden increase of physical activity” with amifampridine may have been a 


 
MSK-003 
Page 17 
 
Proprietary and Confidential 
 
07 February 2020 
contributant (Lundh, 1984; Lundh, 1993); no causality was reported for the other fatal MI 
(Bertorini, 2011). Three deaths occurred in children with congenital myasthenia syndromes 
(CMS), including 2 with fast-channel CMS (Beeson, 2005). Although no causal relationship 
was established with amifampridine, the authors advise its use cautiously in children and in 
fast-channel patients. The other CMS death was not thought to be related to amifampridine 
(Palace, 1991). Overall 7 of 12 deaths were not considered related to amifampridine; neither 
cause nor causality is known for 4 deaths; and amifampridine may have contributed 
indirectly to 1 of the MI-related deaths.   
The most frequent clinically significant or serious event was seizure. A total of 10 (0.69%) 
patients out of 1,454 patients or healthy subjects experienced seizures or convulsions after 
treatment with amifampridine. Electroencephalogram findings, reported for 3 of the 10 
patients, did not show epileptiform activity. Three of 10 seizures occurred in patients with 
LEMS (3/209; 1.44%), 4 occurred in patients with MS (4/774; 0.5%), 1 occurred in a patient 
with CMS (1/88; 1.14%) (Harper, 2000) and 2 seizures were reported in a literature-based 
study where both MG and LEMS patients were enrolled, but the paper did not state the 
indication (Sanders, 1993; Sanders, 2000; Flet, 2010; McEvoy, 1989; Boerma, 1995; Bever, 
1996).  
Three patients (LEMS or MG) experienced seizures on a daily dose of ≥90 mg/day. No other 
cause was apparent in 2 cases; 1 patient had concurrent toxic serum levels of theophylline 
(McEvoy, 1989; Sanders, 1993). A fourth patient with LEMS had multiple seizures 
following accidental ingestion of 360 mg/day amifampridine for 7 days (prescribed dose 
60 mg/day) (Boerma, 1995). There were potentially contributing conditions in 6 patients, 
specifically, concurrent treatment with theophylline (n=1; LEMS or MG), or coexistent brain 
metastases (n=1; LEMS), epilepsy and multiple sclerosis (MS) (n=1); and MS (n=4). In cases 
where follow-up was reported, most seizures did not recur with amifampridine dose 
reduction or treatment withdrawal. In the one accidental overdose case, seizures were 
controlled with intravenous clonazepam and the patient made a full recovery (Boerma, 1995). 
It is noteworthy that a seizure rate of 4% can be expected in the natural course of patients 
with MS (Engelsen, 1997; Moreau, 1998; Kinnunen, 1987). Among the 774 MS patients 
treated with amifampridine included in the safety assessment of this report, 4 (0.5%) 
experienced seizures. 
Other clinically significant or SAEs reported in more than 1 patient were palpitations 
(8/1,454; 0.56%), abnormal liver enzymes (6/1,454; 0.41%), QTc prolongation (2/1,454; 
0.14%), and premature ventricular contraction/increased ventricular extrasystoles (2/1,454; 


 
MSK-003 
Page 18 
 
Proprietary and Confidential 
 
07 February 2020 
0.14%). Each of the following serious or clinically significant events was reported in a single 
patient: chorea, paresthesias, paroxysmal supraventricular tachycardia, cardiac arrest, drug-
induced hepatitis, gastroesophageal reflux, increased lipase and amylase, aspiration 
pneumonia with confusion, and urinary tract infection with confusion. 
6.3 
Overall Risks and Benefits 
Data on amifampridine treatment in 1,454 patients or healthy volunteers support the 
favorable safety profile of amifampridine (both base and phosphate formulations) at doses up 
to 80 mg per day. To date, current data demonstrate that amifampridine phosphate has an 
acceptable tolerability profile with a positive risk-benefit in patients treated with 
amifampridine, but longer-term studies are needed in patients with MG.  
6.4 
Study Rationale 
A considerable amount of clinical experience is available with amifampridine and, in 
December 2009, amifampridine tablets 10 mg, as amifampridine phosphate, received 
marketing approval by the European Commission as Firdapse® for the symptomatic 
treatment of patients with LEMS.  The present long-term extension study will evaluate safety 
and tolerability of amifampridine on clinical laboratory test variables, ECGs, AEs, vital 
signs, physical examinations and the effects on MG-ADL score over several months in 
patients with MuSK or AchR-MG. This information is needed to demonstrate that the 
product is safe and provides continued benefit to patients with MG. 
7 
STUDY OBJECTIVES 
7.1 
Primary Objective 
The primary objective of the study is: 
• 
To evaluate the long-term safety and tolerability of amifampridine in patients with 
MuSK-MG; and with AChR-MG. 
7.2 
Secondary Objective 
The secondary objective of the study is: 
• To assess the effect of amifampridine phosphate on Myasthenia Gravis Activities of 
Daily Living Score (MG-ADL). 
 


 
MSK-003 
Page 19 
 
Proprietary and Confidential 
 
07 February 2020 
8 
INVESTIGATIONAL PLAN 
8.1 
Overall Study Design and Plan 
This open label outpatient extension study is designed to evaluate the long-term safety, 
tolerability of amifampridine in patients diagnosed with MuSK-MG and AChR-MG. In 
addition, evaluation of the effects of amifampridine on the MG-ADL score will be made. The 
study will enroll those patients who have completed the MSK-002 study and after all final 
evaluations for that study have been completed, or those who demonstrated benefit after 
completing the dose titration period but failed to meet the randomization criteria on Day 0 of 
MSK-002.  
The duration of participation for each patient is expected to be at least 9 months as patients 
may continue in the study until amifampridine is approved by Regulatory Agencies or the 
clinical development of amifampridine is terminated for this indication. In addition to 
amifampridine, patients will continue to receive previous concomitant medications, as 
needed.  
After a new informed consent is signed and inclusion / exclusion criteria for the current 
protocol are satisfied, eligible patients will be given the optimal dose and dosing schedule 
that was identified in the Run-in Period from Protocol MSK-002.   
The findings from the physical exam (including vital signs, weight); 12-lead ECG; clinical 
laboratory test results (including pregnancy testing) and any ongoing adverse events will be 
used as the baseline for the Long-Term safety evaluation.   
The only efficacy measurement is the MG-ADL which will be completed every 3 or 6 
months. Safety and tolerability assessments will be made every 3 or 6 months or more 
frequently at the discretion of the Investigator. The study will continue until amifampridine is 
approved by Regulatory Agencies or until development of the product for this indication is 
halted. The Investigator may alter the dose and dosing frequency during the Long-Term 
Study as well as schedule additional clinic visits for any reason.   
Patients will be seen in the clinic at the end of Months 3, 6, 9, 12, 15, 21, 27, 33 and 39 as 
detailed in the Schedule of Assessments in Table 1 and Section 11. In between the 3-or 6-
month visits, patients may also have telephone/video contact with the site, or unscheduled 
visits, if needed. 
Any unused medication must be brought back to the clinic at each visit for drug 
accountability, and an additional supply will be dispensed. 


 
MSK-003 
Page 20 
 
Proprietary and Confidential 
 
07 February 2020 
 
Table 1 Schedule of Events 
Study Assessment  
or Event  
Screening 
and 
Enrollment
* 
Study Month ± 1 week 
3 
6 
9 
12 
15 
21 
27 33 39 
End of 
Studyg 
Informed consent a 
x 
 
 
 
 
 
 
 
 
 
 
Inclusion/Exclusion 
x 
 
 
 
 
 
 
 
 
 
 
Complete physical exam b 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Vital signs  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
12-Lead ECG  
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Clinical laboratory tests c 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Pregnancy test d 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Amifampridine Treatment 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
MG-ADL  
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Dispense IP e 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
 
IP Accountability 
 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Adverse events/SAEs f 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
Concomitant medications 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
x 
a Informed consent must be obtained before any study procedures are performed. 
b Complete physical examination includes evaluation of all major body systems, including weight at 
all visits (Section 9.6.6). 
c Clinical laboratory tests include serum chemistry, hematology, and urinalysis. 
d Urine pregnancy tests will be obtained from female patients of childbearing potential. 
e Pharmacist will dispense sufficient amount of medication until the next clinic visit. All unused 
medication must be returned to the clinic for drug accountability. 
f SAE reporting commences after informed consent is signed. Non-serious adverse event reporting 
commences after the first dose of study drug for the current Long-Term Study. 
g End of Study or early termination visit if the last visit does not coincide the scheduled 3- or 6-month 
visit. 
*These data may be obtained from Study MSK-002. If data not available, then the assessment should 
be repeated. 
 


 
MSK-003 
Page 21 
 
Proprietary and Confidential  
07 February 2020 
8.2 
Selection of Study Population 
Patients who complete Protocol MSK-002 or who have demonstrated benefit after completing 
the dose titration period but failed to meet randomization criteria for MSK-002, and who meet 
the inclusion and exclusion criteria for participation in the current study will be eligible. 
8.2.1 Inclusion Criteria 
Individuals eligible to participate in this study must meet all the following inclusion criteria: 
1. Participated in the MSK-002 study 
2. Willing and able to provide written informed consent after the nature of the study has 
been explained and before the start of any research-related procedures. 
3. Female patients of childbearing potential must have a negative pregnancy test (urine 
human chorionic gonadotropin [HCG] at the end of MSK-002 study); and must 
practice an effective, reliable contraceptive regimen during the study and for up to 30 
days following discontinuation of treatment. 
4. Ability to participate in the study based on overall health of the patient and disease 
prognosis, as applicable, in the opinion of the Investigator; and able to comply with 
all requirements of the protocol, including completion of study questionnaires. 
8.2.2 Exclusion Criteria 
Individuals who met any of the exclusion criteria in the original protocol or those listed 
below are not eligible to participate in the study: 
1. Epilepsy and currently on medication. 
2. Clinically significant abnormalities in 12 lead ECG, in the opinion of the Investigator. 
3. Breastfeeding or pregnant at Screening or planning to become pregnant at any time 
during the study. 
4. Intolerable amifampridine-related side effects   
5. Treatment with an investigational drug (other than amifampridine) or device while 
participating in this study. 
6. Any medical condition that, in the opinion of the Investigator, might interfere with 
the patient’s participation in the study, poses an added risk for the patient, or 
confound the assessment of the patient. 


 
MSK-003 
Page 22 
 
Proprietary and Confidential  
07 February 2020 
8.2.3 Removal of Patients from Treatment or Assessment 
Patients may withdraw their consent to participate in the study or to receive treatment with IP 
at any time without prejudice. The Investigator must withdraw from the study or from 
treatment with IP any patient who requests to be withdrawn. A patient’s participation in the 
study or treatment with IP may be discontinued at any time at the discretion of the 
Investigator and in accordance with his or her clinical judgment.  
Catalyst must be notified of all patient withdrawals from the study or from treatment with IP 
as soon as possible. Catalyst also reserves the right to discontinue the study at any time for 
either clinical or administrative reasons and to discontinue participation by an individual 
Investigator or site for poor enrollment or noncompliance. 
Reasons for which the Investigator or Catalyst may withdraw a patient from the study 
treatment include, but are not limited to, the following: 
• Patient experiences a serious or intolerable AE; 
• Patient requires medication prohibited by the protocol; and 
• Patient becomes pregnant (refer to Section 9.4 for details on the reporting procedures 
to follow in the event of pregnancy). 
Reasons for which the Investigator or Catalyst may withdraw a patient from the study 
include, but are not limited to, the following: 
• Patient does not adhere to study requirements specified in the protocol; 
• Patient was erroneously admitted into the study or does not meet inclusion criteria; 
and 
• Patient is lost to follow-up. 
If a patient fails to return for scheduled visits, a documented effort must be made to 
determine the reason. If the patient cannot be reached by telephone, a certified letter should 
be sent to the patient requesting contact with the Investigator. This information should be 
recorded in the study records. 
The Investigator or designee must explain to each patient, before enrollment into the study, 
that for evaluation of study results, the patient’s protected health information obtained during 
the study may be shared with Catalyst, regulatory agencies, and IRB/IEC/REB. It is the 
Investigator’s (or designee’s) responsibility to obtain written permission to use protected 
health information, per country-specific regulations, from each patient. If permission to use 


 
MSK-003 
Page 23 
 
Proprietary and Confidential  
07 February 2020 
protected health information is withdrawn, it is the Investigator’s responsibility to obtain a 
written request, to ensure that no further data will be collected from the patient and the 
patient will be removed from the study. 
8.2.4 Patient Identification 
Each patient will be assigned a unique patient identifier (2 or 3 digits for the site and 2 or 3 
digits for each patient enrolled). This unique identifier will be on all CRF pages.  
8.3 
Treatments 
8.3.1 Treatments Administered 
Catalyst or its designee will provide the study site with a supply of Investigational product: 
amifampridine tablets 10 mg at various intervals sufficient for the completion of the study. 
Amifampridine will be provided in round, white-scored tablets and containing amifampridine 
phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet. The 
product will be provided in bottles of bulk tablets to the pharmacy representative who will 
dispense an amount for each portion of the study, in a patient-specific labeled bottle. 
8.3.2 Identity of Investigational Product 
The chemical name of amifampridine phosphate is: 
• 3,4-pyridinediamine, phosphate (1:1) diamino-3,4-pyridine, phosphate salt 
• 3,4-diaminopyridine phosphate 
The chemical structure is provided in Figure 1. 
Figure 1. 
Chemical Structure of Amifampridine Phosphate 
 
8.3.3 Product Characteristics and Labeling 
Drug product is formulated as a phosphate salt of amifampridine. Tablets were developed to 
provide the equivalent of 10 mg of amifampridine base for oral administration. Each tablet 
H3PO4
N
NH2
NH2
4
1
2
3


 
MSK-003 
Page 24 
 
Proprietary and Confidential  
07 February 2020 
contains amifampridine phosphate, microcrystalline cellulose, colloidal anhydrous silica, and 
calcium stearate. The bottles of tablets are labeled “Amifampridine Phosphate Tablets, 
10 mg.” 
The tablets are to be dispensed by the pharmacy representative into suitably sized pharmacy 
containers for patient use. Each bottle provided to patients will be labeled to include the 
compound name, site number, patient ID number, date dispensed, storage instructions, the 
statement ‘Caution – New Drug – Limited by Federal law to investigational use,’ trial 
number, manufacturer name and address, and area for instructions for use. Regional label 
requirements and translations should be used in accordance with local regulations. 
8.3.4 Storage 
At the study site, all IP must be stored under the conditions specified, 20-25○ Celsius (C) and 
in a secure area accessible only to the designated pharmacist and clinical site personnel. All 
IP must be stored and inventoried, and the inventories must be carefully and accurately 
documented according to applicable national and local regulations, ICH GCP, and study 
procedures. 
8.3.5 Directions for Administration 
All doses of study drug will be taken as outpatients. Test medication should be taken every 
day at approximately the same time, at the dose and frequency instructed by Investigator. 
The dose of amifampridine will be individually determined by the Investigator, within the 
bounds of a total daily dose of 30 mg to 80 mg, divided into doses taken 3 to 4 times per day 
as prescribed by the Investigator, based on optimal neuromuscular benefit determined from 
the Run-in Period from MSK-002 or may be modified as the discretion of the Investigator. 
The maximum single dose is 20 mg.  
8.3.6 Method of Assigning Patients to Treatment Groups 
All patients will receive open label amifampridine. Details on study drug preparation, 
dispensing medication will be included in the Pharmacy Manual.  
8.3.7 Selection of Doses Used in the Study 
Initially, the daily amifampridine dose will be the one that was determined at the end of the 
Run-in Period from MSK-002. The usual range is 30 to 80 mg total daily dose, given in 3 or 
4 divided doses, with no single dose >20 mg. Safety of a single maximum dose of 20 mg is 
based on completed animal and in vitro pharmacology, PK, and toxicology studies.  


 
MSK-003 
Page 25 
 
Proprietary and Confidential  
07 February 2020 
8.3.8 Blinding 
This is an open label study.  
8.3.9 Treatment Compliance 
Patients will be instructed to take study medication as directed and bring all IP containers and 
remaining test medication at each study visit. Patient compliance with the dosing regimen 
will be assessed by reconciliation of the used and unused IP. The quantity dispensed, 
returned, used, lost, etc., must be recorded on the medication dispensing log provided for the 
study. 
8.3.10 Investigational Product Accountability 
The study site is responsible for maintaining accurate records (including dates and quantities) 
of IP received, patients to whom IP is dispensed (patient-by-patient dose specific 
accounting), IP returned, and IP lost or destroyed. The Investigator, study site coordinator or 
designee must retain all unused or expired study supplies until the study monitor (on-site 
CRA) has confirmed the accountability data. 
8.3.11 Return and Disposition of Clinical Supplies 
Unused IP must be kept in a secure location for accountability and reconciliation by the study 
monitor. The Investigator or designee must provide an explanation for any destroyed or 
missing IP or study materials. 
Unused IP may be destroyed on site, per the site’s standard operating procedures, but only 
after Catalyst has granted approval for drug destruction. The monitor must account for all IP 
in a formal reconciliation process prior to IP destruction. All IP destroyed on site must be 
documented. Documentation must be provided to Catalyst and retained in the Investigator 
study files. If a site is unable to destroy IP appropriately, the site can return unused IP to 
Catalyst upon request. The return of IP or IP materials must be accounted for on a Study 
Drug Return Form provided by Catalyst. 
All IP and related materials should be stored, inventoried, reconciled, and destroyed or 
returned according to applicable regulations and study procedures. 
8.4 
Prior and Concomitant Medications 
All prescription and over-the-counter medications and herbal and nutritional supplements 
taken during the Long-Term study will be recorded on the designated CRF.  


 
MSK-003 
Page 26 
 
Proprietary and Confidential  
07 February 2020 
The Investigator may prescribe additional medications during the study, if the prescribed 
medication is not prohibited by the protocol. In the event of an emergency, any needed 
medications may be prescribed without prior approval, but the medical monitor must be 
notified of the use of any contraindicated medications immediately thereafter. Any 
concomitant medications added or discontinued during the study should be recorded on the 
CRF. 
Medications that should be used with caution in this study are those that prolong QTc interval.  
8.5 
Dietary or Other Protocol Restrictions 
8.5.1 Dietary Restrictions 
There are no dietary restrictions for patients during any part of this study. 
8.5.2 Contraception 
Sexually active males and females of childbearing potential and their partners must use 
effective forms of contraception, such as condom for males or occlusive cap (diaphragm or 
cervical/vault caps) for females, during the study.   
8.6 
Safety Variables 
Safety in this study will be determined from evaluation of AEs/SAEs, vital signs 
assessments, clinical laboratory assessments, ECGs, and physical examinations. Pregnancy 
testing is also required for females of childbearing potential. The timing of the required 
evaluations is described in the Schedule of Events in Table 1 and in Section 11. 
8.6.1 Adverse Events 
The determination, evaluation and reporting of AEs will be performed as outlined in 
Section 9.  
8.6.2 Vital Signs 
Specific visits for obtaining vital signs are provided in Table 1 and in Section 11 Vital signs 
will be measured while in a sitting position, after resting for 5 minutes, and include SBP and 
DBP measured in millimeters of mercury (mmHg), heart rate in beats per minute, respiration 
rate in breaths per minute. Weight (kg) and temperature in degrees C will also be measured. 
Clinically significant changes from baseline will be recorded as AEs. 


 
MSK-003 
Page 27 
 
Proprietary and Confidential  
07 February 2020 
8.6.3 Clinical Laboratory Assessments 
Specific visits for obtaining clinical laboratory assessment samples are provided in Table 1 
for the tests required by Protocol. The scheduled clinical laboratory tests are listed in Table 2. 
In brief, clinical laboratory evaluations are to be performed every 3 to 6 months. These tests 
can be performed more frequently at the discretion of the Investigator. 
All abnormal clinical laboratory result pages should be initialed and dated by an Investigator, 
along with a comment for each abnormal result indicating whether or not it is clinically 
significant. Any abnormal test results determined to be clinically significant by the 
Investigator should be repeated (at the Investigator’s discretion) until the cause of the 
abnormality is determined, the value returns to baseline or to within normal limits, or the 
Investigator determines that the abnormal value is no longer clinically significant. 
Each clinically significant laboratory result should be recorded as an AE. The diagnosis, if 
known, associated with abnormalities in clinical laboratory tests that are considered clinically 
significant by the Investigator will be recorded on the AE CRF. 
Table 2 Clinical Laboratory Tests 
Blood Chemistry 
Hematology 
Urine Tests 
Other 
Albumin  
Hemoglobin  
Appearance 
Pregnancy test, if applicable 
Alkaline phosphatase  
Hematocrit  
Color 
ALT (SGPT) 
WBC count 
pH 
 
AST (SGOT) 
RBC count 
Specific gravity 
 
Direct bilirubin 
Platelet count 
Ketones 
 
Total bilirubin 
Differential cell count  
Protein  
 
BUN 
 
Glucose  
 
Calcium 
 
Bilirubin 
 
Chloride 
 
Nitrite 
Total cholesterol 
 
Urobilinogen 
 
CO2 
 
Hemoglobin 
 
Creatine phosphokinase 
 
 
 
Creatinine 
 
 
 
Glucose 
 
 
 
GGT 
 
 
LDH 
 
 
Phosphorus 
 
 
 
Potassium 
 
 
Total protein  
 
 
 
Sodium  
 
 
 
Uric acid 
 
 
 
 


 
MSK-003 
Page 28 
 
Proprietary and Confidential  
07 February 2020 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CO2, carbon 
dioxide; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; RBC, red blood cell; SGOT, serum 
glutamic-oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase; WBC, white blood cell. 
 
8.6.4 Pregnancy Testing 
Female patients of childbearing potential will have a urine pregnancy test at the end of the 
double blind period on Day 10 and at  other time points specified in the Schedule of Events 
(Table 1) and in Section 11. Female patients with a positive pregnancy test at end of the 
double-blind study are not eligible for enrollment. Additional pregnancy tests will be 
performed at any visit in which pregnancy status is in question. 
Refer to Section 9.4 for details on the reporting procedures to follow in the event of 
pregnancy. 
8.6.5 Electrocardiogram (ECG) 
A standard 12-lead safety ECG (single tracing) will be recorded with the patient resting 
comfortably in the supine position at the time points specified in the Schedule of Events 
(Table 1) and in Section 11. Clinically significant changes from baseline will be recorded as 
AEs.  
8.6.6 Physical Examination 
A complete physical examination is to be performed at each clinic visit or, if applicable, at 
early discontinuation from the study. Complete physical examination will include 
assessments of general appearance as well as the following: 
• Head 
• Eyes 
• Ears 
• Nose 
• Throat 
• Cardiovascular 
• Dermatologic 
• Lymphatic 
• Respiratory 


 
MSK-003 
Page 29 
 
Proprietary and Confidential  
07 February 2020 
• Gastrointestinal 
• Musculoskeletal 
Body weight will be measured with each physical examination throughout the study.  
Other body systems may be examined. Clinically significant changes from baseline will be 
recorded as AEs. 
8.7 
Efficacy Variable 
Every 3 or 6 months, each patient will be assessed with the MG-ADL questionnaire.  
8.7.1 Myasthenia Gravis-Specific Activities of Daily Living (MG-ADL) 
The MG-ADL is a self-report scale designed to assess the patient’s MG symptoms and 
functional performance of activities of daily living. The MG-ADL consists of 8 items 
(derived from symptom-based components of the original 13-item Quantitative Myasthenia 
Gravis test) to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory 
(1 item) and gross motor or limb (2 items) impairment related to effects from MG 
(Appendix 1). Each of the 8 items is rated using a response scale ranging from 0 (normal) to 
3 (most severe). Lower scores indicate better functional performance. In this trial, the recall 
period for MG-ADL will be the preceding 30 days.  
 
9 
REPORTING ADVERSE EVENTS 
9.1 
Adverse Events 
For this protocol, a reportable AE is any untoward medical occurrence (e.g. sign, symptom, 
illness, disease or injury) in a patient administered the IP or other protocol-imposed 
intervention, regardless of attribution. This includes: 
• AEs not previously observed in the patient, that emerge during the study. 
• Pre-existing medical conditions judged by the Investigator to have worsened in 
severity or frequency or changed in character during the study. 
• Complications that occur as a result of non-drug protocol-imposed interventions. 
An adverse drug reaction is any AE for which there is a reasonable possibility that the IP 
caused the AE. “Reasonable possibility” means there is evidence to suggest a causal 
relationship between the IP and the AE. 


 
MSK-003 
Page 30 
 
Proprietary and Confidential  
07 February 2020 
Whenever possible, it is preferable to record a diagnosis as the AE term rather than a series 
of terms relating to a diagnosis. 
All non-serious AEs, even those which began under Protocol MSK-002, will be reported 
from the end of the double-blind study (MSK-002) through the termination visit or at the 
early termination visit and will be recorded on the AE page of the eCRF. All SAEs will be 
reported. The criteria for determining, and the reporting of SAEs is provided in Section 9.2. 
The Investigator should follow all unresolved AEs until the events are resolved or stabilized, 
the patient is lost to follow-up, or it has been determined that the study treatment or 
participation is not the cause of the AE. Resolution of AEs (with dates) should be 
documented on the appropriate CRF page(s) and in the patient’s medical record. 
The Investigator responsible for the care of the patient or qualified designee will assess AEs 
for severity, relationship to IP, and seriousness (refer to Section 9.2 for SAE definition). 
Severity (as in mild, moderate or severe headache) is not equivalent to seriousness, which is 
based on patient/event outcome or action criteria usually associated with events that pose a 
threat to a patient’s life or functioning. Seriousness (not severity) serves as a guide for 
defining regulatory reporting obligations.  
The Investigator will determine the severity of each AE using grades defined in Table 3 
(the event will be recorded on the source documents and AE CRF). Events that are Grades 4 
and 5 are serious events and require completion of both an SAE form and AE CRF.  
 


 
MSK-003 
Page 31 
 
Proprietary and Confidential  
07 February 2020 
Table 1 Categories of Severity of Adverse Events 
Severity 
Description 
Grade 1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Grade 2 
Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental ADL*. 
Grade 3 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care ADL**. 
Grade 4 
Life-threatening consequences; urgent 
intervention indicated. 
Note: Grade 4 and 5 
adverse events should 
always be reported as 
serious adverse events 
Grade 5 
Death related to AE. 
Activities of Daily Living (ADL) 
* Instrumental ADLs refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
** Self-care ADLs refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
The Investigator will suggest the relationship of an AE to the IP and will record it on the 
source documents and AE CRF, using the relationship categories defined in Table 4.  


 
MSK-003 
Page 32 
 
Proprietary and Confidential  
07 February 2020 
Table 2  Description of Relationship to Adverse Event Categories 
Relationship 
Category 
Description 
Not Related 
Exposure to the IP has not occurred 
OR 
The administration of the IP and the occurrence of the AE are not 
reasonably related in time  
OR 
The AE is considered likely to be related to an etiology other than the use 
of the IP; that is, there are no facts [evidence] or arguments to suggest a 
causal relationship to the IP. 
Possibly 
Related 
The administration of the IP and the occurrence of the AE are reasonably 
related in time 
AND 
The AE could be explained equally well by factors or causes other than 
exposure to the IP. 
Probably 
Related 
The administration of IP and the occurrence of the AE are reasonably 
related in time  
AND 
The AE is more likely explained by exposure to the IP than by other factors 
or causes. 
 
In order to classify AEs and diseases, preferred terms will be assigned by the sponsor to the 
original terms entered in the CRF, using Medical Dictionary for Regulatory Activities 
(MedDRA) terminology. 
9.2 
Serious Adverse Events 
A serious adverse event is any untoward medical occurrence that at any dose meets 1 or more 
of the following criteria: 
• Is fatal 
• Is life threatening 
• Note: Life-threatening refers to an event that places the patient at immediate risk 
of death. This definition does not include a reaction that, had it occurred in a more 
severe form, might have caused death 
• Requires or prolongs in-patient hospitalization 


 
MSK-003 
Page 33 
 
Proprietary and Confidential  
07 February 2020 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect, that is, an AE that occurs in the child or fetus 
of a patient exposed to IP prior to conception or during pregnancy 
• Is an important medical event or reaction.  
The reporting period for SAEs begins after informed consent is obtained for the current 
MSK-003 study and continues through 4 weeks after the last visit.  
Any SAE, whether or not considered related to study drug, must be reported within 24 hours 
of knowledge of the event by forwarding (fax, email) the study-specific SAE Report Form to 
Catalyst. The Investigator should not wait to collect information that fully documents the 
SAE before notifying Catalyst. As additional information becomes available, including but 
not limited to the outcome of the SAE and any medication or other therapeutic measures used 
to treat the event, it must be reported within 24 hours in a follow-up report. 
The Investigator should follow all unresolved SAEs until the events are resolved or 
stabilized, the patient is lost to follow-up, or it has been determined that the study treatment 
or participation is not the cause of the AE. Resolution of AEs (with dates) should be 
documented in the CRF and in the patient’s medical record. 
For some SAEs, Catalyst may follow up by telephone, fax, email, and/or a monitoring visit to 
obtain additional case details deemed necessary to appropriately evaluate the SAE report 
(e.g. hospital discharge summary, consultant report, autopsy report). 
At the last scheduled visit, the Investigator should instruct each patient to report any 
subsequent SAEs that the patient’s personal physician(s) believes might be related to prior 
study treatment. 
The Investigator should notify Catalyst of any death or SAE occurring at any time after a 
patient has discontinued, or terminated study participation, if felt to be related to prior study 
treatment. Catalyst should also be notified if the Investigator should become aware of the 
development of cancer, or of a congenital anomaly, in a subsequently conceived offspring of 
a patient that participated in this study.  
Reporting of SAEs to the IRB/IEC/REB will be done in compliance with the standard 
operating procedures and policies of the IRB/IEC/REB and with applicable regulatory 
requirements. Adequate documentation must be provided showing that the IRB/IEC/REB 
was properly and promptly notified as required. 


 
MSK-003 
Page 34 
 
Proprietary and Confidential  
07 February 2020 
9.3 
Safety Blood Collection 
Patients who experience a serious or severe AE should have, at the discretion of the 
Investigator, a blood sample drawn for safety labs as soon as possible after the AE has 
occurred. 
Additional blood sampling may be performed at any time during the study if warranted to 
monitor patient safety. 
9.4 
Pregnancy 
Pregnancy in a patient or partner should be reported within 24 hours of the site becoming 
aware of the pregnancy by fax or email of the Pregnancy Reporting Form in the study 
reference materials to Catalyst. In addition, pregnancy in a patient is also reported on the End 
of Study CRF. The Investigator must make every effort to follow the patient through 
resolution of the pregnancy (delivery or termination) and to report the resolution on the 
follow-up form (Pregnancy Reporting Form: Additional Information) in the study reference 
materials. In the event of pregnancy in the partner of a study patient, the Investigator should 
make every reasonable attempt to obtain the woman’s consent for release of protected health 
information. 
9.5 
Urgent Safety Measures 
The regulations governing clinical trials state that the sponsor and Investigator are required to 
take appropriate urgent safety measures to protect subjects against any immediate hazards 
that may affect the safety of subjects, and that the appropriate regulatory bodies should be 
notified according to their respective regulations. According to the European Union (EU) 
Clinical Trial Directive 2001/20/EC, “…in the light of the circumstances, notably the 
occurrence of any new event relating to the conduct of the trial or the development of the 
investigational medicinal product where that new event is likely to affect the safety of the 
subjects, the sponsor and the Investigator shall take appropriate urgent safety measures to 
protect the subjects against any immediate hazard. The sponsor shall forthwith inform the 
competent authorities of those new events and the measures taken and shall ensure that the 
IRB/IEC/REB is notified at the same time.” The reporting period for urgent safety measures 
is the period from the time of signing of the ICF through the completion of the last study 
visit. Investigators are required to report any urgent safety measures with 24 hours. 


 
MSK-003 
Page 35 
 
Proprietary and Confidential  
07 February 2020 
Examples of situations that may require urgent safety measures include discovery of the 
following: 
• An immediate need to revise IP administration (i.e. modified dose amount or 
frequency not defined in protocol). 
• Lack of study scientific value, or detrimental study conduct or management. 
• Discovery that the quality or safety of IP does not meet established safety 
requirements. 
 
9.6 
Medical Monitor Contact Information 
Contact information and additional requirements will be provided in the MuSK-003 Study 
Reference Manual. 
The Investigator is encouraged to discuss with the medical monitor any AEs for which the 
issue of seriousness is unclear or questioned. Contact information for the study Medical 
Monitor is listed below. 
 
Stanley Iyadurai, PhD, MD 
VP, Clinical Affairs 
Catalyst Pharmaceuticals, Inc. 
Tel: +1 305-420-3239 
Email: siyadurai@catalystpharma.com 
 
10 APPROPRIATENESS OF MEASUREMENTS 
The measures of safety used in this study are routine clinical and laboratory procedures. 
The efficacy measure is a self-report on how the patient is functioning for activities of daily 
living.  This standardized test has been previously used for determination of response to 
therapeutic intervention in patients with MG.  
 
11 STUDY PROCEDURES 
11.1 Start of Long Term Study 
An ICF for the Long-Term Study must be signed and dated by the patient, the Investigator or 
designee, and witness (if required) before any study-related procedures are performed.  


 
MSK-003 
Page 36 
 
Proprietary and Confidential  
07 February 2020 
The following procedures are to be performed as scheduled Day 0 and can serve as baseline 
for the Long-Term study. Any procedure not performed for MSK-002 protocol needs to be 
completed for this trial. 
• Informed Consent for MSK-003; 
• Inclusion/Exclusion criteria for the current study must be verified; 
• Standard 12-lead ECG after 5 minutes in the supine position; 
• Complete physical examination including weight;  
• Vital signs (seated position), including SBP, DBP, heart rate, respiration, and body 
temperature;  
• Clinical laboratory tests including hematology, chemistry, and urinalysis; 
• Urine pregnancy test in females of childbearing potential only; 
• MG-ADL (use data from Day 0 of MSK-002 for all patients); 
• AEs;  
• Concomitant medications. 
11.2 
End of Months 3, 6, 9, 12, 15, 21, 27, 33 and 39 
The following assessments and procedures will be determined at the end of Months 3, 6, 9, 
12, 15 and 21, 27, 33 and 39. Each month has a clinic visit window of ± 1 week. Additional 
visits are allowed as necessary. 
• Assessment of AEs/SAEs; 
• Complete physical exam with weight; 
• Vital signs (seated position), including SBP, DBP, heart rate, respiration, and body 
temperature; 
• Standard 12-lead ECG after 5 minutes in the supine position; 
• Clinical laboratory tests including hematology, chemistry, and urinalysis;  
• Urine pregnancy test in females of childbearing potential only; 
• Concomitant medications; 
• IP accountability of medication; 
• MG-ADL 


 
MSK-003 
Page 37 
 
Proprietary and Confidential  
07 February 2020 
All IP should be collected from the patient at each visit, in order to perform drug 
accountability. The site will dispense sufficient amifampridine for daily outpatient 
administration for 90 days (for 180 days on Months 15, 21, 27, 33 and 39).  If the 
Investigator wants to evaluate the patient more frequently, fewer tablets can be dispensed.   
Patients may continue to receive amifampridine until the study is terminated, the patient 
decides to withdraw from the study, or the development program is discontinued for this 
indication.  
11.2.1 End of Study Visit  
Patients will report to the study site at the end of the study and have the assessments and 
procedures listed below completed.  This visit may be incorporated at the scheduled 3-or 6-
month visit. 
• Assessment of AEs/SAEs; 
• Complete physical exam with weight; 
• Vital signs (seated position), including SBP, DBP, heart rate, respiration, and body 
temperature; 
• 12-Lead ECG; 
• Clinical laboratory tests; 
• Urine pregnancy test in females of childbearing potential only; 
• Concomitant medications;  
• IP accountability; 
• 
MG-ADL  
 
12 DATA QUALITY ASSURANCE 
Catalyst personnel or designees will visit or telephone the study site before initiation of the 
study to review with the site personnel information about the IP, protocol and other 
regulatory document requirements, source document requirements, CRFs, monitoring 
requirements, and procedures for reporting AEs/SAEs.  
At visits during and after the study, a CRA will monitor the site for compliance with 
regulatory documentation, with a focus on accurate and complete recording of data on CRFs 


 
MSK-003 
Page 38 
 
Proprietary and Confidential  
07 February 2020 
from source documents, adherence to protocol, AE/SAE reporting, and drug accountability 
records. The CRA will also verify records at the site pharmacy. 
 
13 STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE 
13.1 Statistical and Analytical Plans 
13.1.1 Interim Analyses 
No interim analyses are planned. 
13.2 Analysis Populations 
The analysis population in this study is the safety population and will consist of all patients 
who are enrolled in the Long-Term study and have received at least one dose of 
amifampridine.  Safety evaluation from MuSK-MG and AChR-MG groups will analyzed 
separately.   
13.3 Primary Endpoint 
The primary endpoint of the study is safety and tolerability of amifampridine at Months 3, 6, 
9, 12, 15 and 21, 27, 33 and 39.  For more details see Section 13.5 below. 
13.4 
Secondary Endpoint  
The secondary endpoint of the study is the MG-ADL score at Months 3, 6, 9, 12, 15, 21, 27, 
33 and 39.  
13.5 Safety Analysis  
Prior to analysis, all AEs will be coded using the MedDRA coding dictionary. Based on these 
coded terms, TEAEs and SAEs will be summarized using system organ class and preferred 
terms, as well as by relationship to treatment. All AEs will be listed, regardless of whether 
they were study treatment related.   
Vital signs will be summarized using descriptive statistics (mean, standard deviation, median, 
minimum, maximum, and number of non-missing observations) by time point.  Changes 
from baseline will also be summarized by post-dose time point. 
Clinical laboratory parameters will be summarized using descriptive statistics (mean, 
standard deviation, median, minimum, maximum, and number of non-missing observations) 
by time point.  Changes from baseline will also be summarized by post-dose time point.  In 


 
MSK-003 
Page 39 
 
Proprietary and Confidential  
07 February 2020 
addition, a shift table will be constructed to show the shifts in laboratory results by parameter 
relative to the normal ranges.  The number and percentage of subjects with the following 
shifts will be presented: normal/normal, normal/low, normal/high, low/low, low/normal, 
low/high, high/low, high/normal, and high/high. Similar shift tables will also be constructed 
for physical exam results. ECG results will be summarized in a shift table with the following 
shifts presented: normal/normal, normal/abnormal, abnormal/normal and 
abnormal/abnormal. A table of descriptive statistics for QTc will be created. 
Additional safety analyses may be performed as described in the SAP for the study. 
13.6 Determination of Sample Size 
This is an observational study and no hypothesis is being tested. Collection of long term 
safety and MG-ADL scores are required to demonstrate that amifampridine is safe and well 
tolerated in the MG population and if there is a change in dose requirements with time.  
13.7 Changes in the Conduct of the Study or Planned Analyses 
Any change in study conduct considered necessary by the Investigator will be made only 
after consultation with Catalyst, who will then issue a formal protocol amendment to 
implement the change. The only exception is when an Investigator considers that a patient’s 
safety is compromised without immediate action. In these circumstances, immediate approval 
of the chairman of the IRB/IEC/REB must be sought, and the Investigator should inform 
Catalyst and the full IRB/IEC/REB within 2 working days after the emergency occurs. 
Except for minor administrative or typographical changes, the IRB/IEC/REB must review 
and approve all protocol amendments. Protocol amendments that influence patient risk or the 
study objectives, or require revision of the ICF, must receive approval from the 
IRB/IEC/REB prior to their implementation. 
When a protocol amendment substantially alters the study design or the potential risks or 
burden to patients, the ICF will be amended and approved by Catalyst and the IRB/IEC/REB, 
and all active patients must again provide informed consent. 
Note: If discrepancies exist between the text of the statistical analysis as planned in the 
protocol, and the final SAP, a protocol amendment will not be issued, and the SAP will 
prevail. 


 
MSK-003 
Page 40 
 
Proprietary and Confidential  
07 February 2020 
14 COMPENSATION, INSURANCE, AND INDEMNITY 
There will be no charge to study patients to be in this study. Catalyst will pay all costs of 
tests, procedures, and treatments that are part of this study (as included in the site budget). In 
addition, after IRB/IEC/REB approval, Catalyst may reimburse the cost of travel for study-
related visits. Catalyst will not pay for any hospitalizations, tests, or treatments for medical 
problems of any sort, whether or not related to the study patient’s disease that are not part of 
this study. Costs associated with hospitalizations, tests, and treatments should be billed and 
collected in the way that such costs are usually billed and collected. 
The Investigator should contact Catalyst immediately upon notification that a study patient 
has been injured by the IP or by procedures performed as part of the study. Any patient who 
experiences a study-related injury should be instructed by the Investigator to seek medical 
treatment at a pre-specified medical institution if possible, or at the closest medical treatment 
facility if necessary. The patient should be given the name of a person to contact to seek 
further information about, and assistance with, treatment for study-related injuries. The 
treating physician should bill the patient’s health insurance company or other third-party 
payer for the cost of this medical treatment. If the patient has followed the Investigator’s 
instructions, Catalyst will pay for reasonable and necessary medical services to treat the 
injuries caused by the IP or study procedures, if these costs are not covered by health 
insurance or another third party that usually pays these costs. In some jurisdictions, Catalyst 
is obligated by law to pay for study-related injuries without prior recourse to third party 
payer billing. If this is the case, Catalyst will comply with the law. 
 
15 CASE REPORT FORMS AND SOURCE DOCUMENTS 
The CRO data management department or designee will perform all data management 
activities, including the writing of a data management plan outlining the systems and 
procedures to be used. 
Electronic case report forms (eCRFs) will be provided. The eCRF system, and procedures, 
and electronic signatures follow ICH requirements and applicable laws and local regulations. 
All system users will be trained on the eCRF before being granted system access. In the 
event of an entry error, or if new information becomes available, users will correct the value 
by deselecting the erroneous response and then selecting or entering the factual response. The 


 
MSK-003 
Page 41 
 
Proprietary and Confidential  
07 February 2020 
documented audit trail will include the reason for the change, the original value, the new 
value, the time of the correction and the identity of the operator. 
In the application, study data on the eCRFs will be verified to the source data, which 
necessitates access to all original recordings, laboratory reports, and patient records. 
In addition, all source data should be attributable (signed and dated). The Investigator must 
therefore agree to allow direct access to all source data. Patients must also allow access to 
their medical records, and patients will be informed of this and will confirm their agreement 
when giving informed consent. The Investigator must review and electronically sign the 
completed eCRF casebook to verify its accuracy. A CRA designated by Catalyst will 
compare the eCRFs in the application with the original source documents at the study site 
and evaluate them for completeness and accuracy before designating them as “Source Data 
Verified” in the application. If an error is discovered at any time or a clarification is needed, 
the Data Manager, CRA, or designee, will create an electronic query on the associated field. 
Site personnel will then answer the query by either correcting the data or responding to the 
query. The Data Manager or CRA will then review the response and determine either to close 
the query or re–query the site if the response does not fully address the question. This process 
will be repeated until all open queries are answered and closed. 
The CRO’s data management department may receive electronic transfers of laboratory data 
from the site’s local laboratory as well as other data from third-party vendors as appropriate.  
The Investigator will then electronically sign the casebook, specifying that the information 
on the eCRFs is accurate and complete. An electronic copy of each site’s casebooks will be 
sent to each site for retention with other study documents.  
 
16 STUDY MONITORING AND AUDITING 
Qualified individuals approved and/or designated by Catalyst will monitor all aspects of the 
study according to GCP and SOPs for compliance with applicable government regulations. 
The monitoring will take place on site as well as remotely as the monitors can view all 
clinical data electronically and can follow-up with any queries for more information. The 
Investigator agrees to allow these monitors direct access to the clinical supplies, dispensing, 
and storage areas and to the clinical files, including original medical records, of the study 
patients, and, if requested, agrees to assist the monitors. The Investigator and staff are 


 
MSK-003 
Page 42 
 
Proprietary and Confidential  
07 February 2020 
responsible for being present or available for consultation during routinely scheduled site 
visits conducted by Catalyst or its designees.  
Members of Catalyst’s GCP Quality Department or designees may conduct an audit of a 
clinical site at any time before, during, or after completion of the study. The Investigator will 
be informed if an audit is to take place and advised as to the scope of the audit. 
Representatives of the FDA or other regulatory agencies may also conduct an audit of the 
study. If informed of such an inspection, the Investigator should notify Catalyst immediately. 
The Investigator will ensure that the auditors have access to the clinical supplies, study site 
facilities, original source documentation, and all study files. 
 
17 RETENTION OF RECORDS 
The Investigator must retain all study records required by Catalyst and by the applicable 
regulations in a secure and safe facility. The Investigator must consult a Catalyst 
representative before disposal of any study records and must notify Catalyst of any change in 
the location, disposition or custody of the study files. The Investigator/institution must take 
measures to prevent accidental or premature destruction of essential documents, that is, 
documents that individually and collectively permit evaluation of the conduct of a study and 
the quality of the data produced, including paper copies of study records (e.g. patient charts) 
as well as any original source documents that are electronic as required by applicable 
regulatory requirements.  
All study records must be retained for at least 2 years after the last approval of a marketing 
application in an ICH region and until (1) there are no pending or contemplated marketing 
applications in an ICH region or (2) at least 2 years have elapsed since the formal 
discontinuation of clinical development of the IP. The Investigator/institution should retain 
patient identifiers and records for at least 15 years after the completion or discontinuation of 
the study. Patient files and other source data must be kept for the maximum period of time 
permitted by the hospital, institution or private practice. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirements or by a 
Catalyst agreement. Catalyst must be notified and will assist with retention should 
Investigator/institution be unable to continue maintenance of patient files. It is the 
responsibility of Catalyst to inform the Investigator /institution as to when these documents 
no longer need to be retained. 


 
MSK-003 
Page 43 
 
Proprietary and Confidential  
07 February 2020 
18 USE OF INFORMATION AND PUBLICATION 
Catalyst recognizes the importance of communicating medical study data and therefore 
encourages their publication in reputable scientific journals and at seminars or conferences. 
The details of the processes of producing and reviewing reports, manuscripts, and 
presentations based on the data from this study will be described in the Clinical Trial 
Agreement between Catalyst and the institution of the Investigator. 


 
MSK-003 
Page 44 
 
Proprietary and Confidential  
07 February 2020 
19 REFERENCES 
Bertorini TE, Rashed H, Zeno M, et al. Effects of 3-4 diaminopyridine (DAP) in motor 
neuron diseases. J Clin Neuromusc Dis 12[3], 129-137. 2011. 
 
Beeson D, Hantaï D, Lochmüller H, Engel AG.  126th International Workshop: Congenital 
Myasthenic Syndromes, 24–26 September 2004, Naarden, The Netherlands.  Neuromuscul 
Disord 2005;15: 498-512. 
 
Bever CT, Anderson PA, Leslie J, Panitch HS, et al. Treatment with oral 3,4 diaminopyridine 
improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, 
placebo-controlled, crossover trial. Neurology 47[6], 1457-1462. 1996.  
 
Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 
3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J 
Toxicol Clin Toxicol 33[3], 249-251. 1995.  
 
Bonanno S; Pasanisi M, Frangiamore R, Maggi L, Antozzi C, Andreetta F, Campanella A, 
Brenna G, Cottini L, and Mantegazza R. Amifampridine phosphate in the treatment of 
musclespecific kinase myasthenia gravis: a phase IIb, randomized, double-blind, placebo-
controlled, double crossover study. SAGE Open Medicine Vol 6: 1-9. 2018. 
Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, et al. Arylamine N-acetyltransferase 
(NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation 
with phenotypic activity. Am J Hum Genet 57[3], 581-592. 1995.  
 
Engelsen BA, Gronning M. Epileptic seizures in patients with multiple sclerosis. Is the 
prognosis of epilepsy underestimated? Seizure 6[5], 377-382. 1997. 
 
Evoli A, Alboini PE, Damato V, Iorio R. 3,4-Diaminopyridine may improve myasthenia 
gravis with MuSK antibodies. Neurology. 2016;86(11):1070–1 
 
Flet L, Polard E, Guillard O, Leray E, et al. 3,4-Diaminopyridine safety in clinical practice: 
an observational, retrospective cohort study. J Neurol . 2010.  
 
Fukino K, Sasaki Y, Hirai S, Nakamura T, et al. Effects of N-acetyltransferase 2 (NAT2), 
CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of 
isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33[2], 187-195. 2008.  
 
Harper CM, Engel AG.  Treatment of 31 congenital myasthenic syndrome (CMS) patients 
with 3,4-diaminopyridine (DAP).  Neurology 2000;54(Suppl 3): A395 
 


 
MSK-003 
Page 45 
 
Proprietary and Confidential  
07 February 2020 
Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, et al. Phenotyping of N-
acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be 
collected? Eur J Clin Pharmacol 65[4], 411-417. 2009.  
 
Kinnunen E, Koskenvuo M, Kaprio J, Aho K. Multiple sclerosis in a nationwide series of 
twins. Neurology 37[10], 1627-1629. 1987. 
 
Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic 
syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 7, 341-349. 2011. 
 
Lundh H, Nilsson O, Rosen I, Johansson S. Practical aspects of 3,4-diaminopyridine 
treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 88[2], 136-140. 
1993.  
 
Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine 
and pyridostigmine. Neurology 34[10], 1324-1330. 1984.  
 
Maddison P, Newsom-Davis J, Mills KR. Effect of 3,4-diaminopyridine on the time course 
of decay of compound muscle action potential augmentation in the Lambert-Eaton 
myasthenic syndrome. Muscle Nerve 21[9], 1196-1198. 1998a. 
 
Maddison P, Newsom-Davis J, Mills KR. Distribution of electrophysiological abnormality in 
Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 65, 213-217. 1998b. 
 
McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of 
Lambert-Eaton myasthenic syndrome. N Engl J Med 321[23], 1567-1571. 1989.  
 
Moreau T, Sochurkova D, Lemesle M, Madinier G, et al. Epilepsy in patients with multiple 
sclerosis: radiological-clinical correlations. Epilepsia 39[8], 893-896. 1998. 
 
Mori S1, Kishi M, Kubo S, Akiyoshi T, Yamada S, Miyazaki T, Konishi T, Maruyama N, 
Shigemoto K. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK 
antibody-induced mouse model of myasthenia gravis. J Neuroimmunol. 245, 75-78, 2012. 
 
Morsch M1, Reddel SW, Ghazanfari N, Toyka KV, Phillips WD. Pyridostigmine but not 3,4-
diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-
specific kinase autoantibody. J Physiol. 591, 2747-2762, 2013. 
 
Palace J, Wiles CM, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital 
(hereditary) myasthenia. J Neurol Neurosurg Psychiatry 54[12], 1069-1072. 1991. 
 


 
MSK-003 
Page 46 
 
Proprietary and Confidential  
07 February 2020 
Pasnoor M, Wolfe GI, Nations S, Trivedi J, et al. Clincal findings in MuSK-antibody positive 
myasthenia gravis: A U.S. experience.  Muscle & Nerve 41, 370 - 374. 2010 
 
Sabbagh A, Darlu P. SNP selection at the NAT2 locus for an accurate prediction of the 
acetylation phenotype. Genet Med 8[2], 76-85. 2006.  
 
Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-
diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54[3], 603-607. 2000.  
 
Sanders DB, Howard JF Jr, Massey JM. 3,4-Diaminopyridine in Lambert-Eaton myasthenic 
syndrome and myasthenia gravis. Ann N Y Acad Sci 681, 588-590. 1993.  
 
Skjei KL, Lennon VA, Kuntz NL: Muscle specific kinase autoimmune myasthenia gravis in 
children: A case series. Neuromuscul Disorders 2013 Nov;23(11):874-882 
 
Skeie GO, Apostolski S, Evoli A, Gilhus NE, et al. Guidelines for the treatment of 
autoimmune neuromuscular transmission disorders. Eur J Neurol 17[7], 893-902. 2010. 
 
Skeie GO, Apostolski S, Evoli A, Gilhus NE, et al. Guidelines for the treatment of 
autoimmune neuromuscular transmission disorders. Eur J Neurol 13[7], 691-699. 2006.  
 
 
 


 
MSK-003 
Page 47 
 
Proprietary and Confidential  
07 February 2020 
20 INVESTIGATOR RESPONSIBILITIES 
20.1 Conduct of Study and Protection of Human Patients 
The Investigator will ensure that: 
• He or she will conduct the study in accordance with the relevant, current protocol and 
will only make changes in a protocol after notifying the sponsor, except when 
necessary to protect the safety, rights, or welfare of patients. 
• He or she will personally conduct or supervise the study. 
• He or she will inform any potential patients, or any persons used as controls, that the 
drugs are being used for investigational purposes and he or she will ensure that the 
requirements relating to obtaining informed consent in compliance with ICH E6 
(Section 4.8), and other applicable local regulations, are met.  
• He or she will report to the sponsor adverse experiences that occur during the 
investigation in compliance with the standard operating procedures and policies of the 
IRB/IEC/REB and with applicable regulatory requirements. 
• He or she has read and understands the information in the Investigator’s Brochure, 
including potential risks and side effects of the drug. 
• His or her staff and all persons who assist in the conduct of the study are informed 
about their obligations in meeting the above commitments. 
• He or she will ensure that adequate and accurate records are kept in accordance with 
ICH and GCP requirements and to ensure those records are available for inspection. 
• He or she will ensure that the IRB/IEC/REB complies with ICH and GCP 
requirements, and other applicable regulations, and conducts initial and ongoing 
reviews and approvals of the study. He or she will also ensure that any change in 
research activity and all problems involving risks to human patients or others are 
reported to the IRB/IEC/REB. Additionally, he or she will not make any changes in 
the research without IRB/IEC/REB approval, except where necessary to eliminate 
apparent immediate hazards to human patients. 
• He or she agrees to comply with all other requirements regarding the obligations of 
clinical Investigators and all other pertinent ICH and GCP requirements. 
• He or she agrees to comply with electronic signature requirements in accordance with 
ICH requirements and applicable laws and local regulations. 




 
MSK-003 
Page 49 
 
Proprietary and Confidential  
07 February 2020 
APPENDIX 1: MYASTHENIA GRAVIS-SPECIFIC ACTIVITIES OF DAILY 
LIVING (MG-ADL) 
The MG-ADL is a self-report scale designed to assess the patient’s MG symptoms and 
functional performance of activities of daily living. Eight items as listed below will be 
assessed by the patient at the protocol specified time points (see Table 1).  
 
 
 
 
 
 
Score 
Grade 
0 
1 
2 
3 
(0, 1, 2, 3) 
1.Talking  
Normal  
Intermittent 
slurring of 
nasal speech 
Constant 
slurring or 
nasal, but can 
be understood 
Difficult to 
understand 
speech 
 
2. Chewing 
Normal 
Fatigue with 
solid food 
Fatigue with 
soft food 
Gastric tube 
 
3.Swallowing 
Normal  
Rare episode of 
choking 
Frequent 
choking 
necessitating 
changes in diet 
Gastric tube 
 
4.Breathing  
Normal 
Shortness of 
breath with 
exertion 
Shortness of 
breath at rest 
Ventilator 
dependence 
 
5. Impairment of 
ability to brush 
teeth or comb hair 
 
None 
Extra effort, but 
no rest 
periods needed 
Rest periods 
needed  
Cannot do one 
of these 
functions 
 
6.Impairment of 
ability to arise 
from a chair 
None  
Mild, 
sometimes uses 
arms 
Moderate, 
always uses 
arms 
Severe, requires 
assistance 
 
7. Double vision  
None 
Occurs, but not 
daily 
Daily, but not 
constant 
Constant 
 
8. Bothersome 
eyelid droop  
None  
Occurs, but not 
daily 
Daily, but not 
constant 
Constant 
 
 
 
 
 
 
MG-ADL 
score 
 
 
 
 
 
(items 1-8) 
 
 
 

Prot_000.pdf: 


 
MSK-003 
Page 1 
 
Proprietary and Confidential  
12 November 2017
CLINICAL STUDY PROTOCOL 
Study Title: 
Long Term Safety Study of Amifampridine Phosphate in 
Patients with MuSK Antibody Positive and AChR Antibody 
Positive Myasthenia Gravis Patients 
Protocol Number: 
MSK-003 
Investigational Product: Amifampridine phosphate (3,4-diaminopyridine phosphate) 
IND/EUDRACT 
Number: 
106263 / 2017-004777-14 
Indication: 
Musk Antibody Positive Myasthenia Gravis 
External Support: 
Catalyst Pharmaceuticals, Inc. 
Development Phase: 
Phase 3 
Medical Officer: 
Gary Ingenito, MD, PhD 
Study Design: 
Open Label  
Dose: 
30-80 mg total daily dose  
Patient Population: 
Patients with MuSK antibody positive Myasthenia Gravis and a 
sample of patients with AChR antibody positive Myasthenia 
Gravis 
Date of Protocol: 
12 November, 2017 – USA 
 
 
Property of Catalyst Pharmaceuticals, Inc. 
CONFIDENTIAL 
May not be divulged, published, or otherwise disclosed to others without prior written 
approval from Catalyst Pharmaceuticals, Inc. 
 
This study will be conducted according to the principles of Good Clinical Practice as 
described in the U.S. Code of Regulations and the International Conference on 
Harmonisation Guidelines, including the archiving of essential documents. 
 
 
 


 
MSK-003 
Page 2 
 
Proprietary and Confidential  
12 November 2017
 
 
PROCEDURES IN CASE OF AN EMERGENCY 
Emergency Contact Information 
Role in Study 
Name 
Contact Information 
Medical Monitor 
Gary Ingenito, MD, PhD 
Chief Medical Officer 
Catalyst Pharmaceuticals, Inc. 
355 Alhambra Circle, Suite 1250 
Coral Gables, FL 33134 
Tel: 305-420-3200, ext. 123 
Email: 
gingenito@catalystpharma.com 
 
Coordinating Investigator 
Renato Mantegazza, MD 
Director Department of 
Neuroimmunology and 
Neuromuscular Diseases 
Carlo Besta Neurological 
Institute 
Via Celoria 11-201332 Milan, 
Italy 
 
Clinical Project Lead 
Adriana Manari 
Catalyst Pharmaceuticals, Inc. 
355 Alhambra Circle, Suite 1250 
Coral Gables, FL 33134 
Tel: 305-420-3217 
Email: 
amanari@catalystpharma.com 
 
Safety Reporting 
 
Jonathan Rubine, MD 
Associate Medical Director 
Catalyst Pharmaceuticals, Inc. 
Tel: 305-420-3233 
Email: 
jrubine@catalystpharma.com 
 
 
 
 


 
MSK-003 
Page 3 
 
Proprietary and Confidential  
12 November 2017
Synopsis 
TITLE OF STUDY: 
Long Term Safety Study of Amifampridine Phosphate in Patients with MuSK Antibody Positive 
and AChR Antibody Positive Myasthenia Gravis Patients 
PROTOCOL NUMBER: 
MSK-003 
STUDY SITES:  
Up to 20 sites in USA and Europe 
PHASE OF DEVELOPMENT: 
Phase 3 
STUDY RATIONALE: 
The purpose of this study is to evaluate the long-term safety and tolerability of amifampridine 
phosphate in patients with MuSK antibody positive and AChR antibody positive myasthenia gravis  
(MG) patients who completed Protocol MSK-002.  
OBJECTIVES: 
Primary 
• 
To characterize the long-term safety and tolerability of amifampridine phosphate in patients 
with MG  
Secondary 
• 
To assess the clinical efficacy of amifampridine phosphate over time in patients with MG 
based on change in Myasthenia Gravis Activities of Daily Living Score (MG-ADL)  
STUDY DESIGN AND PLAN:  
This is a long-term extension study for patients who participated in Protocol MSK-002 where the 
efficacy and safety of amifampridine was evaluated, in patients diagnosed with MuSK-MG or 
AChR-MG. The planned duration of participation for each patient is at least 9 months (i.e. until 
amifampridine is approved by Regulatory Agencies for the treatment of MG or the development 
program is discontinued for this indication). 
All patients who have completed study MSK-002 and sign an informed consent may enroll in the 
long-term study.  Those patients who demonstrated benefit after completing the dose titration 
period but failed to meet the randomization criteria on Day 0 of MSK-002 may also be eligible for 
this study.  The evaluations for MSK-002 can serve as baseline for the Long-Term study, if 
available 
 


 
MSK-003 
Page 4 
 
Proprietary and Confidential  
12 November 2017
The optimal dose and schedule for amifampridine from the end of the Run-in Period from Study 
MSK-002 will initially be used for each patient. The Investigator may adjust the dose of 
amifampridine during the course of this trial, in order to optimize neuromuscular benefit for the 
patient. Clinic visits for safety assessment and for evaluation of MG-ADL will be made at Months 
3, 6, 9, 12, 15, and 21.  Additional visits may occur at the discretion of the Investigator.   
NUMBER OF PATIENTS PLANNED:  
Up to about 60 MuSK-MG patients and 10 AChR-MG patients will be studied. 
CRITERIA FOR INCLUSION AND EXCLUSION:  
Individuals eligible to participate in this study must meet all the following inclusion criteria: 
1. Participated in the MSK-002 study 
2. Willing and able to provide written informed consent after the nature of the study has been 
explained and before the start of any research-related procedures. 
3. Female patients of childbearing potential must have a negative pregnancy test (urine 
human chorionic gonadotropin [HCG] at the end of MSK-002 study); and must practice an 
effective, reliable contraceptive regimen during the study and for up to 30 days following 
discontinuation of treatment. 
4. Ability to participate in the study based on overall health of the patient and disease 
prognosis, as applicable, in the opinion of the Investigator; and able to comply with all 
requirements of the protocol, including completion of study questionnaires. 
 
Individuals who met any of the exclusion criteria in the original protocol or those listed below are 
not eligible to participate in the study: 
1. Epilepsy and currently on medication. 
2. Clinically significant abnormalities in 12 lead ECG, in the opinion of the Investigator. 
3. Breastfeeding or pregnant at Screening or planning to become pregnant at any time during 
the study. 
4. Intolerable amifampridine-related side effects   
5. Treatment with an investigational drug (other than amifampridine) or device while 
participating in this study. 
6. Any medical condition that, in the opinion of the Investigator, might interfere with the 
patient’s participation in the study, poses an added risk for the patient, or confound the 
assessment of the patient. 
 


 
MSK-003 
Page 5 
 
Proprietary and Confidential  
12 November 2017
INVESTIGATIONAL PRODUCT(S), DOSE, ROUTE, AND REGIMEN:  
The investigational product (IP) is amifampridine tablets 10 mg, and it will be provided in round, 
white-scored tablets, containing amifampridine phosphate formulated to be the equivalent of 10 mg 
amifampridine base per tablet. Dosing is up to 80 mg/day in 3 or 4 divided doses. 
 
The investigational product will be provided by Catalyst Pharmaceuticals, Inc., 355 Alhambra 
Circle, Suite 1250, Coral Gables, Florida, 33134, United States. 
REFERENCE THERAPY, DOSE, ROUTE, AND REGIMEN:  
None 
DURATION OF TREATMENT: 
Amifampridine will be continued as long as patients benefit from the treatment until the drug is 
approved by Regulatory Agencies or until the development of the drug is discontinued for this 
indication.  
CRITERIA FOR EVALUATION: 
Safety (primary endpoint): 
Safety will be assessed by the incidence of treatment-emergent adverse events (TEAEs), including 
serious adverse events (SAEs). Vital signs, 12-lead ECGs, clinical laboratory tests, physical 
examination findings, and concomitant medications will also be evaluated.  
Efficacy (secondary endpoint):  
Efficacy will be assessed by change in MG-ADL score over time. 
STATISTICAL METHODS: 
Sample Size Determination 
The study is not powered with respect to any endpoint, but is an observational study to assess long 
term safety and lack of tolerance to the effects of amifampridine on MG-ADL.   
Safety Analysis 
Safety analyses will be conducted on the safety population (i.e. all patients who receive at least 1 
dose of amifampridine. The safety analysis will be descriptive and will be presented on observed 
data only. 
All AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA). Only 
TEAEs will be included in the safety analysis. The incidence of TEAEs will be summarized by 
system organ class, preferred term, relationship to treatment, and severity.  
All other safety measures including ECGs, vital signs, laboratory tests, physical examination and 
concomitant medications data will also be summarized. 
Subgroup analyses for safety will be performed independently on the MuSK-MG and AChR-MG 
groups.  No pooled analyses are planned. 
Efficacy Analysis 
Efficacy analysis will be conducted on all patients who receive at least 1 dose of amifampridine 
and have at least one post-treatment efficacy assessment. The efficacy analysis will be descriptive 
and will be presented on observed data only independently on the MuSK-MG and AChR-MG 


 
MSK-003 
Page 6 
 
Proprietary and Confidential  
12 November 2017
groups.  No pooled analyses are planned. 
 
 


 
MSK-003 
Page 7 
 
Proprietary and Confidential 
 
12 November 2017 
2 TABLE OF CONTENTS 
1 TITLE PAGE .......................................................................................................................1 
2 TABLE OF CONTENTS .....................................................................................................7 
3 LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS ....................................11 
4 ETHICS..............................................................................................................................13 
4.1 Independent Ethics Committee / Institutional Review Board ...................................13 
4.2 Ethical Conduct of Study ..........................................................................................13 
4.3 Patient Information and Informed Consent ...............................................................14 
5 INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE ........................14 
6 INTRODUCTION .............................................................................................................14 
6.1 Effectiveness in MuSK-MG and Other Indications ..................................................15 
6.2 Safety of Amifampridine and Amifampridine Phosphate .........................................16 
6.3 Overall Risks and Benefits ........................................................................................18 
6.4 Study Rationale .........................................................................................................18 
7 STUDY OBJECTIVES ......................................................................................................18 
7.1 Primary Objective .....................................................................................................18 
7.2 Secondary Objective .................................................................................................18 
8 INVESTIGATIONAL PLAN ............................................................................................18 
8.1 Overall Study Design and Plan .................................................................................18 
8.2 Selection of Study Population ...................................................................................21 
8.2.1 
Inclusion Criteria .........................................................................................21 
8.2.2 
Exclusion Criteria ........................................................................................21 
8.2.3 
Removal of Patients from Treatment or Assessment ..................................22 
8.2.4 
Patient Identification ...................................................................................23 
8.3 Treatments .................................................................................................................23 
8.3.1 
Treatments Administered ............................................................................23 
8.3.2 
Identity of Investigational Product ..............................................................23 
8.3.2.1 
Product Characteristics and Labeling ..........................................23 
8.3.2.2 
Storage .........................................................................................24 
8.3.3 
Directions for Administration .....................................................................24 


 
MSK-003 
Page 8 
 
Proprietary and Confidential 
 
12 November 2017 
8.3.4 
Method of Assigning Patients to Treatment Groups ...................................24 
8.3.5 
Selection of Doses Used in the Study .........................................................24 
8.3.6 
Blinding .......................................................................................................25 
8.3.7 
Treatment Compliance ................................................................................25 
8.3.8 
Investigational Product Accountability .......................................................25 
8.3.9 
Return and Disposition of Clinical Supplies ...............................................25 
8.4 Prior and Concomitant Medications .........................................................................25 
8.5 Dietary or Other Protocol Restrictions......................................................................26 
8.5.1 
Dietary Restrictions .....................................................................................26 
8.5.2 
Contraception ..............................................................................................26 
8.6 Safety Variables ........................................................................................................26 
8.6.1 
Adverse Events ............................................................................................26 
8.6.2 
Vital Signs ...................................................................................................26 
8.6.3 
Clinical Laboratory Assessments ................................................................27 
8.6.4 
Pregnancy Testing .......................................................................................28 
8.6.5 
Electrocardiogram (ECG) ............................................................................28 
8.6.6 
Physical Examination ..................................................................................28 
8.7 Efficacy Variable ......................................................................................................29 
8.7.1 
Myasthenia Gravis-Specific Activities of Daily Living (MG-ADL) ..........29 
9 REPORTING ADVERSE EVENTS .................................................................................29 
9.1 Adverse Events .........................................................................................................29 
9.2 Serious Adverse Events ............................................................................................32 
9.3 Safety Blood Collection ............................................................................................34 
9.4 Pregnancy ..................................................................................................................34 
9.5 Urgent Safety Measures ............................................................................................34 
9.6 Medical Monitor Contact Information ......................................................................35 
10 APPROPRIATENESS OF MEASUREMENTS ...............................................................35 
11 STUDY PROCEDURES ...................................................................................................35 
11.1 Start of Long Term Study .........................................................................................35 
11.2 End of Months 3, 6, 9, 12, 15 and 21 in Long Term Study ......................................36 


 
MSK-003 
Page 9 
 
Proprietary and Confidential 
 
12 November 2017 
11.2.1 End of Study Visit .......................................................................................37 
12 DATA QUALITY ASSURANCE .....................................................................................37 
13 STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE ..................38 
13.1 Statistical and Analytical Plans .................................................................................38 
13.1.1 Interim Analyses ..........................................................................................38 
13.2 Analysis Populations .................................................................................................38 
13.3 Primary Endpoint ......................................................................................................38 
13.4 Secondary Endpoint ..................................................................................................38 
13.5 Safety Analysis .........................................................................................................38 
13.6 Determination of Sample Size ..................................................................................39 
13.7 Changes in the Conduct of the Study or Planned Analyses ......................................39 
14 COMPENSATION, INSURANCE, AND INDEMNITY .................................................39 
15 CASE REPORT FORMS AND SOURCE DOCUMENTS ..............................................40 
16 STUDY MONITORING AND AUDITING .....................................................................41 
17 RETENTION OF RECORDS ...........................................................................................42 
18 USE OF INFORMATION AND PUBLICATION ...........................................................42 
19 REFERENCES ..................................................................................................................43 
20 INVESTIGATOR RESPONSIBILITIES ..........................................................................46 
20.1 Conduct of Study and Protection of Human Patients ...............................................46 
21 SIGNATURE PAGE .........................................................................................................47 
APPENDIX 1: MYASTHENIA GRAVIS-SPECIFIC ACTIVITIES OF DAILY 
LIVING (MG-ADL) ..........................................................................................................48 
 
 
 


 
MSK-003 
Page 10 
 
Proprietary and Confidential 
 
12 November 2017 
List of In-text Tables 
Table 1 Schedule of Events......................................................................................................20 
Table 2 Clinical Laboratory Tests ............................................................................................27 
Table 3 Categories of Severity of Adverse Events ..................................................................31 
Table 4 Description of Relationship to Adverse Event Categories .........................................32 
 
List of In-text Figure 
Figure 1 Chemical Structure of Amifampridine Phosphate .....................................................23 
 


 
MSK-003 
Page 11 
 
Proprietary and Confidential 
 
12 November 2017 
3 
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS 
Abbreviations 
Abs 
Antibodies 
ACh 
Acetylcholine 
AChR 
Acetylcholine receptor 
AChR-MG 
Acetylcholine receptor Myasthenia Gravis 
ADL 
Activities of Daily Living 
AE(s) 
adverse event(s) 
ALT 
alanine aminotransferase  
AST 
aspartate aminotransferase 
ATU 
Autorisations Temporaires d'Utilisation Normative 
CMS 
congenital myasthenia syndromes 
CRA(s) 
clinical research associate(s) 
CRF 
CRO 
case report form 
contract research organization 
DBP 
diastolic blood pressure 
ECG(s) 
electrocardiogram(s) 
eCRF 
electronic case report form 
EFNS 
European Federation of Neurological Societies  
FDA 
Food and Drug Administration 
GCP 
Good Clinical Practice 
HCG 
human chorionic gonadotropin 
ICF 
informed consent form 
ICH 
International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use 
ICH E6 
ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 
IEC 
independent ethics committee 
IP 
investigational product 
IRB 
institutional review board 
K+ 
potassium ion 
kg 
kilogram 
LEMS 
Lambert-Eaton myasthenic syndrome 
MedDRA 
Medical Dictionary for Regulatory Activities 
mg 
milligram 


 
MSK-003 
Page 12 
 
Proprietary and Confidential 
 
12 November 2017 
MG-ADL 
Myasthenia Gravis-Specific Activities of Daily Living 
MG 
Myasthenia Gravis 
MI 
myocardial infarction 
mmHg 
millimeters of mercury 
MS 
multiple sclerosis 
MuSK 
muscle-specific receptor tyrosine kinase 
MuSK-MG 
muscle-specific receptor tyrosine Kinase-Myasthenia Gravis 
ng/mL 
nanograms per milliliter 
PI 
Principal Investigator 
PK 
pharmacokinetic 
QTc 
QT wave corrected for heart rate 
REB 
research ethics board 
SAE(s) 
serious adverse event(s) 
SAP 
statistical analysis plan 
SBP 
systolic blood pressure 
SOPs 
standard operating procedures 
TEAE(s) 
treatment emergent adverse event(s) 
US 
United States 
 
Definition of Terms:  
Investigational Product (IP): 
“A pharmaceutical form of an active ingredient or placebo being tested or used as a reference 
in a clinical trial, including a product with a marketing authorization when used or assembled 
(formulated or packaged) in a way different from the approved form, or when used for an 
unapproved indication, or when used to gain further information about an approved use” 
(from International Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline: 
Guideline for Good Clinical Practice E6 [ICH E6]). The terms “IP” and “study drug” may be 
used interchangeably in the protocol. 


 
MSK-003 
Page 13 
 
Proprietary and Confidential 
 
12 November 2017 
4 
ETHICS 
4.1 
Independent Ethics Committee / Institutional Review Board 
Before initiating the study, the Investigator will obtain written confirmation that the 
institutional review board (IRB), independent ethics committee (IEC), or Research Ethics 
Board (REB) is properly constituted and compliant with International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human 
Use (ICH) and Good Clinical Practice (GCP) requirements, applicable laws and local 
regulations. A copy of the confirmation from the IRB/IEC/REB will be provided to Catalyst 
Pharmaceuticals, Inc. (Catalyst) or its designee. The Investigator will provide the 
IRB/IEC/REB with all appropriate material, including the protocol, Investigator’s Brochure 
or Package Insert, the Informed Consent Form (ICF) including compensation procedures, and 
any other written information provided to the patients, including all ICFs translated to a 
language other than the native language of the clinical site. The study will not be initiated 
and Investigational Product (IP) supplies will not be shipped to the site until appropriate 
documents from the IRB/IEC/REB confirming unconditional approval of the protocol, the 
ICF, and all patient recruitment materials are obtained in writing by the Investigator, and 
copies are received at Catalyst or its designee. The approval document should refer to the 
study by protocol title and Catalyst protocol number (if possible), identify the documents 
reviewed, and include the date of the review and approval. The Investigator is responsible to 
ensure that the appropriate reports on the progress of the study are made to the IRB/IEC/REB 
in accordance with applicable guidance documents and governmental regulations. 
4.2 
Ethical Conduct of Study 
This study will be conducted in accordance with the following: 
• ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 
(ICH E6); and 
• The ethical principles established by the Declaration of Helsinki. 
Specifically, this study is based on adequately performed laboratory and animal 
experimentation. The study will be conducted under a protocol reviewed and approved by an 
IRB/IEC/REB and will be conducted by scientifically and medically qualified persons. The 
benefits of the study are in proportion to the risks. The rights and welfare of the patients will 
be respected and the Investigators conducting the study do not find the hazards to outweigh 


 
MSK-003 
Page 14 
 
Proprietary and Confidential 
 
12 November 2017 
the potential benefits. Each patient will provide written, informed consent prior to any 
study-related tests or evaluations being performed. 
4.3 
Patient Information and Informed Consent 
A properly written and executed ICF, in accordance with the Declaration of Helsinki, ICH E6 
(Section 4.8), and other applicable local regulations, will be obtained for each patient before 
entering the patient into the study. The Investigator will prepare the ICF and provide the 
documents to Catalyst, or designee, for review. The IRB/IEC/REB must approve the 
documents before their implementation. A copy of the approved ICF, and if applicable, a 
copy of the approved patient information sheet and all ICFs translated to a language other 
than English must also be received by Catalyst, or designee, prior to any study-specific 
procedures being performed. 
The Investigator will provide copies of the signed ICF to each patient and will maintain the 
original in the record file of the patient. 
5 
INVESTIGATORS AND STUDY ADMINISTRATIVE STRUCTURE 
Before beginning the study, the Investigator must provide to Catalyst or designee, a fully 
executed and signed US Food and Drug Administration (FDA) Form FDA 1572 and a 
Financial Disclosure Form.  All sub-investigators must be listed on Form FDA 1572 and 
provide a Financial Disclosure Form. 
Clinical research associates (CRAs) or trained designees will monitor the site on a periodic 
basis, both remotely and with onsite visits, and perform verification of source documentation 
for a representative sample of patients as well as other required review processes. Principal 
Investigator (PI) will be responsible for the timely reporting of serious adverse events (SAEs) 
to Catalyst, or designee, and the IRB. Catalyst Medical Department (or designee) will be 
responsible for the timely reporting of SAEs to appropriate regulatory authorities, as 
required. 
Laboratory evaluations will be performed at the local laboratory associated with the study 
site.  
6 
INTRODUCTION 
Information on disease background, amifampridine, previously completed nonclinical and 
clinical studies of amifampridine, is described in the Introduction of MSK-002 and in the 


 
MSK-003 
Page 15 
 
Proprietary and Confidential 
 
12 November 2017 
Investigator’s Brochure supplied by Catalyst (June 2017). Investigators are to review this 
document before initiating this study.  
Amifampridine is a non-specific voltage-dependent potassium (K+) channel blocker. 
Blockade of K+ channels causes depolarization of the presynaptic membrane and slows down 
or inhibits repolarization. Prolonged depolarization results in opening of slow voltage-
dependent calcium (Ca2+) channels and allows a subsequent influx of Ca2+. The increased 
concentration of intracellular Ca2+ induces exocytosis of the synaptic vesicles containing 
acetylcholine (ACh), thus releasing an increased level of ACh into the synaptic cleft 
(Maddison, 1998a; Maddison, 1998b). The influx of ACh into the presynaptic cleft enhances 
neuromuscular transmission, providing improved muscle function. 
Mori et al. (2012) found that amifampridine improved neuromuscular transmission by 
predominantly increasing ACh release in the neuromuscular junction of in mice with MG 
induced by antibodies against muscle-specific kinase (MuSK).  Furthermore, a mouse model 
of MuSK-MG, amifampridine significantly enhanced neuromuscular transmission after 1 
week of treatment without exacerbating loss of endplate AChRs (Morsch et al. 2013).  
Multiple studies were conducted to evaluate the cardiac safety, pharmacokinetics and 
toxicity profile in rats and dogs. Reproductive and developmental toxicity studies with 
amifampridine were also conducted in rats and rabbit as well a variety of in vitro and in vivo 
genotoxicity studies, and in vitro metabolism/transporter studies. The main nonclinical 
findings related to amifampridine were central and autonomic nervous system effects, the 
development of Schwannomas, and histologic changes in muscle tissues. Below is an 
abbreviated summary of the effectiveness of amifampridine in MuSK-MG and overall safety 
in other patient populations. 
6.1 
Effectiveness in MuSK-MG and Other Indications 
Small studies have demonstrated the beneficial effects of amifampridine in patients with 
MuSK-MG in 2 children, who achieved some benefit (Skjei, 2013) and 1 adult (Evoli, 2016).  
Following 4 months of treatment, the authors report the adult patient had obvious 
improvement of ptosis, decreased neck weakness and arm fatigability. In an Investigator-
Sponsored MuSK-MG randomized, double-blind, placebo-controlled, cross-over study 
conducted in Italy, 7 MuSK-MG patients demonstrated statistically significantly higher 
functional performance in all validated assessment scales when they were administered 
amifampridine compared to placebo. Tolerability to amifampridine was excellent 
(unpublished data). 


 
MSK-003 
Page 16 
 
Proprietary and Confidential 
 
12 November 2017 
Results from the MSK-002 study will also be used to establish efficacy of amifampridine in 
MuSK-MG. 
A review of the literature documents that amifampridine is a safe and effective treatment in 
multiple neurologic disorders and is recommended by the EFNS for first-line symptomatic 
treatment of patients with LEMS (Skeie, 2006; Skeie, 2010; Lindquist, 2011).  
6.2 
Safety of Amifampridine and Amifampridine Phosphate 
Safety data collected from 1,454 patients or healthy volunteers in controlled study LMS-002 
[(Lambert-Eaton myasthenic syndrome LEMS)], controlled and uncontrolled published 
studies of LEMS or other neurologic conditions, a 3-year safety surveillance study (ATU), 
and pharmacokinetic (PK) studies demonstrate amifampridine is well tolerated up to and 
including 80 mg/day (Firdapse Investigator Brochure, June 2017). The most common 
adverse events observed from the clinical safety data were perioral and peripheral 
paresthesias and gastrointestinal disorders (abdominal pain, nausea, diarrhea, epigastralgia).  
These events were typically mild or moderate in severity, and transient, seldom requiring 
dose reduction or withdrawal from treatment. In the pharmacogenomic study in healthy 
subjects (classified as either slow acetylators or fast acetylators), slow acetylators 
experienced >80% more drug-related AEs compared with fast acetylators (FIR-001). 
Clinically significant or serious adverse events were infrequent in all studies for all 
indications. A total of 12 deaths were reported in the 1,454 patients or healthy subjects. Six 
of 12 deaths were associated with accompanying malignancy (1 of 6 with pulmonary 
embolus as terminal event), 1 due to tracheobronchitis, and 2 due to myocardial infarction 
(MI). Attribution to amifampridine for 2 of 3 deaths from the ATU study was specified as 
unrelated; causality for the third death was not reported. No attribution was specified in the 
academic series, but the author singled out the fatal MI as the only serious incident during 
amifampridine therapy, implying that the 2 deaths due to malignancy, the 1 due to 
malignancy and pulmonary embolus and the 1 due to tracheobronchitis were not related in 
his opinion. The author further states that no pathological findings related to amifampridine 
were found in the patient who died of tracheobronchitis. For 1 of the fatal MIs, the author 
speculates that a “sudden increase of physical activity” with amifampridine may have been a 
contributant (Lundh, 1984; Lundh, 1993); no causality was reported for the other fatal MI 
(Bertorini, 2011). Three deaths occurred in children with congenital myasthenia syndromes 
(CMS), including 2 with fast-channel CMS (Beeson, 2005). Although no causal relationship 
was established with amifampridine, the authors advise its use cautiously in children and in 
fast-channel patients. The other CMS death was not thought to be related to amifampridine 


 
MSK-003 
Page 17 
 
Proprietary and Confidential 
 
12 November 2017 
(Palace, 1991). Overall 7 of 12 deaths were not considered related to amifampridine; neither 
cause nor causality is known for 4 deaths; and amifampridine may have contributed 
indirectly to 1 of the MI-related deaths.   
The most frequent clinically significant or serious event was seizure. A total of 10 (0.69%) 
patients out of 1,454 patients or healthy subjects experienced seizures or convulsions after 
treatment with amifampridine. Electroencephalogram findings, reported for 3 of the 10 
patients, did not show epileptiform activity. Three of 10 seizures occurred in patients with 
LEMS (3/209; 1.44%), 4 occurred in patients with MS (4/774; 0.5%), 1 occurred in a patient 
with CMS (1/88; 1.14%) (Harper, 2000) and 2 seizures were reported in a literature-based 
study where both MG and LEMS patients were enrolled, but the paper did not state the 
indication (Sanders, 1993; Sanders, 2000; Flet, 2010; McEvoy, 1989; Boerma, 1995; Bever, 
1996).  
Three patients (LEMS or MG) experienced seizures on a daily dose of ≥90 mg/day. No other 
cause was apparent in 2 cases; 1 patient had concurrent toxic serum levels of theophylline 
(McEvoy, 1989; Sanders, 1993). A fourth patient with LEMS had multiple seizures 
following accidental ingestion of 360 mg/day amifampridine for 7 days (prescribed dose 
60 mg/day) (Boerma, 1995). There were potentially contributing conditions in 6 patients, 
specifically, concurrent treatment with theophylline (n=1; LEMS or MG), or coexistent brain 
metastases (n=1; LEMS), epilepsy and multiple sclerosis (MS) (n=1); and MS (n=4). In cases 
where follow-up was reported, most seizures did not recur with amifampridine dose 
reduction or treatment withdrawal. In the one accidental overdose case, seizures were 
controlled with intravenous clonazepam and the patient made a full recovery (Boerma, 1995). 
It is noteworthy that a seizure rate of 4% can be expected in the natural course of patients 
with MS (Engelsen, 1997; Moreau, 1998; Kinnunen, 1987). Among the 774 MS patients 
treated with amifampridine included in the safety assessment of this report, 4 (0.5%) 
experienced seizures. 
Other clinically significant or SAEs reported in more than 1 patient were palpitations 
(8/1,454; 0.56%), abnormal liver enzymes (6/1,454; 0.41%), QTc prolongation (2/1,454; 
0.14%), and premature ventricular contraction/increased ventricular extrasystoles (2/1,454; 
0.14%). Each of the following serious or clinically significant events was reported in a single 
patient: chorea, paresthesias, paroxysmal supraventricular tachycardia, cardiac arrest, drug-
induced hepatitis, gastroesophageal reflux, increased lipase and amylase, aspiration 
pneumonia with confusion, and urinary tract infection with confusion. 


 
MSK-003 
Page 18 
 
Proprietary and Confidential 
 
12 November 2017 
6.3 
Overall Risks and Benefits 
Data on amifampridine treatment in 1,454 patients or healthy volunteers support the 
favorable safety profile of amifampridine (both base and phosphate formulations) at doses up 
to 80 mg per day. To date, current data demonstrate that amifampridine phosphate has an 
acceptable tolerability profile with a positive risk-benefit in patients treated with 
amifampridine, but longer-term studies are needed in patients with MG.  
6.4 
Study Rationale 
A considerable amount of clinical experience is available with amifampridine and, in 
December 2009, amifampridine tablets 10 mg, as amifampridine phosphate, received 
marketing approval by the European Commission as Firdapse® for the symptomatic 
treatment of patients with LEMS.  The present long-term extension study will evaluate safety 
and tolerability of amifampridine on clinical laboratory test variables, ECGs, AEs, vital 
signs, physical examinations and the effects on MG-ADL score over several months in 
patients with MuSK or AchR-MG. This information is needed to demonstrate that the 
product is safe and provides continued benefit to patients with MG. 
7 
STUDY OBJECTIVES 
7.1 
Primary Objective 
The primary objective of the study is: 
• 
To evaluate the long-term safety and tolerability of amifampridine in patients with 
MuSK-MG; and with AChR-MG. 
7.2 
Secondary Objective 
The secondary objective of the study is: 
• 
To assess the effect of amifampridine phosphate on Myasthenia Gravis Activities of 
Daily Living Score (MG-ADL). 
8 
INVESTIGATIONAL PLAN 
8.1 
Overall Study Design and Plan 
This open label outpatient extension study is designed to evaluate the long-term safety, 
tolerability of amifampridine in patients diagnosed with MuSK-MG and AChR-MG. In 
addition, evaluation of the effects of amifampridine on the MG-ADL score will be made. The 
study will enroll those patients who have completed the MSK-002 study and after all final 


 
MSK-003 
Page 19 
 
Proprietary and Confidential 
 
12 November 2017 
evaluations for that study have been completed, or those who demonstrated benefit after 
completing the dose titration period but failed to meet the randomization criteria on Day 0 of 
MSK-002.  
The duration of participation for each patient is expected to be at least 9 months as patients 
may continue in the study until amifampridine is approved by Regulatory Agencies or the 
clinical development of amifampridine is terminated for this indication. In addition to 
amifampridine, patients will continue to receive previous concomitant medications, as 
needed.  
After a new informed consent is signed and inclusion / exclusion criteria for the current 
protocol are satisfied, eligible patients will be given the optimal dose and dosing schedule 
that was identified in the Run-in Period from Protocol MSK-002.   
The findings from the physical exam (including vital signs, weight); 12-lead ECG; clinical 
laboratory test results (including pregnancy testing) and any ongoing adverse events will be 
used as the baseline for the Long-Term safety evaluation.   
The only efficacy measurement is the MG-ADL which will be completed every 3 or 6 
months. Safety and tolerability assessments will be made every 3 or 6 months or more 
frequently at the discretion of the Investigator. The study will continue until amifampridine is 
approved by Regulatory Agencies or until development of the product for this indication is 
halted. The Investigator may alter the dose and dosing frequency during the Long-Term 
Study as well as schedule additional clinic visits for any reason.   
Patients will be seen in the clinic at the end of Months 3, 6, 9, 12, 15 and 21 as detailed in the 
Schedule of Assessments in Table 1 and Section 11. In between the 3-or 6-month visits, 
patients may also have telephone/video contact with the site, or unscheduled visits, if needed. 
Any unused medication must be brought back to the clinic at each visit for drug 
accountability, and an additional supply will be dispensed. 
 
 


 
MSK-003 
Page 20 
 
Proprietary and Confidential 
 
12 November 2017 
Table 1 Schedule of Events 
Study Assessment  
or Event  
Screening 
and 
Enrollment* 
Study Month ± 1 week 
3 
6 
9 
12 
15 
21 
End of Studyg 
Informed consent a 
x 
 
 
 
 
 
 
 
Inclusion/Exclusion Criteria 
x 
 
 
 
 
 
 
 
Complete physical exam b 
x 
x 
x 
x 
x 
x 
x 
x 
Vital signs  
x 
x 
x 
x 
x 
x 
x 
x 
12-Lead ECG  
x 
x 
x 
x 
x 
x 
x 
x 
Clinical laboratory tests c 
x 
x 
x 
x 
x 
x 
x 
x 
Pregnancy test d 
x 
x 
x 
x 
x 
x 
x 
x 
Amifampridine Treatment 
x 
x 
x 
x 
x 
x 
x 
 
MG-ADL  
 
x 
x 
x 
x 
x 
x 
x 
Dispense IP e 
x 
x 
x 
x 
x 
x 
 
 
IP accountability 
 
x 
x 
x 
x 
x 
x 
x 
Adverse events/SAEs f 
x 
x 
x 
x 
x 
x 
x 
x 
Concomitant medications 
x 
x 
x 
x 
x 
x 
x 
x 
a Informed consent must be obtained before any study procedures are performed. 
b Complete physical examination includes evaluation of all major body systems, including weight at 
all visits (Section 9.6.6). 
c Clinical laboratory tests include serum chemistry, hematology, and urinalysis. 
d Urine pregnancy tests will be obtained from female patients of childbearing potential. 
e Pharmacist will dispense sufficient amount of medication until the next clinic visit. All unused 
medication must be returned to the clinic for drug accountability. 
f SAE reporting commences after informed consent is signed. Non-serious adverse event reporting 
commences after the first dose of study drug for the current Long-Term Study. 
g End of Study or early termination visit if the last visit does not coincide the scheduled 3- or 6-month 
visit. 
*These data may be obtained from Study MSK-002. If data not available, then the assessment should 
be repeated. 
 


 
MSK-003 
Page 21 
 
Proprietary and Confidential  
12 November 2017 
8.2 
Selection of Study Population 
Patients who complete Protocol MSK-002 or who have demonstrated benefit after completing 
the dose titration period but failed to meet randomization criteria for MSK-002, and who meet 
the inclusion and exclusion criteria for participation in the current study will be eligible. 
8.2.1 Inclusion Criteria 
Individuals eligible to participate in this study must meet all the following inclusion criteria: 
1. Participated in the MSK-002 study 
2. Willing and able to provide written informed consent after the nature of the study has been 
explained and before the start of any research-related procedures. 
3. Female patients of childbearing potential must have a negative pregnancy test (urine human 
chorionic gonadotropin [HCG] at the end of MSK-002 study); and must practice an effective, 
reliable contraceptive regimen during the study and for up to 30 days following 
discontinuation of treatment. 
4. Ability to participate in the study based on overall health of the patient and disease prognosis, 
as applicable, in the opinion of the Investigator; and able to comply with all requirements of 
the protocol, including completion of study questionnaires. 
 
8.2.2 Exclusion Criteria 
Individuals who met any of the exclusion criteria in the original protocol or those listed 
below are not eligible to participate in the study: 
1. Epilepsy and currently on medication. 
2. Clinically significant abnormalities in 12 lead ECG, in the opinion of the Investigator. 
3. Breastfeeding or pregnant at Screening or planning to become pregnant at any time 
during the study. 
4. Intolerable amifampridine-related side effects   
5. Treatment with an investigational drug (other than amifampridine) or device while 
participating in this study. 
6. Any medical condition that, in the opinion of the Investigator, might interfere with 
the patient’s participation in the study, poses an added risk for the patient, or 
confound the assessment of the patient. 


 
MSK-003 
Page 22 
 
Proprietary and Confidential  
12 November 2017 
8.2.3 Removal of Patients from Treatment or Assessment 
Patients may withdraw their consent to participate in the study or to receive treatment with IP 
at any time without prejudice. The Investigator must withdraw from the study or from 
treatment with IP any patient who requests to be withdrawn. A patient’s participation in the 
study or treatment with IP may be discontinued at any time at the discretion of the 
Investigator and in accordance with his or her clinical judgment.  
Catalyst must be notified of all patient withdrawals from the study or from treatment with IP 
as soon as possible. Catalyst also reserves the right to discontinue the study at any time for 
either clinical or administrative reasons and to discontinue participation by an individual 
Investigator or site for poor enrollment or noncompliance. 
Reasons for which the Investigator or Catalyst may withdraw a patient from the study 
treatment include, but are not limited to, the following: 
• Patient experiences a serious or intolerable AE; 
• Patient requires medication prohibited by the protocol; and 
• Patient becomes pregnant (refer to Section 9.4 for details on the reporting procedures 
to follow in the event of pregnancy). 
Reasons for which the Investigator or Catalyst may withdraw a patient from the study 
include, but are not limited to, the following: 
• Patient does not adhere to study requirements specified in the protocol; 
• Patient was erroneously admitted into the study or does not meet inclusion criteria; 
and 
• Patient is lost to follow-up. 
If a patient fails to return for scheduled visits, a documented effort must be made to 
determine the reason. If the patient cannot be reached by telephone, a certified letter should 
be sent to the patient requesting contact with the Investigator. This information should be 
recorded in the study records. 
The Investigator or designee must explain to each patient, before enrollment into the study, 
that for evaluation of study results, the patient’s protected health information obtained during 
the study may be shared with Catalyst, regulatory agencies, and IRB/IEC/REB. It is the 
Investigator’s (or designee’s) responsibility to obtain written permission to use protected 
health information, per country-specific regulations, from each patient. If permission to use 


 
MSK-003 
Page 23 
 
Proprietary and Confidential  
12 November 2017 
protected health information is withdrawn, it is the Investigator’s responsibility to obtain a 
written request, to ensure that no further data will be collected from the patient and the 
patient will be removed from the study. 
8.2.4 Patient Identification 
Each patient will be assigned a unique patient identifier (2 or 3 digits for the site and 2 or 3 
digits for each patient enrolled). This unique identifier will be on all CRF pages.  
8.3 
Treatments 
8.3.1 Treatments Administered 
Catalyst or its designee will provide the study site with a supply of Investigational product: 
amifampridine tablets 10 mg at various intervals sufficient for the completion of the study. 
Amifampridine will be provided in round, white-scored tablets and containing amifampridine 
phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet. The 
product will be provided in bottles of bulk tablets to the pharmacy representative who will 
dispense an amount for each portion of the study, in a patient-specific labeled bottle. 
8.3.2 Identity of Investigational Product 
The chemical name of amifampridine phosphate is: 
• 3,4-pyridinediamine, phosphate (1:1) diamino-3,4-pyridine, phosphate salt 
• 3,4-diaminopyridine phosphate 
The chemical structure is provided in Error! Reference source not found.. 
Figure 1. 
Chemical Structure of Amifampridine Phosphate 
 
8.3.2.1 Product Characteristics and Labeling 
Drug product is formulated as a phosphate salt of amifampridine. Tablets were developed to 
provide the equivalent of 10 mg of amifampridine base for oral administration. Each tablet 
H3PO4
N
NH2
NH2
4
1
2
3


 
MSK-003 
Page 24 
 
Proprietary and Confidential  
12 November 2017 
contains amifampridine phosphate, microcrystalline cellulose, colloidal anhydrous silica, and 
calcium stearate. The bottles of tablets are labeled “Amifampridine Phosphate Tablets, 
10 mg.” 
The tablets are to be dispensed by the pharmacy representative into suitably sized pharmacy 
containers for patient use. Each bottle provided to patients will be labeled to include the 
compound name, site number, patient ID number, date dispensed, storage instructions, the 
statement ‘Caution – New Drug – Limited by Federal law to investigational use,’ trial 
number, manufacturer name and address, and area for instructions for use. Regional label 
requirements and translations should be used in accordance with local regulations. 
8.3.2.2 
Storage 
At the study site, all IP must be stored under the conditions specified, 20-25○ Celsius (C) and 
in a secure area accessible only to the designated pharmacist and clinical site personnel. All 
IP must be stored and inventoried, and the inventories must be carefully and accurately 
documented according to applicable national and local regulations, ICH GCP, and study 
procedures. 
8.3.3 Directions for Administration 
All doses of study drug will be taken as outpatients. Test medication should be taken every 
day at approximately the same time, at the dose and frequency instructed by Investigator. 
The dose of amifampridine will be individually determined by the Investigator, within the 
bounds of a total daily dose of 30 mg to 80 mg, divided into doses taken 3 to 4 times per day 
as prescribed by the Investigator, based on optimal neuromuscular benefit determined from 
the Run-in Period from MSK-002 or may be modified as the discretion of the Investigator. 
The maximum single dose is 20 mg.  
8.3.4 Method of Assigning Patients to Treatment Groups 
All patients will receive open label amifampridine. Details on study drug preparation, 
dispensing medication will be included in the Pharmacy Manual.  
8.3.5 Selection of Doses Used in the Study 
Initially, the daily amifampridine dose will be the one that was determined at the end of the 
Run-in Period from MSK-002. The usual range is 30 to 80 mg total daily dose, given in 3 or 
4 divided doses, with no single dose >20 mg. Safety of a single maximum dose of 20 mg is 
based on completed animal and in vitro pharmacology, PK, and toxicology studies.  


 
MSK-003 
Page 25 
 
Proprietary and Confidential  
12 November 2017 
8.3.6 Blinding 
This is an open label study  
8.3.7 Treatment Compliance 
Patients will be instructed to take study medication as directed and bring all IP containers and 
remaining test medication at each study visit. Patient compliance with the dosing regimen 
will be assessed by reconciliation of the used and unused IP. The quantity dispensed, 
returned, used, lost, etc., must be recorded on the medication dispensing log provided for the 
study. 
8.3.8 Investigational Product Accountability 
The study site is responsible for maintaining accurate records (including dates and quantities) 
of IP received, patients to whom IP is dispensed (patient-by-patient dose specific 
accounting), IP returned, and IP lost or destroyed. The Investigator, study site coordinator or 
designee must retain all unused or expired study supplies until the study monitor (on-site 
CRA) has confirmed the accountability data. 
8.3.9 Return and Disposition of Clinical Supplies 
Unused IP must be kept in a secure location for accountability and reconciliation by the study 
monitor. The Investigator or designee must provide an explanation for any destroyed or 
missing IP or study materials. 
Unused IP may be destroyed on site, per the site’s standard operating procedures, but only 
after Catalyst has granted approval for drug destruction. The monitor must account for all IP 
in a formal reconciliation process prior to IP destruction. All IP destroyed on site must be 
documented. Documentation must be provided to Catalyst and retained in the Investigator 
study files. If a site is unable to destroy IP appropriately, the site can return unused IP to 
Catalyst upon request. The return of IP or IP materials must be accounted for on a Study 
Drug Return Form provided by Catalyst. 
All IP and related materials should be stored, inventoried, reconciled, and destroyed or 
returned according to applicable regulations and study procedures. 
8.4 
Prior and Concomitant Medications 
All prescription and over-the-counter medications and herbal and nutritional supplements 
taken during the Long-Term study will be recorded on the designated CRF.  


 
MSK-003 
Page 26 
 
Proprietary and Confidential  
12 November 2017 
The Investigator may prescribe additional medications during the study, if the prescribed 
medication is not prohibited by the protocol. In the event of an emergency, any needed 
medications may be prescribed without prior approval, but the medical monitor must be 
notified of the use of any contraindicated medications immediately thereafter. Any 
concomitant medications added or discontinued during the study should be recorded on the 
CRF. 
Medications that should be used with caution in this study are those that prolong QTc interval.  
8.5 
Dietary or Other Protocol Restrictions 
8.5.1 Dietary Restrictions 
There are no dietary restrictions for patients during any part of this study. 
8.5.2 Contraception 
Sexually active males and females of childbearing potential and their partners must use 
effective forms of contraception, such as condom for males or occlusive cap (diaphragm or 
cervical/vault caps) for females, during the study.   
8.6 
Safety Variables 
Safety in this study will be determined from evaluation of AEs/SAEs, vital signs 
assessments, clinical laboratory assessments, ECGs, and physical examinations. Pregnancy 
testing is also required for females of childbearing potential. The timing of the required 
evaluations is described in the Schedule of Events in Table 1Table 1 and in Section 11. 
8.6.1 Adverse Events 
The determination, evaluation and reporting of AEs will be performed as outlined in 
Section 9.  
8.6.2 Vital Signs 
Specific visits for obtaining vital signs are provided in Table 1 Schedule of Eventsand in 
Section 11. Vital signs will be measured while in a sitting position, after resting for 5 
minutes, and include SBP and DBP measured in millimeters of mercury (mmHg), heart rate 
in beats per minute, respiration rate in breaths per minute. Weight (kg) and temperature in 
degrees C will also be measured. Clinically significant changes from baseline will be 
recorded as AEs. 


 
MSK-003 
Page 27 
 
Proprietary and Confidential  
12 November 2017 
8.6.3 Clinical Laboratory Assessments 
Specific visits for obtaining clinical laboratory assessment samples are provided in Table 1 
for the tests required by Protocol. The scheduled clinical laboratory tests are listed in Error! 
Reference source not found.. In brief, clinical laboratory evaluations are to be performed 
every 3 to 6 months. These tests can be performed more frequently at the discretion of the 
Investigator. 
All abnormal clinical laboratory result pages should be initialed and dated by an Investigator, 
along with a comment for each abnormal result indicating whether or not it is clinically 
significant. Any abnormal test results determined to be clinically significant by the 
Investigator should be repeated (at the Investigator’s discretion) until the cause of the 
abnormality is determined, the value returns to baseline or to within normal limits, or the 
Investigator determines that the abnormal value is no longer clinically significant. 
Each clinically significant laboratory result should be recorded as an AE. The diagnosis, if 
known, associated with abnormalities in clinical laboratory tests that are considered clinically 
significant by the Investigator will be recorded on the AE CRF. 
Table 2 Clinical Laboratory Tests 
Blood Chemistry 
Hematology 
Urine Tests 
Other 
Albumin  
Hemoglobin  
Appearance 
Pregnancy test, if applicable 
Alkaline phosphatase  
Hematocrit  
Color 
ALT (SGPT) 
WBC count 
pH 
 
AST (SGOT) 
RBC count 
Specific gravity 
 
Direct bilirubin 
Platelet count 
Ketones 
 
Total bilirubin 
Differential cell count  
Protein  
 
BUN 
 
Glucose  
 
Calcium 
 
Bilirubin 
 
Chloride 
 
Nitrite 
Total cholesterol 
 
Urobilinogen 
 
CO2 
 
Hemoglobin 
 
Creatine phosphokinase 
 
 
 
Creatinine 
 
 
 
Glucose 
 
 
 
GGT 
 
 
LDH 
 
 
Phosphorus 
 
 
 
Potassium 
 
 
Total protein  
 
 
 
Sodium  
 
 
 
Uric acid 
 
 
 
 


 
MSK-003 
Page 28 
 
Proprietary and Confidential  
12 November 2017 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CO2, carbon 
dioxide; GGT, gamma-glutamyl transferase; LDH, lactate dehydrogenase; RBC, red blood cell; SGOT, serum 
glutamic-oxaloacetic transaminase; SGPT, serum glutamic-pyruvic transaminase; WBC, white blood cell. 
 
8.6.4 Pregnancy Testing 
Female patients of childbearing potential will have a urine pregnancy test at the end of the 
double blind period on Day 10 and at  other time points specified in the Schedule of Events 
(Error! Reference source not found.) and in Section 11. Female patients with a positive 
pregnancy test at end of the double-blind study are not eligible for enrollment. Additional 
pregnancy tests will be performed at any visit in which pregnancy status is in question. 
Refer to Section 9.4 for details on the reporting procedures to follow in the event of 
pregnancy. 
8.6.5 Electrocardiogram (ECG) 
A standard 12-lead safety ECG (single tracing) will be recorded with the patient resting 
comfortably in the supine position at the time points specified in the Schedule of Events 
(Table 1) and in Section 11. Clinically significant changes from baseline will be recorded as 
AEs.  
8.6.6 Physical Examination 
A complete physical examination is to be performed at each clinic visit or, if applicable, at 
early discontinuation from the study. Complete physical examination will include 
assessments of general appearance as well as the following: 
• Head 
• Eyes 
• Ears 
• Nose 
• Throat 
• Cardiovascular 
• Dermatologic 
• Lymphatic 
• Respiratory 


 
MSK-003 
Page 29 
 
Proprietary and Confidential  
12 November 2017 
• Gastrointestinal 
• Musculoskeletal 
Body weight will be measured with each physical examination throughout the study.  
Other body systems may be examined. Clinically significant changes from baseline will be 
recorded as AEs. 
8.7 
Efficacy Variable 
Every 3 or 6 months, each patient will be assessed with the MG-ADL questionnaire.  
8.7.1 Myasthenia Gravis-Specific Activities of Daily Living (MG-ADL) 
The MG-ADL is a self-report scale designed to assess the patient’s MG symptoms and 
functional performance of activities of daily living. The MG-ADL consists of 8 items 
(derived from symptom-based components of the original 13-item Quantitative Myasthenia 
Gravis test) to assess disability secondary to ocular (2 items), bulbar (3 items), respiratory 
(1 item) and gross motor or limb (2 items) impairment related to effects from MG 
(Appendix 1). Each of the 8 items is rated using a response scale ranging from 0 (normal) to 
3 (most severe). Lower scores indicate better functional performance. In this trial, the recall 
period for MG-ADL will be the preceding 30 days.  
9 
REPORTING ADVERSE EVENTS 
9.1 
Adverse Events 
For this protocol, a reportable AE is any untoward medical occurrence (e.g. sign, symptom, 
illness, disease or injury) in a patient administered the IP or other protocol-imposed 
intervention, regardless of attribution. This includes: 
• AEs not previously observed in the patient, that emerge during the study. 
• Pre-existing medical conditions judged by the Investigator to have worsened in 
severity or frequency or changed in character during the study. 
• Complications that occur as a result of non-drug protocol-imposed interventions. 
An adverse drug reaction is any AE for which there is a reasonable possibility that the IP 
caused the AE. “Reasonable possibility” means there is evidence to suggest a causal 
relationship between the IP and the AE. 


 
MSK-003 
Page 30 
 
Proprietary and Confidential  
12 November 2017 
Whenever possible, it is preferable to record a diagnosis as the AE term rather than a series 
of terms relating to a diagnosis. 
All non-serious AEs, even those which began under Protocol MSK-002, will be reported 
from the end of the double-blind study (MSK-002) through the termination visit or at the 
early termination visit and will be recorded on the AE page of the eCRF. All SAEs will be 
reported. The criteria for determining, and the reporting of SAEs is provided in Section 9.2. 
The Investigator should follow all unresolved AEs until the events are resolved or stabilized, 
the patient is lost to follow-up, or it has been determined that the study treatment or 
participation is not the cause of the AE. Resolution of AEs (with dates) should be 
documented on the appropriate CRF page(s) and in the patient’s medical record. 
The Investigator responsible for the care of the patient or qualified designee will assess AEs 
for severity, relationship to IP, and seriousness (refer to Section 9.2 for SAE definition). 
Severity (as in mild, moderate or severe headache) is not equivalent to seriousness, which is 
based on patient/event outcome or action criteria usually associated with events that pose a 
threat to a patient’s life or functioning. Seriousness (not severity) serves as a guide for 
defining regulatory reporting obligations.  
The Investigator will determine the severity of each AE using grades defined in Table 1 
Categories of Severity of Adverse Events(the event will be recorded on the source documents 
and AE CRF). Events that are Grades 4 and 5 are serious events and require completion of 
both an SAE form and AE CRF.  
 


 
MSK-003 
Page 31 
 
Proprietary and Confidential  
12 November 2017 
Table 1 Categories of Severity of Adverse Events 
Severity 
Description 
Grade 1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
Grade 2 
Moderate; minimal, local or noninvasive intervention indicated; 
limiting age-appropriate instrumental ADL*. 
Grade 3 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care ADL**. 
Grade 4 
Life-threatening consequences; urgent 
intervention indicated. 
Note: Grade 4 and 5 
adverse events should 
always be reported as 
serious adverse events 
Grade 5 
Death related to AE. 
Activities of Daily Living (ADL) 
* Instrumental ADLs refer to preparing meals, shopping for groceries or clothes, using the telephone, 
managing money, etc. 
** Self-care ADLs refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
The Investigator will suggest the relationship of an AE to the IP and will record it on the 
source documents and AE CRF, using the relationship categories defined in Table 2  
Description of Relationship to Adverse Event Categories 


 
MSK-003 
Page 32 
 
Proprietary and Confidential  
12 November 2017 
Table 2  Description of Relationship to Adverse Event Categories 
Relationship 
Category 
Description 
Not Related 
Exposure to the IP has not occurred 
OR 
The administration of the IP and the occurrence of the AE are not 
reasonably related in time  
OR 
The AE is considered likely to be related to an etiology other than the use 
of the IP; that is, there are no facts [evidence] or arguments to suggest a 
causal relationship to the IP. 
Possibly 
Related 
The administration of the IP and the occurrence of the AE are reasonably 
related in time 
AND 
The AE could be explained equally well by factors or causes other than 
exposure to the IP. 
Probably 
Related 
The administration of IP and the occurrence of the AE are reasonably 
related in time  
AND 
The AE is more likely explained by exposure to the IP than by other factors 
or causes. 
 
In order to classify AEs and diseases, preferred terms will be assigned by the sponsor to the 
original terms entered in the CRF, using Medical Dictionary for Regulatory Activities 
(MedDRA) terminology. 
9.2 
Serious Adverse Events 
A serious adverse event is any untoward medical occurrence that at any dose meets 1 or more 
of the following criteria: 
• Is fatal 
• Is life threatening 
• Note: Life-threatening refers to an event that places the patient at immediate risk 
of death. This definition does not include a reaction that, had it occurred in a more 
severe form, might have caused death 
• Requires or prolongs in-patient hospitalization 


 
MSK-003 
Page 33 
 
Proprietary and Confidential  
12 November 2017 
• Results in persistent or significant disability or incapacity 
• Is a congenital anomaly or birth defect, that is, an AE that occurs in the child or fetus 
of a patient exposed to IP prior to conception or during pregnancy 
• Is an important medical event or reaction.  
The reporting period for SAEs begins after informed consent is obtained for the current 
MSK-003 study and continues through 4 weeks after the last visit.  
Any SAE, whether or not considered related to study drug, must be reported within 24 hours 
of knowledge of the event by forwarding (fax, email) the study-specific SAE Report Form to 
Catalyst. The Investigator should not wait to collect information that fully documents the 
SAE before notifying Catalyst. As additional information becomes available, including but 
not limited to the outcome of the SAE and any medication or other therapeutic measures used 
to treat the event, it must be reported within 24 hours in a follow-up report. 
The Investigator should follow all unresolved SAEs until the events are resolved or 
stabilized, the patient is lost to follow-up, or it has been determined that the study treatment 
or participation is not the cause of the AE. Resolution of AEs (with dates) should be 
documented in the CRF and in the patient’s medical record. 
For some SAEs, Catalyst may follow up by telephone, fax, email, and/or a monitoring visit to 
obtain additional case details deemed necessary to appropriately evaluate the SAE report 
(e.g. hospital discharge summary, consultant report, autopsy report). 
At the last scheduled visit, the Investigator should instruct each patient to report any 
subsequent SAEs that the patient’s personal physician(s) believes might be related to prior 
study treatment. 
The Investigator should notify Catalyst of any death or SAE occurring at any time after a 
patient has discontinued, or terminated study participation, if felt to be related to prior study 
treatment. Catalyst should also be notified if the Investigator should become aware of the 
development of cancer, or of a congenital anomaly, in a subsequently conceived offspring of 
a patient that participated in this study.  
Reporting of SAEs to the IRB/IEC/REB will be done in compliance with the standard 
operating procedures and policies of the IRB/IEC/REB and with applicable regulatory 
requirements. Adequate documentation must be provided showing that the IRB/IEC/REB 
was properly and promptly notified as required. 


 
MSK-003 
Page 34 
 
Proprietary and Confidential  
12 November 2017 
9.3 
Safety Blood Collection 
Patients who experience a serious or severe AE should have, at the discretion of the 
Investigator, a blood sample drawn for safety labs as soon as possible after the AE has 
occurred. 
Additional blood sampling may be performed at any time during the study if warranted to 
monitor patient safety. 
9.4 
Pregnancy 
Pregnancy in a patient or partner should be reported within 24 hours of the site becoming 
aware of the pregnancy by fax or email of the Pregnancy Reporting Form in the study 
reference materials to Catalyst. In addition, pregnancy in a patient is also reported on the End 
of Study CRF. The Investigator must make every effort to follow the patient through 
resolution of the pregnancy (delivery or termination) and to report the resolution on the 
follow-up form (Pregnancy Reporting Form: Additional Information) in the study reference 
materials. In the event of pregnancy in the partner of a study patient, the Investigator should 
make every reasonable attempt to obtain the woman’s consent for release of protected health 
information. 
9.5 
Urgent Safety Measures 
The regulations governing clinical trials state that the sponsor and Investigator are required to 
take appropriate urgent safety measures to protect subjects against any immediate hazards 
that may affect the safety of subjects, and that the appropriate regulatory bodies should be 
notified according to their respective regulations. According to the European Union (EU) 
Clinical Trial Directive 2001/20/EC, “…in the light of the circumstances, notably the 
occurrence of any new event relating to the conduct of the trial or the development of the 
investigational medicinal product where that new event is likely to affect the safety of the 
subjects, the sponsor and the Investigator shall take appropriate urgent safety measures to 
protect the subjects against any immediate hazard. The sponsor shall forthwith inform the 
competent authorities of those new events and the measures taken and shall ensure that the 
IRB/IEC/REB is notified at the same time.” The reporting period for urgent safety measures 
is the period from the time of signing of the ICF through the completion of the last study 
visit. Investigators are required to report any urgent safety measures with 24 hours. 


 
MSK-003 
Page 35 
 
Proprietary and Confidential  
12 November 2017 
Examples of situations that may require urgent safety measures include discovery of the 
following: 
• An immediate need to revise IP administration (i.e. modified dose amount or 
frequency not defined in protocol). 
• Lack of study scientific value, or detrimental study conduct or management. 
• Discovery that the quality or safety of IP does not meet established safety 
requirements. 
 
9.6 
Medical Monitor Contact Information 
Contact information and additional requirements will be provided in the MuSK-003 Study 
Reference Manual. 
The Investigator is encouraged to discuss with the medical monitor any AEs for which the 
issue of seriousness is unclear or questioned. Contact information for the study Medical 
Monitor is listed below. 
Gary Ingenito, MD, PhD 
Chief Medical Officer 
Catalyst Pharmaceuticals, Inc. 
Tel: +1 305-420-3223 
Email: gingenito@catalystpharma.com 
 
10 APPROPRIATENESS OF MEASUREMENTS 
The measures of safety used in this study are routine clinical and laboratory procedures. 
The efficacy measure is a self-report on how the patient is functioning for activities of daily 
living.  This standardized test has been previously used for determination of response to 
therapeutic intervention in patients with MG.  
11 STUDY PROCEDURES 
11.1 Start of Long Term Study 
An ICF for the Long-Term Study must be signed and dated by the patient, the Investigator or 
designee, and witness (if required) before any study-related procedures are performed.  
The following procedures are to be performed as schedule for either the Day 0 (in the case 
where patient was not randomized) or the Day 10 visit for the MSK-002 protocol and can 


 
MSK-003 
Page 36 
 
Proprietary and Confidential  
12 November 2017 
serve as baseline for the Long-Term study. Any procedure not performed for MSK-002 
protocol needs to be completed for this trial. 
• Informed Consent for MSK-003; 
• Inclusion/Exclusion criteria for the current study must be verified; 
• Standard 12-lead ECG after 5 minutes in the supine position; 
• Complete physical examination including weight;  
• Vital signs (seated position), including SBP, DBP, heart rate, respiration, and body 
temperature;  
• Clinical laboratory tests including hematology, chemistry, and urinalysis; 
• Urine pregnancy test in females of childbearing potential only; 
• MG-ADL (use data from Day 0 of MSK-002 for all patients); 
• AEs;  
• Concomitant medications. 
11.2 
End of Months 3, 6, 9, 12, 15 and 21 in Long Term Study  
The following assessments and procedures will be determined at the end of Months 3, 6, 9, 
12, 15 and 21. Each month has a clinic visit window of ± 1 week. Additional visits are 
allowed as necessary. 
• Assessment of AEs/SAEs; 
• Complete physical exam with weight; 
• Vital signs (seated position), including SBP, DBP, heart rate, respiration, and body 
temperature; 
• Standard 12-lead ECG after 5 minutes in the supine position; 
• Clinical laboratory tests including hematology, chemistry, and urinalysis;  
• Urine pregnancy test in females of childbearing potential only; 
• Concomitant medications; 
• IP accountability of medication; 
• MG-ADL 
All IP should be collected from the patient at each visit, in order to perform drug 
accountability. The site will dispense sufficient amifampridine for daily outpatient 


 
MSK-003 
Page 37 
 
Proprietary and Confidential  
12 November 2017 
administration for 90 days (or 180 days from Months 15 to 21). If the Investigator wants to 
evaluate the patient more frequently, fewer tablets can be dispensed.   
Patients may continue to receive amifampridine until the study is terminated, the patient 
decides to withdraw from the study, or the development program is discontinued for this 
indication.  
11.2.1 End of Study Visit  
Patients will report to the study site at the end of the study and have the assessments and 
procedures listed below completed.  This visit may be incorporated at the scheduled 3-or 6-
month visit. 
• Assessment of AEs/SAEs; 
• Complete physical exam with weight; 
• Vital signs (seated position), including SBP, DBP, heart rate, respiration, and body 
temperature; 
• 12-Lead ECG; 
• Clinical laboratory tests; 
• Urine pregnancy test in females of childbearing potential only; 
• Concomitant medications;  
• IP accountability; 
• 
MG-ADL  
12 DATA QUALITY ASSURANCE 
Catalyst personnel or designees will visit or telephone the study site before initiation of the 
study to review with the site personnel information about the IP, protocol and other 
regulatory document requirements, source document requirements, CRFs, monitoring 
requirements, and procedures for reporting AEs/SAEs.  
At visits during and after the study, a CRA will monitor the site for compliance with 
regulatory documentation, with a focus on accurate and complete recording of data on CRFs 
from source documents, adherence to protocol, AE/SAE reporting, and drug accountability 
records. The CRA will also verify records at the site pharmacy. 


 
MSK-003 
Page 38 
 
Proprietary and Confidential  
12 November 2017 
13 STATISTICAL METHODS AND DETERMINATION OF SAMPLE SIZE 
13.1 Statistical and Analytical Plans 
13.1.1 Interim Analyses 
No interim analyses are planned. 
13.2 Analysis Populations 
The analysis population in this study is the safety population and will consist of all patients 
who are enrolled in the Long-Term study and have received at least one dose of 
amifampridine.  Safety evaluation from MuSK-MG and AChR-MG groups will analyzed 
separately.   
13.3 Primary Endpoint 
The primary endpoint of the study is safety and tolerability of amifampridine at Months 3, 6, 
9, 12, 15 and 21.  For more details see Section 13.5 below. 
13.4 
Secondary Endpoint  
The secondary endpoint of the study is the MG-ADL score at Months 3, 6, 9, 12, 15 and 21.  
13.5 Safety Analysis  
Prior to analysis, all AEs will be coded using the MedDRA coding dictionary. Based on these 
coded terms, TEAEs and SAEs will be summarized using system organ class and preferred 
terms, as well as by relationship to treatment. All AEs will be listed, regardless of whether 
they were study treatment related.   
Vital signs will be summarized using descriptive statistics (mean, standard deviation, median, 
minimum, maximum, and number of non-missing observations) by time point.  Changes 
from baseline will also be summarized by post-dose time point. 
Clinical laboratory parameters will be summarized using descriptive statistics (mean, 
standard deviation, median, minimum, maximum, and number of non-missing observations) 
by time point.  Changes from baseline will also be summarized by post-dose time point.  In 
addition, a shift table will be constructed to show the shifts in laboratory results by parameter 
relative to the normal ranges.  The number and percentage of subjects with the following 
shifts will be presented: normal/normal, normal/low, normal/high, low/low, low/normal, 
low/high, high/low, high/normal, and high/high. Similar shift tables will also be constructed 
for physical exam results. ECG results will be summarized in a shift table with the following 


 
MSK-003 
Page 39 
 
Proprietary and Confidential  
12 November 2017 
shifts presented: normal/normal, normal/abnormal, abnormal/normal and 
abnormal/abnormal. A table of descriptive statistics for QTc will be created. 
Additional safety analyses may be performed as described in the SAP for the study. 
13.6 Determination of Sample Size 
This is an observational study and no hypothesis is being tested. Collection of long term 
safety and MG-ADL scores are required to demonstrate that amifampridine is safe and well 
tolerated in the MG population and if there is a change in dose requirements with time.  
13.7 Changes in the Conduct of the Study or Planned Analyses 
Any change in study conduct considered necessary by the Investigator will be made only 
after consultation with Catalyst, who will then issue a formal protocol amendment to 
implement the change. The only exception is when an Investigator considers that a patient’s 
safety is compromised without immediate action. In these circumstances, immediate approval 
of the chairman of the IRB/IEC/REB must be sought, and the Investigator should inform 
Catalyst and the full IRB/IEC/REB within 2 working days after the emergency occurs. 
Except for minor administrative or typographical changes, the IRB/IEC/REB must review 
and approve all protocol amendments. Protocol amendments that influence patient risk or the 
study objectives, or require revision of the ICF, must receive approval from the 
IRB/IEC/REB prior to their implementation. 
When a protocol amendment substantially alters the study design or the potential risks or 
burden to patients, the ICF will be amended and approved by Catalyst and the IRB/IEC/REB, 
and all active patients must again provide informed consent. 
Note: If discrepancies exist between the text of the statistical analysis as planned in the 
protocol, and the final SAP, a protocol amendment will not be issued, and the SAP will 
prevail. 
14 COMPENSATION, INSURANCE, AND INDEMNITY 
There will be no charge to study patients to be in this study. Catalyst will pay all costs of 
tests, procedures, and treatments that are part of this study (as included in the site budget). In 
addition, after IRB/IEC/REB approval, Catalyst may reimburse the cost of travel for study-
related visits. Catalyst will not pay for any hospitalizations, tests, or treatments for medical 
problems of any sort, whether or not related to the study patient’s disease that are not part of 


 
MSK-003 
Page 40 
 
Proprietary and Confidential  
12 November 2017 
this study. Costs associated with hospitalizations, tests, and treatments should be billed and 
collected in the way that such costs are usually billed and collected. 
The Investigator should contact Catalyst immediately upon notification that a study patient 
has been injured by the IP or by procedures performed as part of the study. Any patient who 
experiences a study-related injury should be instructed by the Investigator to seek medical 
treatment at a pre-specified medical institution if possible, or at the closest medical treatment 
facility if necessary. The patient should be given the name of a person to contact to seek 
further information about, and assistance with, treatment for study-related injuries. The 
treating physician should bill the patient’s health insurance company or other third-party 
payer for the cost of this medical treatment. If the patient has followed the Investigator’s 
instructions, Catalyst will pay for reasonable and necessary medical services to treat the 
injuries caused by the IP or study procedures, if these costs are not covered by health 
insurance or another third party that usually pays these costs. In some jurisdictions, Catalyst 
is obligated by law to pay for study-related injuries without prior recourse to third party 
payer billing. If this is the case, Catalyst will comply with the law. 
15 CASE REPORT FORMS AND SOURCE DOCUMENTS 
The CRO data management department or designee will perform all data management 
activities, including the writing of a data management plan outlining the systems and 
procedures to be used. 
Electronic case report forms (eCRFs) will be provided. The eCRF system, and procedures, 
and electronic signatures follow ICH requirements and applicable laws and local regulations. 
All system users will be trained on the eCRF before being granted system access. In the 
event of an entry error, or if new information becomes available, users will correct the value 
by deselecting the erroneous response and then selecting or entering the factual response. The 
documented audit trail will include the reason for the change, the original value, the new 
value, the time of the correction and the identity of the operator. 
In the application, study data on the eCRFs will be verified to the source data, which 
necessitates access to all original recordings, laboratory reports, and patient records. 
In addition, all source data should be attributable (signed and dated). The Investigator must 
therefore agree to allow direct access to all source data. Patients must also allow access to 
their medical records, and patients will be informed of this and will confirm their agreement 
when giving informed consent. The Investigator must review and electronically sign the 


 
MSK-003 
Page 41 
 
Proprietary and Confidential  
12 November 2017 
completed eCRF casebook to verify its accuracy. A CRA designated by Catalyst will 
compare the eCRFs in the application with the original source documents at the study site 
and evaluate them for completeness and accuracy before designating them as “Source Data 
Verified” in the application. If an error is discovered at any time or a clarification is needed, 
the Data Manager, CRA, or designee, will create an electronic query on the associated field. 
Site personnel will then answer the query by either correcting the data or responding to the 
query. The Data Manager or CRA will then review the response and determine either to close 
the query or re–query the site if the response does not fully address the question. This process 
will be repeated until all open queries are answered and closed. 
The CRO’s data management department may receive electronic transfers of laboratory data 
from the site’s local laboratory as well as other data from third-party vendors as appropriate.  
The Investigator will then electronically sign the casebook, specifying that the information 
on the eCRFs is accurate and complete. An electronic copy of each site’s casebooks will be 
sent to each site for retention with other study documents.  
16 STUDY MONITORING AND AUDITING 
Qualified individuals approved and/or designated by Catalyst will monitor all aspects of the 
study according to GCP and SOPs for compliance with applicable government regulations. 
The monitoring will take place on site as well as remotely as the monitors can view all 
clinical data electronically and can follow-up with any queries for more information. The 
Investigator agrees to allow these monitors direct access to the clinical supplies, dispensing, 
and storage areas and to the clinical files, including original medical records, of the study 
patients, and, if requested, agrees to assist the monitors. The Investigator and staff are 
responsible for being present or available for consultation during routinely scheduled site 
visits conducted by Catalyst or its designees.  
Members of Catalyst’s GCP Quality Department or designees may conduct an audit of a 
clinical site at any time before, during, or after completion of the study. The Investigator will 
be informed if an audit is to take place and advised as to the scope of the audit. 
Representatives of the FDA or other regulatory agencies may also conduct an audit of the 
study. If informed of such an inspection, the Investigator should notify Catalyst immediately. 
The Investigator will ensure that the auditors have access to the clinical supplies, study site 
facilities, original source documentation, and all study files. 


 
MSK-003 
Page 42 
 
Proprietary and Confidential  
12 November 2017 
17 RETENTION OF RECORDS 
The Investigator must retain all study records required by Catalyst and by the applicable 
regulations in a secure and safe facility. The Investigator must consult a Catalyst 
representative before disposal of any study records, and must notify Catalyst of any change 
in the location, disposition or custody of the study files. The Investigator/institution must 
take measures to prevent accidental or premature destruction of essential documents, that is, 
documents that individually and collectively permit evaluation of the conduct of a study and 
the quality of the data produced, including paper copies of study records (e.g. patient charts) 
as well as any original source documents that are electronic as required by applicable 
regulatory requirements.  
All study records must be retained for at least 2 years after the last approval of a marketing 
application in an ICH region and until (1) there are no pending or contemplated marketing 
applications in an ICH region or (2) at least 2 years have elapsed since the formal 
discontinuation of clinical development of the IP. The Investigator/institution should retain 
patient identifiers and records for at least 15 years after the completion or discontinuation of 
the study. Patient files and other source data must be kept for the maximum period of time 
permitted by the hospital, institution or private practice. These documents should be retained 
for a longer period, however, if required by the applicable regulatory requirements or by a 
Catalyst agreement. Catalyst must be notified and will assist with retention should 
Investigator/institution be unable to continue maintenance of patient files. It is the 
responsibility of Catalyst to inform the Investigator /institution as to when these documents 
no longer need to be retained. 
18 USE OF INFORMATION AND PUBLICATION 
Catalyst recognizes the importance of communicating medical study data and therefore 
encourages their publication in reputable scientific journals and at seminars or conferences. 
The details of the processes of producing and reviewing reports, manuscripts, and 
presentations based on the data from this study will be described in the Clinical Trial 
Agreement between Catalyst and the institution of the Investigator. 


 
MSK-003 
Page 43 
 
Proprietary and Confidential  
12 November 2017 
19 REFERENCES 
Bertorini TE, Rashed H, Zeno M, et al. Effects of 3-4 diaminopyridine (DAP) in motor 
neuron diseases. J Clin Neuromusc Dis 12[3], 129-137. 2011. 
 
Beeson D, Hantaï D, Lochmüller H, Engel AG.  126th International Workshop: Congenital 
Myasthenic Syndromes, 24–26 September 2004, Naarden, The Netherlands.  Neuromuscul 
Disord 2005;15: 498-512. 
 
Bever CT, Anderson PA, Leslie J, Panitch HS, et al. Treatment with oral 3,4 diaminopyridine 
improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, 
placebo-controlled, crossover trial. Neurology 47[6], 1457-1462. 1996.  
 
Boerma CE, Rommes JH, van Leeuwen RB, Bakker J. Cardiac arrest following an iatrogenic 
3,4-diaminopyridine intoxication in a patient with Lambert-Eaton myasthenic syndrome. J 
Toxicol Clin Toxicol 33[3], 249-251. 1995.  
 
Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, et al. Arylamine N-acetyltransferase 
(NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation 
with phenotypic activity. Am J Hum Genet 57[3], 581-592. 1995.  
 
Engelsen BA, Gronning M. Epileptic seizures in patients with multiple sclerosis. Is the 
prognosis of epilepsy underestimated? Seizure 6[5], 377-382. 1997. 
 
Evoli A, Alboini PE, Damato V, Iorio R. 3,4-Diaminopyridine may improve myasthenia 
gravis with MuSK antibodies. Neurology. 2016;86(11):1070–1 
 
Flet L, Polard E, Guillard O, Leray E, et al. 3,4-Diaminopyridine safety in clinical practice: 
an observational, retrospective cohort study. J Neurol . 2010.  
 
Fukino K, Sasaki Y, Hirai S, Nakamura T, et al. Effects of N-acetyltransferase 2 (NAT2), 
CYP2E1 and Glutathione-S-transferase (GST) genotypes on the serum concentrations of 
isoniazid and metabolites in tuberculosis patients. J Toxicol Sci 33[2], 187-195. 2008.  
 
Harper CM, Engel AG.  Treatment of 31 congenital myasthenic syndrome (CMS) patients 
with 3,4-diaminopyridine (DAP).  Neurology 2000;54(Suppl 3): A395 
 
Jetter A, Kinzig M, Rodamer M, Tomalik-Scharte D, et al. Phenotyping of N-
acetyltransferase type 2 and xanthine oxidase with caffeine: when should urine samples be 
collected? Eur J Clin Pharmacol 65[4], 411-417. 2009.  
 


 
MSK-003 
Page 44 
 
Proprietary and Confidential  
12 November 2017 
Kinnunen E, Koskenvuo M, Kaprio J, Aho K. Multiple sclerosis in a nationwide series of 
twins. Neurology 37[10], 1627-1629. 1987. 
 
Lindquist S, Stangel M. Update on treatment options for Lambert-Eaton myasthenic 
syndrome: focus on use of amifampridine. Neuropsychiatr Dis Treat 7, 341-349. 2011. 
 
Lundh H, Nilsson O, Rosen I, Johansson S. Practical aspects of 3,4-diaminopyridine 
treatment of the Lambert-Eaton myasthenic syndrome. Acta Neurol Scand 88[2], 136-140. 
1993.  
 
Lundh H, Nilsson O, Rosen I. Treatment of Lambert-Eaton syndrome: 3,4-diaminopyridine 
and pyridostigmine. Neurology 34[10], 1324-1330. 1984.  
 
Maddison P, Newsom-Davis J, Mills KR. Effect of 3,4-diaminopyridine on the time course 
of decay of compound muscle action potential augmentation in the Lambert-Eaton 
myasthenic syndrome. Muscle Nerve 21[9], 1196-1198. 1998a. 
 
Maddison P, Newsom-Davis J, Mills KR. Distribution of electrophysiological abnormality in 
Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 65, 213-217. 1998b. 
 
McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-Diaminopyridine in the treatment of 
Lambert-Eaton myasthenic syndrome. N Engl J Med 321[23], 1567-1571. 1989.  
 
Moreau T, Sochurkova D, Lemesle M, Madinier G, et al. Epilepsy in patients with multiple 
sclerosis: radiological-clinical correlations. Epilepsia 39[8], 893-896. 1998. 
 
Mori S1, Kishi M, Kubo S, Akiyoshi T, Yamada S, Miyazaki T, Konishi T, Maruyama N, 
Shigemoto K. 3,4-Diaminopyridine improves neuromuscular transmission in a MuSK 
antibody-induced mouse model of myasthenia gravis. J Neuroimmunol. 245, 75-78, 2012. 
 
Morsch M1, Reddel SW, Ghazanfari N, Toyka KV, Phillips WD. Pyridostigmine but not 3,4-
diaminopyridine exacerbates ACh receptor loss and myasthenia induced in mice by muscle-
specific kinase autoantibody. J Physiol. 591, 2747-2762, 2013. 
 
Palace J, Wiles CM, Newsom-Davis J. 3,4-Diaminopyridine in the treatment of congenital 
(hereditary) myasthenia. J Neurol Neurosurg Psychiatry 54[12], 1069-1072. 1991. 
 
Pasnoor M, Wolfe GI, Nations S, Trivedi J, et al. Clincal findings in MuSK-antibody positive 
myasthenia gravis: A U.S. experience.  Muscle & Nerve 41, 370 - 374. 2010 
 
Sabbagh A, Darlu P. SNP selection at the NAT2 locus for an accurate prediction of the 
acetylation phenotype. Genet Med 8[2], 76-85. 2006.  


 
MSK-003 
Page 45 
 
Proprietary and Confidential  
12 November 2017 
 
Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-
diaminopyridine in Lambert-Eaton myasthenic syndrome. Neurology 54[3], 603-607. 2000.  
 
Sanders DB, Howard JF Jr, Massey JM. 3,4-Diaminopyridine in Lambert-Eaton myasthenic 
syndrome and myasthenia gravis. Ann N Y Acad Sci 681, 588-590. 1993.  
 
Skjei KL, Lennon VA, Kuntz NL: Muscle specific kinase autoimmune myasthenia gravis in 
children: A case series. Neuromuscul Disorders 2013 Nov;23(11):874-882 
 
Skeie GO, Apostolski S, Evoli A, Gilhus NE, et al. Guidelines for the treatment of 
autoimmune neuromuscular transmission disorders. Eur J Neurol 17[7], 893-902. 2010. 
 
Skeie GO, Apostolski S, Evoli A, Gilhus NE, et al. Guidelines for the treatment of 
autoimmune neuromuscular transmission disorders. Eur J Neurol 13[7], 691-699. 2006.  
 
 
 


 
MSK-003 
Page 46 
 
Proprietary and Confidential  
12 November 2017 
20 INVESTIGATOR RESPONSIBILITIES 
20.1 Conduct of Study and Protection of Human Patients 
The Investigator will ensure that: 
• He or she will conduct the study in accordance with the relevant, current protocol and 
will only make changes in a protocol after notifying the sponsor, except when 
necessary to protect the safety, rights, or welfare of patients. 
• He or she will personally conduct or supervise the study. 
• He or she will inform any potential patients, or any persons used as controls, that the 
drugs are being used for investigational purposes and he or she will ensure that the 
requirements relating to obtaining informed consent in compliance with ICH E6 
(Section 4.8), and other applicable local regulations, are met.  
• He or she will report to the sponsor adverse experiences that occur during the 
investigation in compliance with the standard operating procedures and policies of the 
IRB/IEC/REB and with applicable regulatory requirements. 
• He or she has read and understands the information in the Investigator’s Brochure, 
including potential risks and side effects of the drug. 
• His or her staff and all persons who assist in the conduct of the study are informed 
about their obligations in meeting the above commitments. 
• He or she will ensure that adequate and accurate records are kept in accordance with 
ICH and GCP requirements and to ensure those records are available for inspection. 
• He or she will ensure that the IRB/IEC/REB complies with ICH and GCP 
requirements, and other applicable regulations, and conducts initial and ongoing 
reviews and approvals of the study. He or she will also ensure that any change in 
research activity and all problems involving risks to human patients or others are 
reported to the IRB/IEC/REB. Additionally, he or she will not make any changes in 
the research without IRB/IEC/REB approval, except where necessary to eliminate 
apparent immediate hazards to human patients. 
• He or she agrees to comply with all other requirements regarding the obligations of 
clinical Investigators and all other pertinent ICH and GCP requirements. 
• He or she agrees to comply with electronic signature requirements in accordance with 
ICH requirements and applicable laws and local regulations. 




 
MSK-003 
Page 48 
 
Proprietary and Confidential  
12 November 2017 
APPENDIX 1: MYASTHENIA GRAVIS-SPECIFIC ACTIVITIES OF DAILY 
LIVING (MG-ADL) 
The MG-ADL is a self-report scale designed to assess the patient’s MG symptoms and 
functional performance of activities of daily living. Eight items as listed below will be 
assessed by the patient at the protocol specified time points (see Error! Reference source 
not found. 
 
 
 
 
 
 
Score 
Grade 
0 
1 
2 
3 
(0, 1, 2, 3) 
1.Talking  
Normal  
Intermittent 
slurring of 
nasal speech 
Constant 
slurring or 
nasal, but can 
be understood 
Difficult to 
understand 
speech 
 
2. Chewing 
Normal 
Fatigue with 
solid food 
Fatigue with 
soft food 
Gastric tube 
 
3.Swallowing 
Normal  
Rare episode of 
choking 
Frequent 
choking 
necessitating 
changes in diet 
Gastric tube 
 
4.Breathing  
Normal 
Shortness of 
breath with 
exertion 
Shortness of 
breath at rest 
Ventilator 
dependence 
 
5. Impairment of 
ability to brush 
teeth or comb hair 
 
None 
Extra effort, but 
no rest 
periods needed 
Rest periods 
needed  
Cannot do one 
of these 
functions 
 
6.Impairment of 
ability to arise 
from a chair 
None  
Mild, 
sometimes uses 
arms 
Moderate, 
always uses 
arms 
Severe, requires 
assistance 
 
7. Double vision  
None 
Occurs, but not 
daily 
Daily, but not 
constant 
Constant 
 
8. Bothersome 
eyelid droop  
None  
Occurs, but not 
daily 
Daily, but not 
constant 
Constant 
 
 
 
 
 
 
MG-ADL 
score 
 
 
 
 
 
(items 1-8)